

IMIDAZOLYL DERIVATIVES

Background of the invention

5

The present invention is directed to compounds and compositions containing said compounds which bind selectively to somatostatin receptor subtypes and the use of said compounds for treating medical disorders which are mediated by somatostatin receptor subtypes. Somatostatin (somatotropin release inhibiting factor, SRIF), a
10 tetradecapeptide hormone, originally isolated from bovine hypothalami (Brazeau, P. et al., Science 179, 77-79, 1973) has been shown to have a wide range of regulatory effects on the release of a variety of hormones such as growth hormone, prolactin, glucagon, insulin, gastrin (Bloom, S.R. and Poldack, J.M., Brit. Med. J. 295, 288-289, 1987). In addition, antiproliferative properties (Reichlin, S., N. Engl. J. Med. 309, 1495-
15 1501, 1983) have been obtained with somatostatin analogs in metastatic prostatic cancer (Parmar, H. et al, Clin. Exp. Metastasis, 10, 3-11, 1992) and in several other neuroendocrine neoplasms in man (Anthony, L. et al. Acta Oncol., 32, 217-223, 1993). Metabolism of somatostatin by aminopeptidases and carboxypeptidases leads to a short duration of action.

20

The actions of somatostatin are mediated via membrane bound receptors. The heterogeneity of its biological functions has led to studies to identify structure-activity relationships of peptides analogs at the somatostatin receptors which resulted in the discovery of five receptor subtypes (Yamada, et al, Proc . Natl. Acad. Sci. U.S.A, 89, 251-255, 1992 ; Raynor, K. et al, Mol. Pharmacol., 44, 385-392, 1993). The functional
25 roles of these receptors are under extensive investigation. Binding to the different types of somatostatin subtypes have been associated with the treatment of the following conditions and/or diseases. Activation of types 2 and 5 have been associated with growth hormone suppression and more particularly GH secreting adenomas (Acromegaly) and TSH secreting adenomas. Activation of type 2 but not type 5 has
30 been associated with treating prolactin secreting adenomas. Other indications associated with activation of the somatostatin subtypes are restenosis, inhibition of insulin and/or glucagon and more particularly diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon and Nephropathy; inhibition of gastric acid secretion and more particularly peptic ulcers,
35 enterocutaneous and pancreaticocutaneous fistula, irritable bowel syndrome, Dumping


syndrome, watery diarrhea syndrome, AIDS related diarrhea, chemotherapy-induced diarrhea, acute or chronic pancreatitis and gastrointestinal hormone secreting tumors; treatment of cancer such as hepatoma; inhibition of angiogenesis, treatment of inflammatory disorders such as arthritis; chronic allograft rejection; angioplasty;
 5 preventing graft vessel and gastrointestinal bleeding. Somatostatin agonists can also be used for decreasing body weight in a patient.

In drug research, it is a key issue to minimize side effects by developing highly potent and selective drug molecules. Recent work on the development of nonpeptide structures (Hirschmann, R. et al, J.Am.Chem.Soc. 115, 12550-12568, 1993 ;
 10 Papageorgiou, C. and Borer, X., Bioorg. Med.Chem.Lett. 6, 267-272, 1996) have described compounds with low somatostatin receptor affinity.

The present invention is directed to a family of nonpeptide compounds, which are selective and potent somatostatin receptor ligands.

Summary of the Invention

15 In one aspect the present invention is directed to a compound of the formula (I),




the racemic-diastereomeric mixtures and optical isomers of said compound of formula
 20 (I), the pharmaceutically-acceptable salts and prodrugs thereof or a pharmaceutically acceptable salt thereof,

wherein

— represents an optional bond;

R¹ is H, -(CH₂)_m-C(O)-(CH₂)_n-Z¹, -(CH₂)_m-Z¹, -(CH₂)_m-O-Z¹ or -(C₆-C₈)alkyl-C(O)-NH-
 25 (CH₂)_m-Z²;


Z¹ is an optionally substituted moiety selected from the group consisting of (C₁-C₁₂)alkyl, benzo[b]thiophene, phenyl, naphthyl, benzo[b]furanyl, thiophene,



isoxazolyl, indolyl,

R² is H or (C₁-C₆)alkyl;

- 5 or R¹ and R² are taken together with the nitrogen atoms to which they are attached to form a compound of formula (Ia), (Ib) or (Ic),



R³ is -(CH₂)_m-E-(CH₂)_n-Z²;

- 10 E is O, S, -C(O)-, -C(O)-O-, -NH-C(O)-O- or a bond;

Z² is H, (C₁-C₁₂)alkyl, amino, (C₁-C₁₂)alkylamino, N,N-di-(C₁-C₁₂)alkylamino, (C₁-C₁₂)alkylguanidino, or an optionally substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl;

- 15 R⁴ is H or -(CH₂)_m-A¹;

A¹ is -C(=Y)-N(X¹X²), -C(=Y)-X², -C(=NH)-X² or X²;

Y is O or S;

X¹ is H, (C₁-C₁₂)alkyl, -(CH₂)_m-NH-(C₁-C₆)alkyl, -(CH₂)_m-N-di-(C₁-C₆)alkyl or -(CH₂)_m-aryl;

- 20 X² is -(CH₂)_m-Y¹-X³ or optionally substituted (C₁-C₁₂)alkyl;


Y¹ is O, S, NH, C=O, (C₂-C₁₂)alkenyl having one or more double bonds,

-NH-CO-, -CO-NH-, -NH-CO-O-(CH₂)_m-, -C≡C-, SO₂ or a bond;


X³ is H, an optionally substituted moiety selected from the group consisting of (C₁-C₁₂)alkyl, (C₃-C₆)cycloalkyl, (C₁-C₁₂)alkoxy, aryloxy, (C₁-C₁₂)alkylamino, N,N-di-(C₁-C₁₂)alkylamino, -CH-di-(C₁-C₁₂)alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl, indolyl,

25

morpholino, benzo[b]furanyl, quinolinyl, isoquinolinyl, $-(CH_2)_m$ -phenyl, naphthyl, fluorenyl, phthalamidyl, pyrimidinyl,



5 or X¹ and X² are taken together with the nitrogen to which they are attached to form an optionally substituted moiety selected from the group consisting of thiazolyl




Y^2 is $CH-X^4$, $N-X^4$, $-C(X^4X^4)$, O or S;

X^4 for each occurrence is independently $-(CH_2)_m-Y^3-X^5$;

Y^3 is $-C(O)-$, $-C(O)O-$ or a bond;

X^5 is hydroxy, (C_1-C_{12}) alkyl, amino, (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, or an optionally substituted moiety selected from the group consisting of aryl, aryl- (C_1-C_6) alkyl, furanyl, pyridinyl, indolyl, $-CH(phenyl)_2$,




R^5 is (C_1-C_{12}) alkyl, (C_6-C_8) alkyl- $C(O)-O-Z^5$, (C_6-C_8) alkyl- $C(O)-NH-(CH_2)_m-Z^5$ or optionally substituted aryl;

Z^5 for each occurrence is independently amino, (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, $-NH-C(O)-O-(CH_2)_m-phenyl$, $-NH-C(O)-O-(CH_2)_m-(C_1-C_6)$ alkyl or an optionally substituted moiety selected from the group consisting of imidazolyl, pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl and thiophene;

R^6 is H or (C_1-C_6) alkyl;

R^7 is (C_1-C_{12}) alkyl or $-(CH_2)_m-Z^4$;

Z^4 is an optionally substituted moiety selected from the group consisting of phenyl, naphthyl, indolyl, thiophene, benzo[b]furan, benzo[b]thiophene, isoxazolyl,



Z^5 is H, (C_1-C_{12}) alkyl, $(CH_2)_m-aryl$;

wherein an optionally substituted moiety is optionally substituted by one or more substituents, each independently selected from the group consisting of Cl, F, Br, I, CF_3 , CN, N_3 , NO_2 , OH, SO_2NH_2 , $-OCF_3$, (C_1-C_{12}) alkoxy, $-(CH_2)_m-phenyl-(X^6)_n$, $-S-phenyl-(X^6)_n$, $-S-(C_1-C_{12})$ alkyl, $-O-(CH_2)_m-phenyl-(X^6)_n$, $-(CH_2)_m-C(O)-O-(C_1-C_6)$ alkyl, $-(CH_2)_m-C(O)-(C_1-C_6)$ alkyl,

$-O-(CH_2)_m-NH_2$, $-O-(CH_2)_m-NH-(C_1-C_6)$ alkyl, $-O-(CH_2)_m-N-di-((C_1-C_6)$ alkyl) and $-(C_6-C_{12})$ alkyl- $(X^6)_n$;

X^6 for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, NO_2 , N_3 , CN, OH, $-\text{CF}_3$, $-\text{OCF}_3$, $(\text{C}_1\text{-C}_{12})\text{alkyl}$, $(\text{C}_1\text{-C}_{12})\text{alkoxy}$, $-(\text{CH}_2)_m\text{-NH}_2$, $-(\text{CH}_2)_m\text{-NH}-(\text{C}_1\text{-C}_6)\text{alkyl}$, $-(\text{CH}_2)_m\text{-N-di}-(\text{C}_1\text{-C}_6)\text{alkyl}$ and $-(\text{CH}_2)_m\text{-phenyl}$;
 m for each occurrence is independently 0 or an integer from 1 to 6; and

5 n for each occurrence is independently an integer from 1 to 5;

provided that:

(a) when R^5 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$, or $-\text{C}(\text{O})-\text{O}-\text{Z}^5$ and Z^5 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ or optionally substituted aryl; R^6 is H or $(\text{C}_1\text{-C}_6)\text{alkyl}$; R^7 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ or Z^6 and Z^6 is thiophene or optionally substituted phenyl, then R^3 is not $-\text{C}(\text{O})-\text{O}-(\text{CH}_2)_m\text{-Z}$ where m is 0 and Z is H or $(\text{C}_1\text{-C}_{12})\text{alkyl}$ or where m is 1 to 6 and Z is H;

10 (b) when R^5 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ or optionally substituted phenyl; R^6 is H or $(\text{C}_1\text{-C}_6)\text{alkyl}$; R^7 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ and R^3 is $-\text{O}-(\text{CH}_2)_m\text{-Z}^2$, then Z^2 is not an optionally substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl, and naphthyl; and

15 (c) when R^5 is H or $(\text{C}_1\text{-C}_{12})\text{alkyl}$; R^6 is $(\text{C}_1\text{-C}_6)\text{alkyl}$; R^7 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$; and R^3 is $-\text{O}-\text{Z}^2$ or $-\text{S}-\text{Z}^2$, then Z^2 is not an optionally substituted moiety selected from the group consisting of phenyl, naphthyl, thiophene, benzothiophenyl and indolyl.


A preferred compound of formula I is where R^1 is H; R^2 is H; R^3 is $-\text{CH}_2\text{-phenyl}$; R^4 is $-(\text{CH}_2)_m\text{-A}^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

20 where A^1 is $-\text{C}(=\text{Y})-\text{N}(\text{X}^1\text{X}^2)$;

Y is O; X^1 is H or methyl;

X^2 is $-(\text{CH}_2)_m\text{-Y}^1\text{-X}^3$;

25 m in the definition of X^2 is 0, 1, 2 or 3; Y^1 is a bond or O; and X^3 is N-methylpyrrolidin-2-yl, diethylamino, pyridinyl, thiophene, imidazolyl, diethoxymethyl, 1-benzyl-piperidin-4-yl, optionally substituted phenyl or




Another preferred compound of formula (I) is where R^1 is H; R^2 is H; R^3 is $-\text{CH}_2\text{-phenyl}$; R^4 is $-(\text{CH}_2)_m\text{-A}^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

where A^1 is $-\text{C}(=\text{Y})-\text{N}(\text{X}^1\text{X}^2)$;

30 Y is O;

X^1 is benzyl and X^2 is 2-hydroxyethyl;


or X^1 and X^2 are taken together with the nitrogen atom to which they are



where Y^2 is $C-X^4$ or $N-X^4$;

5 X^4 is $-(CH_2)_m-Y^2-X^5$ where m in the definition of X^4 is 0 or 1; and

X^5 is selected from the group consisting of furanyl, benzyl, phenyl, amino,




Another preferred compound of formula (I) is where R^1 is H; R^2 is H; R^3 is $-CH_2-$ phenyl; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H; 10 where A^1 is $-C(=Y)-X^2$;

Y is O; X^2 is $-(CH_2)_m-Y^1-X^3$;

where m in the definition of X^2 is 0, 1 or 2;

Y^1 is O, $-NH-CO-$, $-CO-NH-$, $-NH-CO-O-CH_2-$, SO_2 or a bond; and

15 X^3 is methyl, furanyl, pentyl, phenyl, indolyl, $p-NO_2$ -phenyl, naphthyl, fluorenyl, $-CH(phenyl)_2$, benzothiazolyl, phthalamidyl, N,N -dimethylamino,



Another preferred compound of formula (I) is where R^1 is H; R^2 is H; R^3 is $-CH_2-$ indol-3-yl; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl or $t-Bu$; R^6 is 20 H;


A^1 is $-C(=Y)-N(X^1X^2)$;

Y is O or S; X^1 is H; X^2 is $-(CH_2)_m-Y^1-X^3$;

m in the definition of X^2 is 0, 1 or 2;

25 Y^1 is a bond; and X^3 is phenyl, o -Cl-phenyl, m -Cl-phenyl, p -phenyloxy-phenyl, 2,6-di-isopropylphenyl, m - CF_3 -phenyl, p -ethoxycarbonyl-phenyl, 2,4-

difluorophenyl, m-NO₂-phenyl, p-benzyloxyphenyl, o-isopropylphenyl, n-hexyl, 4-



morpholino, naphthyl or


Another compound of formula (I) is where R¹ is H; R² is H; R³ is -CH₂-indol-3-yl; R⁴ is -(CH₂)_m-A¹ where m in the definition of R⁴ is 0; R⁵ is phenyl or t-Bu; R⁶ is H;

5 where A¹ is -C(=Y)-X²;

Y is O; X² is -(CH₂)_m-Y¹-X³;

where m in the definition of X² is 0, 1 or 2;

Y¹ is O, -CO-NH-, -NH-CO-O-CH₂- or a bond; and X³ is methyl, 3-pentyl, phenyl, p-NO₂-phenyl, phthalamidyl, N,N-dimethylamino, p-aminophenyl, fluorenyl or



10


Another preferred compound of formula (I) is where R¹ is H; R² is H; R³ is -CH₂-indol-3-yl; R⁴ is -(CH₂)_m-A¹ where m in the definition of R⁴ is 0; R⁵ is phenyl or t-Bu; R⁶ is H;

where A¹ is -C(=Y)-N(X¹X²);

15 Y is O; X¹ is hydrogen; X² is -(CH₂)_m-Y¹-X³;

where m in the definition of X² is 0, 1, 2 or 3;

Y¹ is O, or a bond; and X³ is cyclopentyl, 4-OH-butyl, N,N-diethylamino, N-methyl-pyrrolidin-3-yl, -CH(ethoxy)₂, phenyl, p-SO₂NH₂-phenyl p-OH-phenyl, o-CF₃-phenyl, p-Cl-phenyl, -CH(phenyl)₂.



20

Another preferred compound of formula (I) is where R¹ is H; R² is H; R³ is -CH₂-indol-3-yl; R⁴ is -(CH₂)_m-A¹ where m in the definition of R⁴ is 0; R⁵ is phenyl or t-Bu; R⁶ is H;

where A¹ is -C(=Y)-X²;

25 Y is O; X² is -(CH₂)_m-Y¹-X³;

where m in the definition of X² is 0, 1, 2 or 3;

Y^1 is $-NH-CO-$, $-C=C-$, $-C\equiv C-$ or a bond; and X^3 is t-butyl, 1-methylcarbonyl-piperidin-4-yl, phenyl, p-Cl-phenyl, m- CF_3 -phenyl, 4-nitro-naphthyl, p-methoxy-phenyl, m-(phenylethyl)-phenyl, indol-3-yl or p-aminophenyl.

Another preferred compound of formula (I) is where R^1 is H; R^2 is H; R^3 is
 5 $-CH_2$ -indol-3-yl, $-(CH_2)_4-NH-CO-O-t-Bu$ or $-(CH_2)_4-NH_2$; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl, o-methoxyphenyl, p-Br-phenyl, p-nitro-phenyl or p-N,N-diethylamino-phenyl; R^6 is H;

where A^1 is $-C(=Y)-N(X^1X^2)$;

Y is O; X^1 is H; X^2 is $-(CH_2)_m-Y^1-X^3$;

10 where m in the definition of X^2 is 0;

Y^1 is a bond; and X^3 is o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, o-Cl-phenyl, m-Cl-phenyl, p-Cl-phenyl, o-nitro-phenyl, m-nitro-phenyl, p-nitro-phenyl, o- CF_3 -phenyl, m- CF_3 -phenyl, p- CF_3 -phenyl, p-F-phenyl, 2,4-di-F-phenyl, 2,5-di-F-phenyl, 2,5-di-methoxy-phenyl, m-OMe-phenyl, p-OMe-phenyl, 2- CF_3 -4-Cl-phenyl or 3-nitro-4-F-phenyl.

15

Of the immediately above compounds it is preferred that when R^5 is phenyl and R^3 is $-(CH_2)$ -indol-3-yl that the stereochemistry at the carbon to which R^3 is attached is in the R-configuration.

Another preferred compound of formula (I) is where R^1 is H; R^2 is H; R^3 is $-CH_2$ -indol-3-yl, $-(CH_2)_4-NH-CO-O-t-Bu$ or $-(CH_2)_4-NH_2$; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl, o-methoxyphenyl, p-methoxyphenyl, p-Br-phenyl, p-nitro-phenyl or p-N,N-diethylamino-phenyl; R^6 is H;

20

where A^1 is $-C(=Y)-X^2$;

Y is O; X^2 is $-(CH_2)_m-Y^1-X^3$;

25 where m in the definition of X^2 is 1;

Y^1 is a bond; and X^3 is phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, o-Cl-phenyl, m-Cl-phenyl, p-Cl-phenyl, o-nitro-phenyl, m-nitro-phenyl, p-nitro-phenyl, o- CF_3 -phenyl, m- CF_3 -phenyl, p- CF_3 -phenyl, o-F-phenyl, m-F-phenyl, p-F-phenyl, N,N-di-methylamino-phenyl, o-OMe-phenyl, m-OMe-phenyl, p-OMe-phenyl, 3,4-di-Cl-phenyl, 3,4,5-tri-OMe-phenyl, p-Me-phenyl, p-OH-phenyl or 2,4-di-F-phenyl.

30

Of the immediately foregoing compounds when R^5 is phenyl or o-OMe-phenyl and R^3 is $-(CH_2)$ -indol-3-yl; it is preferred that the compounds are the separated enantiomers (R or S configuration) according to the carbon to which R^3 is attached.

Another preferred compound of formula (I) is where R^1 is H; R^2 is H; R^3 is $-(CH_2)_4-NH-CO-O-t-Bu$ or $-(CH_2)_4-NH_2$; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

where A^1 is $-C(=Y)-X^2$;

5 Y is O; X^2 is $-(CH_2)_m-Y^1-X^3$;

where m in the definition of X^2 is 0, 1 or 2;

Y^1 is S, SO_2 or a bond; and X^3 is phenyl, 3,4-di-Cl-phenyl, 3,4,5-tri-OMe-phenyl, p-Me-phenyl, p-OH-phenyl, 2,4-di-F-phenyl, 2-furanyl, 2-pyridinyl, 3-pyridinyl, naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 8-quinolinyl, 1-isoquinolinyl, 2-thiophene or 2-pyrimidinyl.

10

Another preferred compound of formula (I) is where R^1 is H; R^2 is H; R^3 is $-(CH_2)_4-NH-CO-O-t-Bu$ or $-(CH_2)_4-NH_2$; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

where A^1 is $-C(=Y)-X^2$;

15 Y is O; X^2 is $-(CH_2)_m-Y^1-X^3$;

where m in the definition of X^2 is 0, 1, 2 or 3;

Y^1 is a bond; and X^3 is 5-indolyl, 3-indolyl, 4-indolyl, 2-indolyl, 5-OMe-indol-3-yl, 5-OMe-indol-2-yl, 5-OH-indol-2-yl, 5-OH-indol-3-yl, 5-Br-indol-3-yl, 2-Me-indol-3-yl, 2-benzothiophene, 3-benzothiophene or 2-benzofuran.

20

Another preferred compound of formula (I) is where R^1 is H; R^2 is H; R^3 is $-(CH_2)_m$ -indol-3-yl, $-(CH_2)_4-NH-CO-O-t-Bu$ or $-(CH_2)_4-NH_2$; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl, o-OMe-phenyl or p-OMe-phenyl; R^6 is H;

where A^1 is X^2 ;

X^2 is $-(CH_2)_m-Y^1-X^3$;

25

where m in the definition of X^2 is 1, 2 or 3;

Y^1 is S, O or a bond; and X^3 is phenyl, o-OH-phenyl, p-OH-phenyl, o-F-phenyl, m-F-phenyl, p-F-phenyl, o- CF_3 -phenyl, o-OMe-phenyl, m-OMe-phenyl, o-nitro-phenyl, p-nitro-phenyl, 3,4-di-Cl-phenyl, 2-nitro-3-OMe-phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, 2-thiophene, 3,4,5-tri-OMe-phenyl, p-N,N-dimethylamino-phenyl, p- OCF_3 -phenyl, p-(3-(N,N-dimethylamino)propoxy)phenyl, 3-F-4-OMe-phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-Cl-quinolin-3-yl, 2-quinolinyl, methyl, n-butyl, n-pentyl, n-hexyl, 3,3-dimethyl-butyl, benzyl, cyclohexyl or p-t-Bu-phenyl.

30

Another preferred compound of formula (I) is where R^1 is H; R^2 is H; R^3 is $-(CH_2)_4-NH-CO-O-t-Bu$ or $-(CH_2)_4-NH_2$; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

where A^1 is X^2 ;

5 X^2 is $-(CH_2)_m-Y^1-X^3$;

where m in the definition of X^2 is 1, 2 or 3;

Y^1 is O or a bond; and X^3 is phenyl, o-OH-phenyl, p-OH-phenyl, o-F-phenyl, m-F-phenyl, p-F-phenyl, o- CF_3 -phenyl, o-OMe-phenyl, m-OMe-phenyl, p-OMe-phenyl, o-nitro-phenyl, p-nitro-phenyl, 3,4-di-Cl-phenyl, 2-nitro-3-OMe-phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, p-phenyl-phenyl, 2-thiophene, 3,4,5-tri-OMe-phenyl, p-N,N-dimethylamino-phenyl, p-benzyloxy-phenyl, p- OCF_3 -phenyl, p-(3-(N,N-dimethylamino)propoxy)phenyl, 3-F-4-OMe-phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-Cl-quinolin-3-yl, 2-quinolinyl, 3-indolyl, 6-methoxycarbonyl-indol-3-yl, 1-methyl-indol-3-yl, 2-methyl-indol-3-yl, methyl, n-butyl, n-pentyl, n-hexyl, 3,3-dimethyl-butyl, benzyl, cyclohexyl or p-t-Bu-phenyl.

Another preferred compound of formula (I) is where R^1 is $-(CH_2)-CO-Z^1$; R^2 is H; R^3 is $-(CH_2)_4-NH-CO-O-t-Bu$, $-(CH_2)_4-NH-CO-O-benzyl$, $-(CH_2)$ -phenyl or $-(CH_2)$ -indol-3-yl; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

where Z^1 is ethyl, phenyl, p-OMe-phenyl, p-phenyl-phenyl, p-Cl-phenyl, p-Br-phenyl, 20 p- N_3 -phenyl, p-F-phenyl, m-nitro-phenyl, p-nitro-phenyl, p-CN-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, N,N-dimethylamino-phenyl, 3-methyl-4-Cl-phenyl or naphthyl;

A^1 is $-C(=Y)-X^2$;


Y is O; X^2 is $-(CH_2)_m-Y^1-X^3$;

25 where m in the definition of X^2 is 0;

Y^1 is O; and X^3 is t-Bu.

Another preferred compound of formula (I) is where R^1 is $-(CH_2)-CO-(CH_2)_m-Z^1$ where m in the definition of R^1 is 0, 1 or 2; R^2 is H; R^3 is $-(CH_2)$ -indol-3-yl or $-(CH_2)_4-NH-CO-O-t-Bu$; R^4 is H or $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl, o-OMe-phenyl, p-nitro-phenyl, p-Br-phenyl, t-Bu, $-CH(CH_3)_2-CO-NH-(CH_2)_2-CO-O-t-Bu$, $-CH(CH_3)_2-CO-NH-(CH_2)_3$ -imidazol-1-yl, $-CH(CH_3)_2-CO-NH-(CH_2)_2$ -pyridin-2-yl, $-CH(CH_3)_2-CO-NH-(CH_2)_3$ -4-morpholino, $-CH(CH_3)_2-CO-NH-(CH_2)$ -pyridin-4-yl or $-CH(CH_3)_2-CO-NH-(CH_2)_2$ -N,N-diethylamino; R^6 is H;

where Z' is ethyl, propyl, phenyl, p-OMe-phenyl, p-Cl-phenyl, p-Br-phenyl, p-F-phenyl, p-nitro-phenyl, m-nitro-phenyl, p-CN-phenyl, p-N₃-phenyl, p-phenyl-phenyl, 3-Me-4-Cl-phenyl, p-N,N-diethylamino-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, 3,4-di-F-phenyl, p-OCF₃-phenyl, p-benzyloxy-phenyl, p-pentyl-phenyl, 3,4,5-tri-OMe-phenyl, 3-nitro-4-Cl-phenyl, 3-Cl-4-nitro-phenyl, 3-methyl-5-chloro-benzothiophen-2-yl, 2-benzofuranyl, 3-benzothiophene, 3-phenyl-isoxazol-5-yl, 3-(2,4-di-Cl-phenyl)-isoxazol-5-yl, 3-indolyl, 5-Br-thiophen-2-yl, naphthyl,



A' is -C(=Y)-X²;

Y is O; X² is -(CH₂)_m-Y'-X³;

where m in the definition of X² is 0;


Y' is O; and X³ is t-Bu.

Another preferred compound of formula (I) is where R' and R² are taken together to form a compound of formula (Ib) or (Ic);


R³ is -(CH₂)₄-indol-3-yl, -(CH₂)₄-phenyl, -(CH₂)₄-NH-CO-O-benzyl or -(CH₂)₄-NH₂;

R⁵ is phenyl, o-OMe-phenyl, p-OMe-phenyl, p-Br-phenyl, p-nitro-phenyl, t-Bu or -CH(CH₃)₂-CO-NH-(CH₂)₂-NH₂; R⁶ is H;

R⁷ is ethyl, propyl, phenyl, p-OMe-phenyl, p-Cl-phenyl, p-Br-phenyl, p-F-phenyl, p-nitro-phenyl, m-nitro-phenyl, p-CN-phenyl, p-N₃-phenyl, p-phenyl-phenyl, 3-Me-4-Cl-phenyl, p-N,N-diethylamino-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, 3,4-di-F-phenyl, p-OCF₃-phenyl, p-benzyloxy-phenyl, p-pentyl-phenyl, 3,4,5-tri-OMe-phenyl, 3-nitro-4-Cl-phenyl, 3-Cl-4-nitro-phenyl, 3-methyl-5-chloro-benzothiophen-2-yl, 2-benzofuranyl, 3-benzothiophene, 3-phenyl-isoxazol-5-yl, 3-(2,4-di-Cl-phenyl)-isoxazol-5-yl, 3-indolyl, 5-Br-thiophen-2-yl, naphthyl,



In another aspect, the present invention is directed to a compound of the formula (II).



(II)

the racemic-diastereomeric mixtures and optical isomers of said compound of formula (II), the pharmaceutically-acceptable salts or prodrugs thereof or a pharmaceutically


5 acceptable salt of said prodrug,

wherein

— represents an optional bond;

R¹ is H, -(CH₂)_m-C(O)-(CH₂)_m-Z¹, -(CH₂)_m-Z¹, -(CH₂)_m-O-Z¹ or -(C₆-C₈)alkyl-C(O)-NH-(CH₂)_m-Z¹;

10 Z¹ is an optionally substituted moiety selected from the group consisting of (C₁-C₁₂)alkyl, benzo[b]thiophene, phenyl, naphthyl, benzo[b]furanyl, thiophene,




isoxazolyl, indolyl,

R² is H or (C₁-C₈)alkyl;

or R¹ and R² are taken together with the nitrogen atoms to which they are attached to

15 form a compound of formula (IIa), (IIb) or (IIc),



R³ is -(CH₂)_m-E-(CH₂)_m-Z²;

E is O, S, -C(O)-, -C(O)-O-, -NH-C(O)-O-, -N(C₁-C₈)alkyl-C(O)-O- or a bond;

20 Z² is H, (C₁-C₁₂)alkyl, amino, (C₁-C₁₂)alkylamino, N,N-di-(C₁-C₁₂)alkylamino, (C₁-C₁₂)alkylguanidino, or an optionally substituted moiety selected from the group

consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl;

R^4 is H or $-(CH_2)_m-A^1$;

A^1 is $-C(=Y)-N(X^1X^2)$, $-C(=Y)-X^2$, $-C(=NH)-X^2$ or X^2 ;

5 Y is O or S;


X^1 is H, (C_1-C_{12}) alkyl, $-(CH_2)_m-NH-(C_1-C_6)$ alkyl, $-(CH_2)_m-N$ -di- (C_1-C_6) alkyl or $-(CH_2)_m$ -aryl;

X^2 is $-(CH_2)_m-Y^1-X^3$ or optionally substituted (C_1-C_{12}) alkyl;


Y^1 is O, S, NH, C=O, (C_2-C_{12}) alkenyl having one or more double bonds,

10 $-NH-CO-$, $-CO-NH-$, $-NH-CO-O-(CH_2)_m-$, $-C\equiv C-$, SO_2 or a bond;

X^3 is H, an optionally substituted moiety selected from the group consisting of (C_1-C_{12}) alkyl, (C_3-C_6) cycloalkyl, (C_1-C_{12}) alkoxy, aryloxy, (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, $-CH$ -di- (C_1-C_{12}) alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl, indolyl, morpholino, benzo[b]furanyl, quinolinyl, isoquinolinyl, $-(CH_2)_m$ -phenyl, naphthyl, fluorenyl, phthalamidyl, pyrimidinyl.



20 or X^1 and X^2 are taken together with the nitrogen to which they are attached to form an optionally substituted moiety selected from the group consisting of thiazolyl,




Y^2 is $CH-X^4$, $N-X^4$, $-C(X^4X^4)$, O or S.

X^4 for each occurrence is independently H or $-(CH_2)_m-Y^3-X^5$;

Y^3 is $-C(O)-$, $-C(O)O-$ or a bond;


- 5 X^5 is hydroxy, (C_1-C_{12}) alkyl, amino, (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, or an optionally substituted moiety selected from the group consisting of aryl, aryl- (C_1-C_4) alkyl, furanyl, pyridinyl, indolyl, piperidinyl, $-CH(phenyl)_2$.



- 10 R^5 is (C_1-C_{12}) alkyl, (C_5-C_8) alkyl- $C(O)-O-Z^3$, (C_5-C_8) alkyl- $C(O)-NH-(CH_2)_m-Z^3$ or optionally substituted aryl;

Z^3 for each occurrence is independently amino, (C_1-C_{12}) alkylamino, amino- (C_1-C_{12}) alkyl, (C_5-C_7) cycloalkylamino, amino- (C_5-C_7) cycloalkyl, N- (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, $-NH-C(O)-O-(CH_2)_m-phenyl$, $-NH-C(O)-O-(CH_2)_m-(C_1-C_8)$ alkyl, $-CH(phenyl)_2$, (C_5-C_7) cycloalkyl,

- 15 $H_2N-(C_1-C_8)$ alkyl- $C(O)-O-(C_1-C_8)$ alkyl




or an optionally substituted moiety selected from the group consisting of imidazolyl, pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl, phenyl, indolyl and thiophene, provided that when m is 0 in the formula for R⁵ then Z³ is not -NH-

5 C(O)-O-(CH₂)_m-phenyl or -NH-C(O)-O-(CH₂)_m-(C₁-C₈)alkyl;

R⁶ is H or (C₁-C₈)alkyl;

R⁷ is (C₁-C₁₂)alkyl or -(CH₂)_m-Z⁴;

Z⁴ is an optionally substituted moiety selected from the group consisting of phenyl, naphthyl, indolyl, thiophene, benzo[b]furan, benzo[b]thiophene, isoxazolyl,



Z⁵ is H, (C₁-C₁₂)alkyl, or -(CH₂)_m-aryl;

wherein an optionally substituted moiety is optionally substituted by one or more substituents, each independently selected from the group consisting of Cl, F, Br, I, CF₃,

15 CN, N₃, NO₂, OH, SO₂NH₂, -OCF₃, (C₁-C₁₂)alkoxy, -(CH₂)_m-phenyl-(X⁶)_n, -S-phenyl-(X⁶)_n, -S-(C₁-C₁₂)alkyl, -O-(CH₂)_m-phenyl-(X⁶)_n, -(CH₂)_m-C(O)-O-(C₁-C₈)alkyl, -(CH₂)_m-C(O)-(C₁-C₈)alkyl, -O-(CH₂)_m-NH₂, -O-(CH₂)_m-NH-(C₁-C₈)alkyl, -O-(CH₂)_m-N-di-((C₁-C₈)alkyl), -(C₆-C₁₂)alkyl-(X⁶)_n and -(CH₂)_m-phenyl-X⁷;

20 X⁶ for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, NO₂, N₃, CN, OH, -CF₃, -OCF₃, (C₁-C₁₂)alkyl, (C₁-C₁₂)alkoxy, -(CH₂)_m-NH₂, -(CH₂)_m-NH-(C₁-C₈)alkyl, -(CH₂)_m-N-di-((C₁-C₈)alkyl) and -(CH₂)_m-phenyl;

X⁷ is -NH-C(=NH-HI)-X⁸, wherein X⁸ is thiophene, (C₁-C₈)alkyl or phenyl;


m for each occurrence is independently 0 or an integer from 1 to 6; and

n for each occurrence is independently an integer from 1 to 5;


provided that:

- (a) when R^5 is (C_1-C_{12}) alkyl, or $-C(O)-O-Z^5$ and Z^5 is (C_1-C_{12}) alkyl or optionally substituted aryl; R^6 is H or (C_1-C_6) alkyl; R^7 is (C_1-C_{12}) alkyl or Z^6 and Z^6 is thiophene or optionally substituted phenyl, then R^3 is not $-C(O)-O-(CH_2)_m-Z$ where m is 0 and Z is H or (C_1-C_{12}) alkyl or where m is 1 to 6 and Z is H;
- (b) when R^5 is (C_1-C_{12}) alkyl or optionally substituted phenyl; R^6 is H or (C_1-C_6) alkyl; R^7 is (C_1-C_{12}) alkyl and R^3 is $-O-(CH_2)-Z^2$, then Z^2 is not an optionally substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl, and naphthyl; and
- (c) when R^5 is H or (C_1-C_{12}) alkyl; R^6 is (C_1-C_6) alkyl; R^7 is (C_1-C_{12}) alkyl; and R^3 is $-O-Z^2$ or $-S-Z^2$, then Z^2 is not an optionally substituted moiety selected from the group consisting of phenyl, naphthyl, thiophene, benzothiophenyl and indolyl.

A preferred group of compounds of formula (II), have the following formula:




wherein



Z^3 is $-CH_2-NH_2$, $-(CH_2)_2-NH_2$, $-(CH_2)_3-NH_2$ or


X^1 is $-(CH_2)_2-N(CH_3)_2$ and X^2 is benzyl; or

X^1 and X^2 are taken together with the nitrogen atom to which they are attached, to form




20

Another preferred group of compounds of formula (II) have the following formula:




wherein

Z³ is




- 5 X¹ is -(CH₂)₂-N(CH₃)₂ and X² is benzyl; or

X¹ and X² are taken together with the nitrogen atom to which they are attached, to form




Yet another preferred group of compounds of formula (II) have the following formula:



10


wherein X² is *p*-chloro-phenyl, *p*-methoxy-phenyl, 2,4-difluoro-phenyl or thienyl.

Still another preferred group of compounds of formula (II) have the following formula:




wherein X^2 is *p*-chloro-phenyl, *p*-methoxy-phenyl, phenyl or thienyl.


Further still a preferred compound of formula (II) has the following formula:



5 Further still another preferred compound of formula (II) has the following formula:




Further still another preferred group of compounds of formula (II) have the following formula:



10

wherein



5 In another aspect, this invention is directed to a pharmaceutical composition comprising one or more of a compound of formula (I) or formula (II), as defined hereinabove, and a pharmaceutically acceptable carrier.

In another aspect, the present invention is directed to a method of eliciting an agonist effect from one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound of formula (I) or formula (II) or a
 10 pharmaceutically acceptable salt thereof to said subject.

In another aspect, the present invention is directed to a method of eliciting an antagonist effect from one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound of formula (I) or formula (II)
 15 or a pharmaceutically acceptable salt thereof to said subject.

In another aspect, the present invention is directed to a method of binding one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt thereof to said subject.

20 In another aspect, the present invention is directed to a method of treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel

obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas, in a
5 subject in need thereof, which comprises administering a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt thereof to said subject.

In another aspect, the present invention is directed to a method of treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, Nephropathy, peptic ulcers,
10 enterocutaneous and pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, acute or chronic pancreatitis, gastrointestinal hormone secreting tumors, angiogenesis, inflammatory disorders, chronic allograft rejection, angioplasty, graft vessel bleeding or gastrointestinal bleeding in a subject in need thereof, which comprises administering a compound of formula (I) or formula (II) or a pharmaceutically
15 acceptable salt thereof to said subject.

In another aspect, the present invention is directed to a method of inhibiting the proliferation of helicobacter pylori in a subject in need thereof, which comprises administering a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt thereof, to said subject.

Detailed Description of the Invention

20 One of ordinary skill will recognize that certain substituents listed in this invention may have reduced chemical stability when combined with one another or with heteroatoms in the compounds. Such compounds with reduced chemical stability are not preferred.

25 In general, the compounds of Formula I or II can be made by processes which include processes known in the chemical arts for the production of compounds. Certain processes for the manufacture of Formula I or II compounds are provided as further features of the invention and are illustrated by the following reaction schemes and examples.

30 In the above structural formulae and throughout the instant application, the following terms have the indicated meanings unless expressly stated otherwise:

The alkyl groups are intended to include those alkyl groups of the designated length in either a straight or branched configuration. Exemplary of such alkyl groups

are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl and the like.

When the definition "C_n-alkyl" occurs in the definition, it means a single covalent bond.

5 The alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration. Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.

10 The term halogen or halo is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.

The term cycloalkyl is intended to include a mono-cycloalkyl group or a bi-cycloalkyl group of the indicated carbon number known to those of skill in the art.

The term aryl is intended to include aromatic rings known in the art, which can be mono-cyclic, bi-cyclic or tri-cyclic, such as phenyl, naphthyl and anthracene.


15 The term heterocycle includes mono-cyclic, bi-cyclic and tri-cyclic systems having one or more heteroatoms, such as oxygen, nitrogen and/or sulfur. The ring systems may be aromatic, for example pyridine, indole, quinoline, pyrimidine, thiophene (also known as thienyl), furan, benzothiophene, tetrazole, dihydroindole, indazole, N-formylindole, benzimidazole, thiazole, and thiadiazole. The ring systems may be non-
20 aromatic, for example pyrrolidine, piperidine, morpholine and the like.

The chemist of ordinary skill will recognize that certain combinations of heteroatom-containing substituents listed in this invention define compounds which will be less stable under physiological conditions. Accordingly, such compounds are less preferred.


25 When a chemical structure as used herein has an arrow emanating from it, the arrow indicates the point of attachment. For example, the structure



is a pentyl group. When an arrow is drawn through a cyclic moiety, the arrow indicates that the cyclic moiety can be attached at any of the available



30 bonding points, for example means that the phenyl can be bonded ortho, meta or para to the X group. When an arrow is drawn through a bi-cyclic or a tri-cyclic moiety, the arrow indicates that the bi-cyclic or tri-cyclic ring can be attached at any of



the available bonding points in any of the rings, for example means that the indole is bonded either through the phenyl portion of the ring or the nitrogen containing ring portion.

The compounds of the instant invention have at least one asymmetric center as noted by the asterisk in the structural formula (I), (Ia) and (Ib), above. Additional asymmetric centers may be present on the molecule depending upon the nature of the various substituents on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers, racemic mixtures or diastereomeric mixtures thereof, be included within the scope of the instant invention.

The instant compounds can be generally isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids. Examples of such acids are hydrochloric, nitric, sulfuric, phosphoric, acetic, propionic, maleic, succinic, D-tartaric, L-tartaric, malonic, methane sulfonic and the like. In addition, certain compounds containing an acidic function such as a carboxy can be isolated in the form of their inorganic salt in which the counter-ion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.

The pharmaceutically acceptable salts are formed by taking about 1 equivalent of a compound of formula (I) or (II) and contacting it with about 1 equivalent of the appropriate corresponding acid of the salt which is desired. Work-up and isolation of the resulting salt is well-known to those of ordinary skill in the art.

As is known in the art, agonists and antagonists of somatostatin are useful for treating a variety of medical conditions and diseases, such as inhibition of H. pylori proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Elison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux and in treating endocrinological diseases and/or conditions, such as Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's

disease, and polycystic ovary disease; in treating various types of cancer such as thyroid cancer, hepatome, leukemia, meningioma and conditions associated with cancer such as cancer cachexia; in the treatment of such conditions as hypotension such as orthostatic hypotension and postprandial hypotension and panic attacks; GH secreting adenomas (Acromegaly) and TSH secreting adenomas. Activation of type 2 but not type 5 subtype receptor has been associated with treating prolactin secreting adenomas. Other indications associated with activation of the somatostatin subtypes are inhibition of insulin and/or glucagon and more particularly diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon and Nephropathy; inhibition of gastric acid secretion and more particularly peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, acute or chronic pancreatitis and gastrointestinal hormone secreting tumors; inhibition of angiogenesis, treatment of inflammatory disorders such as arthritis; chronic allograft rejection; angioplasty; preventing graft vessel and gastrointestinal bleeding. Somatostatin agonists can also be used for decreasing body weight in a patient. Accordingly, the compounds of the instant invention are useful for the foregoing methods.

Accordingly, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of Formula (I) or (II) in association with a pharmaceutically acceptable carrier.

The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.

Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.

Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.

Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.

Further, a compound of this invention can be administered in a sustained release composition such as those described in the following patents. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form. U.S. Application No. 08/929,363 filed September 9, 1997, teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. U.S. Application No. 08/740,778 filed November 1, 1996, teaches sustained release compositions comprising a bioactive agent and cyclodextrin. U.S. Application No. 09/015,394 filed January 29, 1998, teaches absorbable sustained release compositions of a bioactive agent. The teachings of the foregoing patents and applications are incorporated herein by reference.

In general, an effective dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active

ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment, all of which are within the realm of knowledge of one of ordinary skill in the art. Generally, dosage levels of between 0.0001 to 100 mg/kg of body weight daily are administered to humans and other animals, e.g., mammals.

A preferred dosage range is 0.01 to 10.0 mg/kg of body weight daily, which can be administered as a single dose or divided into multiple doses.

Compounds of the instant invention can be and were assessed for its ability to bind to a somatostatin subtype receptor according to the following assays.

10 Human somatostatin subtype receptor binding studies:

The affinity of a compound for human somatostatin subtype receptors 1 to 5 (*sst*₁, *sst*₂, *sst*₃, *sst*₄, and *sst*₅, respectively) is determined by measuring the inhibition of [¹²⁵I-Tyr¹¹]SRIF-14 binding to CHO-K1 transfected cells.

The human *sst*₁ receptor gene was cloned as a genomic fragment. A 1.5 Kb *Pst*I-*Xmn*I segment containing 100 bp of the 5'-untranslated region, 1.17 Kb of the entire coding region, and 230 bp of the 3'-untranslated region was modified by the *Bgl*II linker addition. The resulting DNA fragment was subcloned into the *Bam*HI site of a pCMV-81 to produce the mammalian expression plasmid (provided by Dr. Graeme Bell, Univ. Chicago). A clonal cell line stably expressing the *sst*₁ receptor was obtained by transfection into CHO-K1 cells (ATCC) using the calcium phosphate co-precipitation method (1). The plasmid pRSV-neo (ATCC) was included as a selectable marker. Clonal cell lines were selected in RPMI 1640 media containing 0.5 mg/ml of G418 (Gibco), ring cloned, and expanded into culture.

The human *sst*₂ somatostatin receptor gene, isolated as a 1.7Kb *Bam*HI-*Hind*III genomic DNA fragment and subcloned into the plasmid vector pGEM3Z (Promega), was kindly provided by Dr. G. Bell (Univ. of Chicago). The mammalian cell expression vector is constructed by inserting the 1.7Kb *Bam*HI-*Hind*III fragment into compatible restriction endonuclease sites in the plasmid pCMV5. A clonal cell line is obtained by transfection into CHO-K1 cells using the calcium phosphate co-precipitation method. The plasmid pRSV-neo is included as a selectable marker.

The human *sst*₃ was isolated as a genomic fragment, and the complete coding sequence was contained within a 2.4 Kb *Bam*HI/*Hind*III fragment. The mammalian expression plasmid, pCMV-h3 was constructed by inserting the a 2.0 Kb *Nco*I-*Hind*III fragment into the *Eco*R1 site of the pCMV vector after modification of the ends and

addition of EcoR1 linkers. A clonal cell line stably expressing the sst₃ receptor was obtained by transfection into CHO-K1 cells (ATCC) using the calcium phosphate co-precipitation method. The plasmid pRSV-neo (ATCC) was included as a selectable marker. Clonal cell lines were selected in RPMI 1640 media containing 0.5 mg/ml of G418 (Gibco), ring cloned, and expanded into culture.

The human sst₄ receptor expression plasmid, pCMV-HX was provided by Dr. Graeme Bell (Univ. Chicago). The vector contains the 1.4 Kb *NheI-NheI* genomic fragment encoding the human sst₄, 456 bp of the 5'-untranslated region and 200 bp of the 3'-untranslated region, clone into the *XbaI/EcoR1* sites of pCMV-HX. A clonal cell line stably expressing the sst₄ receptor was obtained by transfection into CHO-K1 cells (ATCC) using the calcium phosphate co-precipitation method. The plasmid pRSV-neo (ATCC) was included as a selectable marker. Clonal cell lines were selected in RPMI 1640 media containing 0.5 mg/ml of G418 (Gibco), ring cloned, and expanded into culture.

The human sst₅ gene was obtained by PCR using a λ genomic clone as a template, and kindly provided by Dr. Graeme Bell (Univ. Chicago). The resulting 1.2 Kb PCR fragment contained 21 base pairs of the 5'-untranslated region, the full coding region, and 55 bp of the 3'-untranslated region. The clone was inserted into EcoR1 site of the plasmid pBSSK(+). The insert was recovered as a 1.2 Kb *HindIII-XbaI* fragment for subcloning into pCVM5 mammalian expression vector. A clonal cell line stably expressing the SST₅ receptor was obtained by transfection into CHO-K1 cells (ATCC) using the calcium phosphate co-precipitation method. The plasmid pRSV-neo (ATCC) was included as a selectable marker. Clonal cell lines were selected in RPMI 1640 media containing 0.5 mg/ml of G418 (Gibco), ring cloned, and expanded into culture.

CHO-K1 cells stably expressing one of the human sst receptor are grown in RPMI 1640 containing 10% fetal calf serum and 0.4 mg/ml geneticin. Cells are collected with 0.5 mM EDTA, and centrifuged at 500 g for about 5 min. at about 4°C. The pellet is resuspended in 50 mM Tris, pH 7.4 and centrifuged twice at 500 g for about 5 min. at about 4°C. The cells are lysed by sonication and centrifuged at 39000 g for about 10 min. at about 4°C. The pellet is resuspended in the same buffer and centrifuged at 50000 g for about 10 min. at about 4°C and membranes in resulting pellet are stored at -80°C.

Competitive inhibition experiments of [¹²⁵I-Tyr¹¹]SRIF-14 binding are run in duplicate in polypropylene 96 well plates. Cell membranes (10 μ g protein/well) are incubated with [¹²⁵I-Tyr¹¹]SRIF-14 (0.05 nM) for about 60 min. at about 37°C in 50 mM

HEPES (pH 7.4), 0.2% BSA, 5 mM $MgCl_2$, 200 KIU/ml Trasylol, 0.02 mg/ml bacitracin and 0.02 mg/ml phenylmethylsulphonylfluoride.

Bound from free [^{125}I -Tyr ^{11}]SRIF-14 is separated by immediate filtration through GF/C glass fiber filter plate (Unifilter, Packard) presoaked with 0.1 % polyethylenimine (P.E.I.), using Filtermate 196 (Packard) cell harvester. Filters are washed with 50 mM HEPES at about 0-4°C for about 4 sec. and assayed for radioactivity using Packard Top Count.

Specific binding is obtained by subtracting nonspecific binding (determined in the presence of 0.1 μ M SRIF-14) from total binding. Binding data are analyzed by computer-assisted nonlinear regression analysis (MDL) and inhibition constant (K_i) values are determined.

The determination of whether a compound of the instant invention is an agonist or an antagonist is determined by the following assay.

Functional assay: Inhibition of cAMP intracellular production:

CHO-K1 Cells expressing human somatostatin (SRIF-14) subtype receptors are seeded in 24-well tissue culture multidishes in RPMI 1640 media with 10% FCS and 0.4 mg/ml geneticin. The medium is changed the day before the experiment.

Cells at 10^5 cells/well are washed 2 times by 0.5 ml and fresh RPMI with 0.2% BSA supplemented with 0.5 mM (1) 3-isobutyl-1-methylxanthine (IBMX) and incubated for about 5 min at about 37°C.

- Cyclic AMP production is stimulated by the addition of 1mM forskolin (FSK) for about 15-30 minutes at about 37°C.
- The agonist effect of a compound is measured by the simultaneous addition of FSK (1 μ M), SRIF-14 (10^{-12} M to 10^{-6} M) and a test compound (10^{-10} M to 10^{-5} M).
- The antagonist effect of a compound is measured by the simultaneous addition of FSK (1 μ M), SRIF-14 (1 to 10 nM) and a test compound (10^{-10} M to 10^{-5} M).


The reaction medium is removed and 200 μ l 0.1 N HCl is added. cAMP is measured using radioimmunoassay method (Kit FlashPlate SMP001A, New England Nuclear).

The compounds of the instant invention are synthesized according to the following procedures and examples.

SYNTHESIS OF BROMOKETONES :

General Procedure: Two different methods can be applied: starting either from a carboxylic acid or an arylketone.

First method: Starting from a carboxylic acid (Macholan, L.; Skursky, L., *Chemistry*, 1955, 49, 1385-1388. Bestman, H.J., Seng, F., *Chem. Ber.*, 1963, 96, 465-469).




A carboxylic acid is first converted into an acyl chloride using oxalyl chloride or thionyl chloride or activated as a mixed anhydride with an alkylchloroformate (isobutylchloroformate (Krantz, A., Copp, L.J., *Biochemistry*, 1991, 30, 4678-4687) or ethylchloroformate (Podlech, J., Seebach, D., *Liebigs Ann.*, 1995, 1217-1228)) in the presence of a base (triethylamine or N-methyl morpholine).

The activated carboxyl group is then transformed into a diazoketone using ethereal diazomethane or trimethylsilyldiazomethane (Aoyama, T., Shiori, T., *Chem. Pharm. Bull.*, 1981, 29, 3249-3255) in an aprotic solvent such as diethyl ether, tetrahydrofuran or acetonitrile.

The bromination is then carried out using a brominating agent such as HBr in acetic acid, hydrobromic acid in water or in diethyl-ether.

Preparation 1

1-Bromo-3-(4-chloro-phenoxy)-3-methyl-butan-2-one :



To a solution of chloro-4-phenoxy-2-isobutyric acid (2.15 g, 10 mmol) in 10 ml of anhydrous dichloromethane at about 0°C were added oxalyl chloride (5.5 ml, 11 mmol of a 2M solution in dichloromethane) and DMF (2 drops, catalytic amount) via a septum under nitrogen atmosphere. The solution was stirred and allowed to warm up to room temperature over about 3 hrs. Concentration under reduced pressure afforded the crude acid chloride which was used directly without further purification.


The acylchloride was added dropwise at about 0°C to a solution of TMSCHN₂ (11 ml, 22 mmol) in THF-acetonitrile (1:1, 10 ml). The mixture was stirred at about 25°C for about 1 hour and then evaporated *in vacuo*.





A solution of the diazoketone in dichloromethane (10 ml) was added dropwise during about 10 minutes to a vigorously stirred mixture of concentrated hydrobromic acid (5 ml) in dichloromethane (20 ml). Nitrogen was evolved and a slight temperature rise occurred. After stirring for about a further 10 min., the mixture was diluted and the organic layer was washed with water (3 times 20 ml), dried over magnesium sulfate and evaporated. Flash chromatography of the residue eluting with AcOEt/Heptane (1:4) afforded the desired product with a yield of 79% (2.3g).

¹H-NMR in CDCl₃ (100 MHz) δ: 7.05 (m, 4 H, arom. H), 4.41 (s, 2 H, CH₂), 1.53 (s, 6H, 2 CH₃).

Preparations 2-6


The following compounds were prepared analogously to the procedure described for Preparation 1:



Prep. #	R	Yield
2		78%
3		60%
4		10%
5		79%
6		41%

* Compounds already described in literature.

Second method: Starting from a methyl ketone




A methyl ketone is converted to a bromoketone by using different brominating agents:

- CuBr₂ (King, L.C., Ostrum, G.K., *J. Org. Chem.*, 1964, 29, 3459-3461) heated in AcOEt or dioxane.
- N-bromosuccinimide in CCl₄.
- Bromine in glacial acetic acid or sulfuric acid.
- Phenyltrimethylammonium tribromide (Sanchez, J. P., Parcell, R. P., *J. Heterocyclic Chem.*, 1988, 25, 469-474) at 20-80 °C in an aprotic solvent such as THF.
- Use of a polymer supported brominating agent such as perbromide on Amberlyst A-26, poly(vinylpyridinium hydrobromide perbromide) resin (Frechet, J. M. J., Farrall, M. J., *J. Macromol. Sci. Chem.*, 1977, 507-514) in a protic solvent such as methanol at about 20-35°C for about 2-100 h.

Preparation 7

1-Bromo-2-(3,4,5-trimethoxy-phenyl)-ethanone :














To a solution of 3,4,5-trimethoxyacetophenone (2.1 g, 10 mmol) in methanol (30 ml) was added pyridine hydrobromide perbromide polymer (1.4 eq). The resulting mixture was shaken at room temperature for about 2 hours and the reaction was stopped by filtration. The polymer was washed with methanol and the filtrate was evaporated *in vacuo*. The product was then purified by flash chromatography (AcOEt/Heptane, 1:4) affording 1.5 g (53%) of a white solid.

¹H-NMR in CDCl₃ (100 MHz) δ : 7.2 (s, 2H, H arom.), 4.4 (s, 2H, CH₂), 3.9 (m, 9H, 3 OCH₃).

Preparations 8-17

The following compounds were prepared analogously to the procedure described for Preparation 7:




Prep. #	R	Reaction time (h)	Yield
8		8	78
9		7	72
10		85	62
11		2	62
12		10	56
13		2	53
14		8.5	27
15		3	43
16		3	77
17		3	95

* Compound already described in literature.

SYNTHESIS OF IMIDAZOYL COMPOUNDS :


General Procedure: An amino acid is transformed to its cesium salt using
 5 cesium carbonate in a polar solvent such as DMF/H₂O (1:1) or EtOH/H₂O (1:1). An

ester is then obtained using an appropriate bromoketone in a polar aprotic solvent such as dry DMF. The cesium bromide formed is filtered off and ammonium acetate is added in an aprotic solvent having a high boiling point such as xylene or toluene or in a protic acidic solvent such as acetic acid. The mixture is refluxed using a Dean-Stark trap for about 0.5-10 hours. In the scheme immediately below, PG is a protecting group, preferably a carbamate, such as t-Boc or benzyl carbamate.



Example 1

2-((1S)-1-(tert-butoxycarbonylamino)-2-((1H)-indol-3-yl)ethyl)-4-(2-methoxyphenyl)-1H-imidazole :



A solution of Boc-(D,L)-Trp-OH (10 g, 32.8 mmol) and cesium carbonate (0.5 eq., 5.34 g) in EtOH/H₂O (1:1, 70 ml) was shaken for about 30 minutes at room temperature, and then concentrated *in vacuo* at about 40°C.

To the resulting salt in 40 mL of dry DMF was added 40ml of a solution of 2-bromo-2'-methoxyacetophenone (7.66 g, 1 eq.) in dry DMF. The mixture was stirred for about 1 hr at room temperature under argon and then concentrated under reduced pressure. Ethyl acetate was added (100 ml), the mixture filtered, and the CsBr washed with ethyl acetate. The filtrate was then concentrated under reduced pressure.

A solution of the foregoing filtrate and ammonium acetate (50.5 g, 20 eq.) in xylene (240 ml) was refluxed for about 3 hours at about 150°C. Excess NH₄OAc and H₂O were removed using a Dean-Stark trap. The progress of the reaction was monitored by T.L.C. (eluent: CH₂Cl₂:MeOH, 95:5). The mixture was then concentrated under reduced pressure. The resulting residue was dissolved in ethyl acetate (100 ml) and washed with saturated aqueous NaHCO₃ solution until basic pH, and with brine


until neutral pH. The organic layer was then dried over MgSO_4 , and concentrated under reduced pressure.

Purification of the resulting residue by flash chromatography (eluent: $\text{CH}_2\text{Cl}_2:\text{MeOH}$, 95:5) afforded the desired compound (8.7 g, yield: 61%).

- 5 $^1\text{H-NMR}$ (CDCl_3 , 100 MHz) δ : 8.00 (s, 1H, NH), 7.80 (m, 2H, arom. H), 7.20 (m, 9H, arom. H, NH), 5.40 (m, 1H, NH), 5.10 (m, 1H, CH), 3.80 (s, 3H, OCH_3), 3.50 (m, 2H, CH_2), 1.50 (s, 9H, 6 CH_3). LC/MS : m/z = 433.3 (M+H).

Example 2

- 10 *N*-[2-*tert*butoxycarbonylamino ethyl]-2-{2-[(1*S*)-1-(*tert*butoxycarbonylamino)-2-(1*H*)-indol-3-yl)ethyl]-1*H*-imidazol-4-yl}-isobutyramide :



- A solution of the 2-{2-[(1*S*)-1-(*tert*butoxycarbonylamino)-2-(indol-3-yl)ethyl]-1*H*-imidazol-4-yl}-2-methyl-propionic acid-methyl ester 1 (2.6g, 6 mmol), (prepared according to the procedure described in Example 1) and $\text{LiOH}\cdot\text{H}_2\text{O}$ (1.7g, 6.6 eq.) in THF (50 ml) were stirred at about 80°C for about 3 hours. The progress of the reaction was monitored by t.l.c. ($\text{CH}_2\text{Cl}_2:\text{MeOH}$, 95:5). The resulting mixture was then concentrated *in vacuo*. About 50 ml of water was added to the residue which was then acidified with glacial acetic acid until about pH 5. The product of the reaction was then extracted with ethyl acetate (3 x 50 ml) and washed with brine until neutral pH. The organic layer was dried with MgSO_4 , and concentrated under reduced pressure. The resulting intermediate 2 was obtained after crystallization in diethyl ether with a yield of 80% (2g). $^1\text{H-NMR}$ (400 MHz, DMSO) δ : 10.9 (s, 1H, NH), 7.1 (m, 7H, arom. H, NH), 5.00 (m, 1H, CH), 3.3 (m, 2H, CH_2), 1.3 (m, 15H, 5 CH_3). LC/MS : m/z = 525.1 (M+TFA), m/z = 413.2 (M+H).

The 2-{2-[(1S)-1-(tert-butoxycarbonylamino)-2-[(1H)-indol-3-yl]ethyl]-1H-imidazol-4-yl}-2-methyl-propionic acid **2** can be activated preferentially by carbonyldiimidazole in an aprotic solvent such as THF or DMF at about 20-100°C for about 1-4 hours.

A solution of the acid **2** (1g, 2.4 mmol) and carbonyldiimidazole (0.39g, 2.4 mmol) in dry THF (20 ml) was shaken for about 1 hour at room temperature (25°C).

N-Boc-ethylene-diamine (0.43g, 2.7 mmol) was added and the mixture was shaken for about 1 hour at about 25°C.


The mixture was diluted in ethyl acetate (100 ml) and washed with saturated aqueous NaHCO₃ solution (2 x 50 ml) and brine until neutral pH. The organic layer was then dried over MgSO₄ and concentrated *in vacuo*.

Purification of the resulting residue by flash-chromatography (in CH₂Cl₂:MeOH, 95:5) afforded the desired product **3** with a yield of 77% (1g).



¹H-NMR (400 MHz, DMSO) δ : 11.6 (s, 1H, NH), 10.7 (s, 1H, NH), 7.00 (m, 9H, arom. H, NH), 4.8 (m, 1H, CH), 3.00 (m, 6H, 3 CH₂), 1.3 (m, 24H, 8 CH₃). LC/MS : m/z = 667.3 (M+TFA), 555.3 (M+H).

Examples 3-1178

The following compounds were prepared analogously to the procedure described for Example 1 or 2 using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R³, R⁵ shown below, were or can be synthesized, therefore, the number of Examples are calculated by multiplying (PG (2 substituents)R³ (12 substituents)(R⁵ (49 substituents)) = 1176.




PG can also be hydrogen in the foregoing formula.


R³:R⁵:

* for this substituent, the corresponding imidazole derivative was obtained after deprotection via catalytic hydrogenation of the benzyloxyphenyl substituent


** for this substituent, the corresponding imidazole derivative was obtained after deprotection via catalytic hydrogenation of the nitrophenyl substituent

5

Z³:



SYNTHESIS OF AMIDES FROM IMIDAZOYL INTERMEDIATES




General procedure: Carboxylic acids are activated overnight at room temperature with carbonyldiimidazole in an aprotic solvent such as chloroform, THF or THF/DMF before addition of an amino starting material as shown above followed by a further 12-15 hours of stirring. The excess acylating agent is quenched with aminomethylated resin for about 12-15 hours and then purified on silica gel pad with dichloromethane or ethyl acetate as eluent.

For protected basic derivatives ($R^3 = (CH_2)_4NHBoc$ and/or X^2 containing $NHBoc$ group), the corresponding deprotected compounds were obtained after treatment under acidic condition (DCM/TFA 10%) to remove the Boc group.

Example 1179

2-((1S)-1-[(2-Furanyl)carbonylamino]-2-[indol-3-yl]ethyl)-4-phenyl-1H-imidazole ($C_{24}H_{23}N_4O_2$ MW=396.45):




2-Furancarboxylic acid (12.6 mg, 0.11 mmol) was activated overnight at about 22°C with carbonyldiimidazole (0.11 mmol, 0.2M in chloroform). 2-((1S)-1-Amino-2-[indol-3-yl]ethyl)-4-phenyl-1H-imidazole (0.1 mmol, 0.5M in chloroform) was added to the media and the mixture was stirred for about 12 hours at about 22°C. Aminomethylated resin was then added (50-60 mg, 1.2 mmol/g, Novabiochem) in order to quench the excess of acylating agent for about 12 hours. Purification on silica gel pad (200 mg, Alltech) with ethyl acetate as eluent gave the expected product (37.2 mg,


94%). ¹H-NMR (CDCl₃, 100MHz) δ: 8.36 (br s, 1H); 7.67-6.4 (m, 16H); 5.48 (qd, J=7.1Hz, 1H); 3.6 (ABX system, 2H). LC/MS: m/z = 397 (M+H).

Examples 1180 - 3615


The following compounds were prepared analogously to the procedure described for Example 1179 using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R³, R⁵ and X², shown below, were or can be synthesized, therefore, the number of Examples are calculated by multiplying (R³ (4 substituents))(R⁵ (7 substituents))(X² (87 substituents)) = 2436.




R³:




R⁵:




15

$x^2:$ 



SYNTHESIS OF UREAS AND THIOUREAS FROM IMIDAZOYL INTERMEDIATES

From isocyanates and isothiocyanates:



5


General procedure: Isocyanates or isothiocyanates are shaken overnight at room temperature with an imidazoyl intermediate in an aprotic solvent like dichloromethane, chloroform or chloroform/DMF. The reaction is quenched by addition of aminomethylated resin for about 12-15 hours and purified on silica gel pad with ethyl acetate as eluent.

10

For protected basic derivatives ($R^3 = (CH_2)_4NHBoc$), the corresponding deprotected compounds were obtained after treatment under acidic condition (DCM/TFA 10%) to remove the Boc group.

Example 3616


- 15 2-((1R)-1-((2,4-Difluorophenyl)aminocarbonylamino)-2-[indol-3-yl]ethyl)-4-phenyl-1H-imidazole ($C_{29}H_{27}F_2N_5O$, MW=457.49):




2,6-Difluorophenylisocyanate (36 μ L, 0.3 mmol) and 2-((1*R*)-1-amino-2-[indol-3-yl]ethyl)-4-phenyl-1H-imidazole (60.4 mg, 0.2 mmol) were stirred overnight in 2 mL of anhydrous dichloromethane. Filtration and purification by flash chromatography on silica gel (ethyl acetate/heptane 1:1 as eluent) afforded the expected product as a white powder (27 mg, 30%). $^1\text{H-NMR}$ (DMSO D_6 , 400MHz) δ : 12.03 (s, 1H); 10.77 (s, 1H); 8.47 (s, 1H); 8.1 (dd, 1H); 7.8-6.92 (m, 14H); 5.11 (dd, $J=7$ and 14Hz, 1H); 3.3 (m, 2H). LC/MS: m/z = 458 (M+H).

Examples 3617 - 4435


The following compounds were prepared analogously to the procedure described for Example 3616, using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R^3 , R^5 , and X^2 with Y is O or X^2 with Y is S, shown below, were or can be synthesized, therefore, the number of Examples are calculated by multiplying (R^3 (3 substituents))(R^5 (7 substituents))(X^2 (39 substituents)) = 819.




R^3 :




R^5 :



X² when Y is O:




X² when Y is S:




From carbamate intermediates and primary and secondary amines:

General Procedure: The preparation of carbamate intermediates is described in the literature (Takeda, K. et al., *Tetrahedron Letters* **1983**, *24*, 4569-4572; Nimura, N. et al., *Anal. Chem.* **1986**, *58*, 2372-2375) from amino derivatives and N,N'-disuccinimidylcarbonate in acetonitrile at room temperature.




Example 4436

- 10 2-[(1R)-1-[(2,5-Dioxo-1-pyrrolidinyloxy)carbonylamino]-2-[indol-3-yl]ethyl]-4-phenyl-1H-imidazole (C₂₄H₂₁N₅O₄, MW=443.46):



302.4 mg (1 mmol) of 2-((1*R*)-1-amino-2-[indol-3-yl]ethyl)-4-phenyl-1*H*-imidazole previously dissolved in 20 mL of anhydrous acetonitrile was added dropwise to a solution of *N,N'*-disuccinimidylcarbonate (528 mg, 2 mmol, DSC) in 20 mL of anhydrous acetonitrile during 1.5 hour. After a further 4 hours of stirring at room temperature, the solvent was evaporated *in vacuo* and the residue redissolved in 30 mL of chloroform. Excess DSC was then discarded and the organic layer washed with water (4x30 mL), dried over MgSO_4 and concentrated to obtain a brown solid (215 mg, 49%). $^1\text{H-NMR}$ (CDCl_3 , 100 MHz) δ : 8.22 (br s, 1H) ; 8.1-7.08 (m, 12H) ; 5.9 (br s, 1H) ; 4.97 (dd, $J=3.6$ and 9.3Hz, 1H) ; 3.75 (dd, $J=3.6$ and 14.8Hz, 1H) ; 3.06 (dd, $J=9.7$ and 14.6Hz, 1H) ; 2.96 (s, 2H) ; 2.89 (s, 2H). LC/MS : m/z = 329 (($\text{M}+\text{H}$)- SuOH).




General procedure: A primary or secondary amine is stirred for about 2-15 hours at room temperature with a carbamate intermediate in an aprotic solvent like acetonitrile. Tetrahydrofuran and aminomethylated resin are then added and the reaction is then stirred for about 12-15 hours. Ureas are isolated after filtration, rinsed with ethyl acetate and evaporated *in vacuo*.

For protected basic derivatives ($\text{R}^3 = (\text{CH}_2)_4\text{NHBoc}$), the corresponding deprotected compounds were obtained after treatment under acidic condition (DCM/TFA 10%) to remove the Boc group.

Example 4437


2-((1*R*)-1-[(Benzylamino)carbonylamino]-2-[indol-3-yl]ethyl)-4-phenyl-1*H*-imidazole ($\text{C}_{27}\text{H}_{25}\text{N}_5\text{O}$, $\text{MW}=435.53$):





Benzylamine (5 μ L, 50 mmol) and 2-((1*R*)-1-amino-2-[indol-3-yl]ethyl)-4-phenyl-1H-imidazole (24 mg, 54 mmol) were stirred for about 2 hours at room temperature in anhydrous acetonitrile. Aminomethylated resin (50 mg, 0.75 mmol/g, Novabiochem) was then added and after further stirring overnight, the title product was obtained by filtration on silica gel pad (200 mg) and evaporated *in vacuo* as a brown powder (20 mg, 92%). ¹H-NMR (DMSO *d*₆, 100 MHz) δ : 10.8 (br s, 1H); 7.9-6.88 (m, 17H); 6.53 (m, 2H); 5.12 (dd, *J*=6 and 14.6Hz, 1H); 4.28 (m, 2H); 3.25 (m, 2H). LC/MS: *m/z* = 436 (M+H).

Examples 4438 - 8469


The following compounds were prepared analogously to the procedure described for Example 4437, using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R³, R⁵ and NX¹X², shown below, were or can be synthesized, therefore, the number of Examples are calculated by multiplying (R³ (3 substituents))(R⁵ (12 substituents))(NX¹X² (112 substituents)) = 4032.




20 R³:



R⁵:




Z^3 :




$$X^1 X^2 N:$$

Primary amines




Secondary amines



SYNTHESIS OF SECONDARY AMINES BY REDUCTIVE AMINATIONS OF IMIDAZOLYL INTERMEDIATES

(Kaldor, S.W.; Siegel, M.G.; Fritz, J.E.; Dressman, B.A.; Hahn, P.J.
Tetrahedron Letters 1996, 37, 7193-7196)



5

General procedure: Condensation of aldehydes with an imidazolyl intermediate in a protic solvent like methanol yields imines which are reduced in presence of AMBERLITE® IRA-400 borohydride. The slurry is then shaken overnight and the excess amino intermediate is quenched by addition of dichloromethane and aldehyde Wang resin. After further overnight stirring, the mixture is filtered, evaporated and purified on silica gel pad with ethyl acetate as eluent.


10

For protected basic derivatives ($R^3 = (CH_2)_4NHBoc$), the corresponding deprotected compounds were obtained after treatment under acidic condition (DCM/TFA 10%) to remove the Boc group.

15

Example 8470

2-((1R)-1-[(4-Methoxybenzyl)amino]-2-[indol-3-yl]ethyl)-4-phenyl-1H-imidazole ($C_{27}H_{26}N_4O$, MW=422.54):




2-((1R)-1-Amino-2-[indol-3-yl]ethyl)-4-phenyl-1H-imidazole (36.3 mg, 0.12 mmol) and p-anisaldehyde (12 μ L, 0.1 mmol) in 1 mL of methanol were shaken for about 2 hours at about 22°C. Borohydride resin (76 mg, 2.5 mmol/g, AMBERLITE® IRA-400) was then added and the slurry was stirred overnight before addition of dichloromethane

20



(1 mL) and aldehyde Wang resin (31 mg, 3.22 mmol/g, Novabiochem). After about 8 hours of stirring, the slurry was then filtered and evaporated *in vacuo* to give a yellow solid (32.2 mg, 76%). ¹H-NMR (CDCl₃, 100MHz) δ: 8.86 (br s, 1H); 7.73-6.68 (m, 15H); 4.62 (s, 1H); 4.33 (dd, J=4.7 and 8.5Hz, 1H); 3.81 (s, 2H); 3.74 (s, 3H); 3.27 (ABX system, 2H); 2.26 (s, 1H). LC/MS : m/z = 423 (M+H).

Examples 8471 - 9331






The following compounds were prepared analogously to the procedure described for Example 8470, using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R³, R⁵ and A¹, shown below, were or can be synthesized, therefore, the number of Examples are calculated by multiplying (R³ (3 substituents))(R⁵ (7 substituents))(X² (41 substituents)) = 861.




R³:




R⁵:



A¹:

SYNTHESIS OF AMIDINES BY CONDENSATION OF AN IMIDAZOLYL WITH THIOIMIDATES




5 A series of thioimides were previously synthesized by condensation of thioamides and iodomethane in acetone at room temperature. The precipitate was collected and then rinsed with acetone. Thioimides so formed were used without further purification.

General procedure: Thioimides are stirred overnight at room temperature with
 10 an amino intermediate in 2-propanol or 2-propanol/DMF before addition of tetrahydrofuran and aminomethylated resin. Further stirring overnight followed by filtration and washing with ethyl acetate yields an iodohydrate amidine after evaporation *in vacuo*.

For protected basic derivatives ($R^3 = (CH_2)_4NH\text{Boc}$), the corresponding
 15 deprotected compounds were obtained after treatment under acidic condition (DCM/TFA 10%) to remove the Boc group.

Example 9332

2-((1*R*)-1-[(2-Thienyl(imino)methyl)amino]-2-[indol-3-yl]ethyl)-4-phenyl-1*H*-imidazole hydroiodide ($C_{24}H_{21}N_5S.HI$, MW=539.43) :



20


2-((1*R*)-1-Amino-2-[indol-3-yl]ethyl)-4-phenyl-1*H*-imidazole (15.1 mg, 0.05 mmol) and *S*-methyl-2-thiophenethiocarboximide hydroiodide (13 mg, 0.06 mmol) were shaken in 1 mL of 2-propanol for about 16 hours. Aminomethylated resin (50 mg, 1.31 mmol/g,

Novabiochem) was then added and after further stirring overnight, a brown solid (19.8 mg, 84%) was isolated by filtration and evaporation *in vacuo*. ¹H-NMR (MeOD, 100MHz) δ : 8.15 (m, 1H); 7.84-6.96 (m, 13H); 5.3 (m, 1H); 3.61 (m, 2H). LC/MS :m/z = 412 (M+H).


5


Examples 9333 - 9920

The following compounds were prepared analogously to the procedure described for Example 9332, using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R³, R⁵ and X², shown below, were or can be synthesized, therefore, the number of Examples are calculated by multiplying (R³ (7 substituents))(R⁵ (7 substituents))(X² (12 substituents)) = 588.




15

X²:





SYNTHESIS OF AMIDINES BY CONDENSATION OF AN ANILINE WITH THIOIMIDATES




Examples 9921 - 9926

The following compounds were prepared analogously to the procedure described for Example 9332, using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R^4 and X^7 , shown below, were or can be synthesized, therefore, the number of Examples are calculated by multiplying (R^4 (2 substituents))(X^7 (3 substituents)) = 6.




IMIDAZOLE DERIVATIVES N-ALKYLATION



General procedure: A solution of an imidazole intermediate, an alkylating agent such as an α -bromoketone, an α -bromoester, an aryl or alkyl bromide or a sulfonyl chloride, in the presence of an organic or non-organic base which can be or not be supported on a resin such as polystyrene resin, in an aprotic solvent like THF, CH₃CN, DMF is heated at 20-80°C for 2-48 hours. The resulting *N*-alkylated compound can be isolated either by aqueous work-up followed by flash chromatography on silica gel, or by addition to the reaction mixture of a nucleophile supported on polymer (to trap the excess of electrophile) such as aminomethyl or thiomethyl polystyrene resin followed by filtration and then rapid purification of the resulting residue on a silica gel pad (using Alltech silica cartridge and Alltech manifold).

Example 9927

2-[1(S)-{(1,1-Dimethylethoxy)carbonylamino}-2-phenylethyl]-1-(2-oxo-butyl)-4-phenyl-1H-imidazole




15


To a solution of 2-[1(S)-{(1,1-dimethylethoxy)carbonylamino}-2-phenylethyl]-4-phenyl-1H-imidazole (100 mg, 1eq) in DMF (2 mL) were successively added morpholinomethyl polystyrene resin (Novabiochem, loading : 3.51 mmol/g, 159 mg, 2 eq) and 1-bromo-2-butanone (28 mL, 2 eq). After about 18 hours of stirring at about 20°C, 2 mL DMF were added to the reaction mixture followed by aminomethylpolystyrene resin (Novabiochem, loading : 1.73 mmol/g, 319 mg). The mixture was stirred overnight at 20°C and filtered. The filtrate was concentrated under reduced pressure and then purified by a rapid filtration on a silica gel pad (Alltech silica

cartridges) with ethylacetate as eluent to yield 107 mg (90% yield) of the title compound. NMR (^1H , 400 MHz, CDCl_3) δ : 7.80-6.98 (m, 11H, arom. H), 5.45 (d, 1H, NH), 4.80 (m, 1H, CH), 4.40 (AB, $J = 18\text{Hz}$, NCH_2CO), 3.33 (m, 2H, CH_2Ph), 2.25 (m, 2H, CH_2CH_3), 1.0 (t, 3H, CH_3). LC/MS: calculated MW = 433.5, $m/z = 434.2$ ($\text{M}+\text{H}$), $m/z = 432.2$ ($\text{M}-\text{H}$).

Examples 9928 - 12307


The following compounds were prepared analogously to the procedure described for Example 9927, using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R^3 , R^5 and R^1 , shown below, were or can be synthesized, therefore, the number of Examples are calculated by multiplying (R^1 (34 substituents {see definitions of Z^1 }))(R^3 (5 substituents))(R^5 (14 substituents)) = 2380.




R⁵:

*In case of bromide derivatives, cesium carbonate was used instead of
5 morpholinomethylpolystyrene resin and thiomethyl resin was used instead of
aminomethylresin.

Z¹:




IMIDAZO-PYRAZINES



5 General procedure: Intermediate (a) is treated with an acidic solution preferably TFA in DCM at about 20-30°C for about 1-4 hours. The mixture is then concentrated under reduced pressure to afford a dihydro-imidazo-pyrazine.

Example 12308


5,8-Dihydro-8-(3-indolyl)methyl-2,6-diphenyl-imidazo[1,2-a]pyrazine :




A solution of 2-[1(S)-{1,1-dimethylethoxy)carbonylamino}-2-(3-indolyl)ethyl]-1-(benzoylmethyl)-4-phenyl-1H-imidazole (prepared as described previously) (100 mg) in a mixture of 10% TFA in DCM (1.3 mL) was stirred for about 3 hours at about 20°C and concentrated under reduced pressure to yield the expected dihydro-imidazo-pyrazine (yield = 95%). LC/MS : calculated MW : 402.19, m/z = 403.2 (M+H).


Examples 12309 - 12532

10 The following compounds were prepared analogously to the procedure described for Example 12308, using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R⁵ and R⁷, shown below, were or can be synthesized, therefore, the number of Examples are
15 calculated by multiplying (R⁵ (7 substituents))(R⁷ (32 substituents)) = 224.




R⁵:



R⁷:

IMIDAZO-PYRAZINES




5

General procedure: Intermediate (b) is treated with an acidic solution preferably TFA in DCM at 20-30°C for 1-4 hours. The mixture is then concentrated under reduced pressure to afford compound (c) which is oxidized to the corresponding fully aromatized imidazopyrazine either by keeping it in solution in methanol or DMSO for 5 hours-3 days at about 20°C or by using an oxidative reagent such as manganese dioxide in a protic or aprotic solvent such as MeOH, toluene or chloroform at 20-70°C for 2-10 hours or

chromic acid supported or not on a resin in a protic solvent like methanol at 40-70°C for 3-15 hours.

Example 12533

2,6-Diphenyl-imidazo[1,2-a]pyrazine-8-butanamine :



5


A solution of 2-[1,5-bis((1,1-dimethylethoxy)carbonylamino)pentyl]-4-phenyl-1H-imidazole (50 mg) in a mixture of TFA/DCM 10% (700 mL) was stirred at about 20°C for about 3 hours and then concentrated under reduced pressure to yield the intermediate dihydro-imidazo-pyrazine as its trifluoroacetate salt. This salt was dissolved in MeOH (1mL) and manganese dioxide (30 mg) was added. After about 3 hours of stirring at about 20°C, the mixture was filtered on a CELITE® pad and the filtrate concentrated under reduced pressure to afford the fully aromatized imidazo-pyrazine (78% yield).
 NMR (¹H, 400 MHz, CD₃OD) : 8.75-7.34 (m, 12H, arom. H), 3.32 (m, 4H, CH₂), 2.10 (m, 2H, CH₂), 1.90 (m, 2H, CH₂). LC/MS : calculated MW = 342.4, m/z = 343.2 (M+H).



15

Examples 12534 - 13773


The following compounds were prepared analogously to the procedure described for Example 12533, using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein. Each combination of R³ and R⁷, shown below, were or can be synthesized, therefore, the number of Examples are calculated by multiplying (R³ (5 substituents))(R⁵ (8 substituents))(R⁷ (31 substituents)) = 1240.

20




R³:R⁵:

R⁷:



TETRAHYDRO-IMIDAZO-PYRAZINES



5


General procedure: Intermediate (d) is treated with an acidic solution preferably TFA in DCM at 20-30°C for 1-4 hours. The mixture is then concentrated under reduced pressure to afford the intermediate dihydro-imidazopyrazine (e). Reduction of (e) to the

corresponding tetrahydro-imidazopyrazine is achieved by catalytic hydrogenation or by using any reducing agent such as NaBH_4 (which can be supported on a resin), $\text{NaBH}(\text{OAc})_3$, NaBH_3CN in a protic solvent such as MeOH at pH maintained weakly acidic (around pH 5) by addition of acetic acid or TFA.

5

Example 13774

6-Ethyl-5,6,7,8-tetrahydro-2-phenyl-8(S)-phenylmethyl-imidazo[1,2-a]pyrazine :




2-[1(S)-{1,1-Dimethylethoxy)carbonylamino}-2-phenylethyl]-1-(2-oxo-butyl)-4-phenyl-1H-imidazole (60 mg) in a mixture of 10% TFA in DCM was stirred at about 20°C for about 3 hours and then concentrated under reduced pressure. The resulting intermediate dihydro-imidazo-pyrazine was dissolved in methanol and borohydride supported on resin (AMBERLITE® IRA 400, Aldrich, 2.5 mmol BH_4^-/g ; 4 eq) was added. The pH was maintained at about 5 by addition of drops of TFA. After about 2 hours of stirring at about 20°C, the mixture was filtered and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (ethyl acetate/Heptane 7:3 ; R_f = 0.30). The tetrahydro-imidazo-pyrazine was obtained as a single diastereoisomer in 86% yield (38 mg). NMR (^1H , 400 MHz, CDCl_3) δ : 7.80-7.10 (m, 11H, arom. H), 4.28 (dd, 1H, ^3J = 10 Hz, ^3J = 3 Hz, H8), 3.95 (dd, 1H, ^2J = 11.5 Hz, ^3J = 3.6 Hz), 3.85 (dd, 1H, ^2J = 13.6 Hz, ^3J = 3.0 Hz), 3.60 (t, 1H, ^2J = ^3J = 11.5 Hz), 3.85 (dd, 1H, ^2J = 13.6 Hz, ^3J = 10. Hz), 2.98 (m, 2H), 1.85 (s, 1H, NH), 1.55 (m, 2H, CH_2), 0.95 (t, 3H, CH_3). NMR (^{13}C , 100 MHz, CDCl_3) : 146.3, 140.9, 138.0, 134.4, 129.4, 128.6, 128.5, 126.6, 126.5, 124.8, 113.8, 55.9, 54.4, 50.2, 40.0, 26.6, 10.0. LC/MS : calculated MW = 317.43, m/z = 318.20 (M+H).


Example 13775

25

The following compound was prepared analogously to the procedure described for Example 13774 using the appropriate starting materials, which can be obtained from commercial sources or synthesized according to methods known to those skilled in the art or as enabled by the teachings herein.




N-SUBSTITUTED TETRAHYDRO-IMIDAZO-PYRAZINES



General procedure: A compound of formula (f) can react with isocyanates, isothiocyanates, N-succinimidyl carbamates, acyl chlorides or activated carboxylic acids in an aprotic solvent at 20-70°C for 2-18 hours. The resulting derivative can be isolated by evaporation of the mixture followed by flash chromatography on silica gel or by addition to the mixture of a nucleophile supported on polymer such as aminomethyl or thiomethyl polystyrene resin followed by a filtration.

Example 13776

5,6,7,8-Tetrahydro-7-(methoxymethylcarbonyl)-2,6-diphenyl-8(S)-phenylmethyl-imidazo[1,2-a]pyrazine



To a solution of 5,6,7,8-tetrahydro-2,6-diphenyl-8(S)-phenylmethyl-imidazo[1,2-a]pyrazine (29 mg) in chloroform were successively added morpholinomethylpolystyrene resin (Novabiochem, loading = 3.51 mmol/g, 50 mg, 2eq) and methoxyacetylchloride (10 mL, 1.3 eq). After about 3 hours of stirring at about

20°C, chloroform was added to the mixture followed by aminomethylpolystyrene resin (Novabiochem, loading = 1.2 mmol/g, 132 mg, 2 eq). The reaction mixture was stirred for another 2 hours and then filtered. The filtrate was concentrated under reduced pressure to afford 23 mg of the title compound (yield = 68%). NMR (¹H, 100 MHz, CDCl₃) : 7.9-7.0 (m, 16H, arom. H), 6.6 (m, 1H, H₈), 5.3 (m, 1H, H₄), 4.6 (dd, 1H, ²J = 13Hz, H5), 4.35 (dd, 1H, ²J = 13 Hz, ³J = 5 Hz, H5'), 3.7-2.9 (m, 5H, CH₂Ph, OCH₃).

The following tables of compounds illustrate some of the compounds of the present invention that were synthesized and provide the hplc retention time (denoted Rt or Tr) in minutes and mass spectra results of each compound.

Mass spectra were acquired on a single quadrupole electrospray mass spectrometer (Micromass, Platform model), 0.8 Da resolution. A monthly calibration, between 80 and 1000 Da, is performed with sodium and rubidium iodide solution isopropanol/water (1/1 Vol.).

HPLC retention times were acquired on an HPLC system: HP1100 (Hewlett-Packard) equipped with a photodiode array UV detector.

The HPLC conditions are as follows and the conditions used for each of the following tables of compounds are noted below, the wavelength of the UV detector is noted in parenthesis after the formula number.

Condition A :

Solvent : A : Water + 0.4% Formic acid
B : Acetonitrile + 0.4% Formic acid

T(min)	A%	B%
0	90	10
5	90	10
16	40	60
17	10	90
20	10	90

Flow rate: 1 ml/min

Injection volume : 20 µL

Column : Kromasil ODS 5µm 150*4.6 mm i.d.

Temp. : 40 °C

Condition A₂ :

Solvent : A : Water + 0.4% Formic acid
 B : Acetonitrile + 0.4% Formic acid

T(min)	A%	B%
0	90	10
2	90	10
14	10	90
20	10	90

5

Flow rate : 1 ml/min
 Injection volume : 20 μ L
 Column : Kromasil ODS 5 μ m 150*4.6 mm i.d.
 Temp. : 40 °C

10 **Condition A₃ :**

Solvent : A : Water + 0.4% Formic acid
 B : Acetonitrile + 0.4% Formic acid

T(min)	A%	B%
0	90	10
5	90	10
16	46	54
17.5	10	90
22	10	90

15

Flow rate : 1 ml/min
 Injection volume : 20 μ L
 Column : Kromasil ODS 5 μ m 150*4.6 mm i.d.
 Temp. : 40 °C

Condition A_s :

Solvent : A : Water + 0.4% Formic acid
B : Acetonitrile + 0.4% Formic acid

T(min)	A%	B%
0	90	10
5	90	10
20	10	90
25	10	90

5

Flow rate : 1 ml/min
Injection volume : 20 μ L
Column : Kromasil ODS 5 μ m 150*4.6 mm i.d.
Temp. : 40 °C

10 **Condition A_s :**

Solvent : A : Water + 0.4% Formic acid
B : Acetonitrile + 0.4% Formic acid

T(min)	A%	B%
0	90	10
5	90	10
25	10	90
30	10	90

15

Flow rate : 1 ml/min
Injection volume : 20 μ L
Column : Kromasil ODS 5 μ m 150*4.6 mm i.d.
Temp. : 40 °C

Condition B :

Solvent : A : Water + 0.02% Trifluoroacetic acid

B : Acetonitrile

T(min)	A%	B%
0	100	0
1	100	0
8	30	70
10	30	70

5

Flow rate : 1.1 ml/min

Injection volume : 5 μ LColumn : Uptisphere ODS 3 μ m 33*4.6 mm i.d.

Temp. : 40 °C

Condition C :

10 Solvent : A : Water + 0.02% Trifluoroacetic acid

B : Acetonitrile

T(min)	A%	B%
0	100	0
1	100	0
10	85	25
12	85	25

15

Flow rate : 1.1 ml/min

Injection volume : 5 μ LColumn : Uptisphere ODS 3 μ m 33*4.6 mm i.d.

Temp. : 40 °C

Condition D :

Solvent : A : Water + 0.04% Trifluoroacetic acid

20

B : Acetonitrile

T(min)	A%	B%
0	100	0
1	100	0
8	30	70
10	30	70

Flow rate : 1.1 ml/min
 Injection volume : 5 μ L
 Column : Uptisphere ODS 3 μ m 33*4.6 mm i.d
 Temp. : 40 °C

Condition E :


Solvent : A : Water + 0.04% Trifluoroacetic acid
 B : Acetonitrile

T(min)	A%	B%
0	90	10
1	90	10
8	0	100
10	0	100

Flow rate : 1.1 ml/min
 Injection volume : 5 μ L
 Column : Uptisphere ODS 3 μ m 33*4.6 mm i.d
 Temp. : 40 °C


















In the following description Formula numbers are noted in bold and the the wavelength is in parenthesis.


- > Method A = Used for Tables of compounds of Formulas: **17** (250), **18** (250) and **57** (220).
- > Method A_u = Used for Tables of compounds of Formulas: **58** (210). –
- > Method B = Used for Tables of compounds of Formulas: **7** (220), **8** (220), **9** (220), **10** (220), **11** (220), **12** (250), **19** (220), **20** (260), **21** (250), **25** (240), **26** (220), **27** (220), **28** (220), **29** (220), **37** (220), **38** (220), **39** (220), **40** (240), **44** (220), **45** (220), **46** (220), **47** (220), **48** (220), **49** (250), **55** (260), and **56** (220).
- > Method C = Used for Tables of compounds of Formulas: **1** (220), **2** (220), **3** (220), **4** (260), **5** (220), **6** (220), **13** (220), **14** (220), **16** (260), **23** (250), **24** (250), **30** (220), **31** (254), **32** (250), **33** (250), **34** (250), **35** (250), and **36** (254).
- > Method D = Used for Tables of compounds of Formulas: **15** (220), **51** (220), **52** (220), **53** (220), and **54** (220).
- > Method E = Used for Tables of compounds of Formulas: **22** (250), **41** (220), **42** (250), **43** (220), and **50** (250).



FORMULA 1
















	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
1			7.0	666.5
2			7.1	668.5
3			6.2	712.5
4			6.1	698.5
5			5.0	649.5
6			7.2	656.5
7			6.2	658.5


				
FORMULA 1				
	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
8			6.4	543.5
9			6.7	661.5
10			7.0	689.5
11			5.8	661.4
12			5.3	657.5
13			5.4	701.5
14			6.2	733.5
15			6.7	653.5



FORMULA 1


	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
16			5.5	659.5
17			4.8	611.4
18			6.4	681.5
19			6.4	667.5
20			5.4	671.5
21			7.2	680.5
22			7.2	682.5

				
FORMULA 1				
	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
23			6.4	726.5
24			6.2	712.5
25			5.1	663.5
26			7.2	670.5
27			6.3	672.5
28			6.6	667.5
29			6.8	675.5




FORMULA 1

	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
30			7.1	703.5
31			5.9	675.4
32			5.4	671.5
33			5.5	715.5
34			6.3	747.5
35			6.8	667.5
36			5.6	673.5
37			4.9	625.5




















FORMULA 1














	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
38			6.5	681.5
39			6.5	695.5
40			5.5	685.5
41			7.2	694.5
42			7.3	696.5
43			6.4	740.5




FORMULA 1

	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
44			6.3	726.5
45			5.2	677.5
46			7.3	684.5
47			6.4	686.5
48			6.6	671.5
49			6.8	689.5
50			7.1	717.5
51			6.0	689.5
















				
FORMULA 1				
	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
52			5.5	685.5
53			5.5	729.5
54			6.4	761.5
55			6.9	681.4
56			5.6	687.5
57			5.0	639.5
58			6.6	709.5
59			6.6	695.5













				
FORMULA 1				
	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
60			5.5	699.5
61			7.68+7.8	748.5
62			7.7	750.5
63			7.0	794.5
64			6.8	780.5
65			5.8	731.6




FORMULA 1

	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
66			7.8	738.5
67			6.9	735.5
68			7.2	725.5
69			7.3	743.5
70			7.6	771.5
71			6.5	743.5
72			6.0	739.5
73			6.0	783.5


				
FORMULA 1				
	R1	R2	Analysis	
			Rt (min)	[M+H] ⁺
74			6.8	815.6
75			7.4	735.5
76			6.1	741.5
77			5.6	693.5
78			7.1+7.2	749.5
79			7.1+7.2	753.5
80			6.0	753.5

 FORMULA 2				
	R1	R3	Rt (min.)	(M+H) ⁺
1			5.5	566.3
2			5.6	568.3
3			4.9	612.3
4			4.8	598.3
5			3.8	549.4
6			5.6	556.3
7			5.3	540.3




FORMULA 2

FORMULA 2				
	R1	R3	Rt (min.)	[M+H] ⁺
8			4.9	543.3
9			5.1	561.3
10			5.4	589.3
11			4.3	561.3
12			4.1	557.3
13			4.1	601.3
14			4.9	633.4
15			5.3	533.3




FORMULA 2

	R1	R3	Rt (min.)	[M+H] ⁺
16			4.2	559.3
17			3.5	511.3
18			3.5	481.3
19			3.5	467.3
20			4.1	571.3
21			5.6	580.4
22			5.6	582.4













FORMULA 2


	R1	R3	Rt (min.)	[M+H] ⁺
23			4.9	626.4
24			4.8	612.4
25			3.8	563.4
26			5.6	570.4
27			5.4	554.3
28			4.9	557.3
29			5.1	575.3



FORMULA 2


	R1	R3	Rt (min.)	[M+H] ⁺
30			5.4	603.3
31			4.4	575.3
32			4.1	571.3
33			4.1	615.4
34			4.9	647.4
35			5.3	567.3
36			4.2	573.3
37			3.5	525.3
38			3.5	495.3

 FORMULA 2				
	R1	R3	R1 (mm.)	[M+H] ⁺
39			3.5	481.3
40			4.1	585.4
41			5.6	594.4
42			5.6	596.4
43			5.0	640.4
44			4.8	626.4
45			5.6	584.4




FORMULA 2

	R1	R3	Rt (min.)	[M+H] ⁺
46			5.7	568.3
47			5	571.3
48			5.1	589.4
49			5.5	617.4
50			4.4	589.3
51			4.1	585.4
52			4.2	529.4
53			4.9	661.5




FORMULA 2

	R1	R3	Rt (min.)	[M+H] ⁺
54			4.3	587.4
55			3.6	539.4
56			3.6	509.4
57			3.5	495.3
58			4.1	599.3
59			5.8	648.5
60			5.9	650.5




FORMULA 2

	R1	R3	Tr	[M++] ⁺
61			5.2	694.5
62			5	680.5
63			5.9	638.5
64			5.2	625.5
65			5.4	643.5
66			5.7	671.4
67			4.6	643.4




FORMULA 2

	R1	R3	Tr	[M+H] ⁺
68			4.4	639.5
69			4.4	689.5
70			5.2	715.5
71			4.5	641.5
72			3.9	593.4







FORMULA 3

			Analysis	
		Structure	Rt (min)	[M+H] ⁺
1			9.1	842.5
2		Chiral 	9.2	844.5
3		Chiral 	8.3	888.5




FORMULA 3

FORMULA 3			Analysis	
	Structure		Rt (min)	[M+H] ⁺
4	Chiral 	8.1	874.5	
5	Chiral 	6.9	825.5	
6	Chiral 	9.2	832.5	




FORMULA 3

		Structure	Analysis	
			Rt (min)	[M+H] ⁺
7		Chiral	8.2	834.5
8		Chiral	8.6	819.4
9		Chiral	8.7	837.5




FORMULA 3

		Structure	Analysis	
			Rt (min)	[M+H] ⁺
10			9	865.5
11			7.8	837.4
12			7.1	833.5




FORMULA 3

		Structure	Analysis	
			Rt (min)	[M+H] ⁺
13		Chiral 	7.1	877.5
14			8.1	909.5
15		Chiral 	8.7	829.5




FORMULA 3

		Analysis		
		Structure	Rt (min)	[M+H] ⁺
16		Chiral 	7.2	835.5
17		Chiral 	5.7	787.4
18		Chiral 	8.5	843.5




FORMULA 3

			Analysis	
		Structure	Rt (min)	[M+H] ⁺
19			8.5	857.5
20			7.1	847.5
21			4.5	710.5
22			4.1	754.5




FORMULA 3

		Analysis	
	Structure	Rt (min)	[M+H] ⁺
23	Chiral 	4	740.5
24	Chiral 	3.1	691.6
25	Chiral 	4.5	698.5
26	Chiral 	3.9	700.5




FORMULA 3

		Analysis	
	Structure	Rt (min)	[M+H] ⁺
27		4.1	685.5
28		4.2	703.5
29		3.1	721.4
30		3.3	743.5




FORMULA 3

		Analysis		
		Structure	Rt (min)	[M+H] ⁺
31		Chiral 	4.2	695.5
32		Chiral 	3.4	701.5
33		Chiral 	3	653.4
34			4.1	709.5




FORMULA 3

			Analysis	
		Structure	Rt (min)	[M+H] ⁺
35		Chiral	4	723.5
36		Chiral	3.2	623.4




FORMULA 4

	R1	R2	Tr (min)	(M+H) ⁺
1			4.53	454.24
2			4.87	488.21
3			4.79	465.24
4			4.53	454.25




FORMULA 5

	R1	R2	Tr (min)	[M+H] ⁺
1			8.0	732.2
2			7.7	706.2
3			6.4	755.2
4			7.3	697.3
5			7.6	731.2
6			7.6	760.3
7			7.9	794.3
8			7.8	743.4
9			7.5	774.4




FORMULA 5

	R1	R2	Tr (min)	[M+H] ⁺
10			7.8	808.3
11			7.8	757.4
12			7.6	743.4
13			7.8	785.4
14			7.6	774.4
15			7.8	763.4
16			8.5	783.3
17			8.9	817.3




FORMULA 6

		R2	Tr (min)	[M+H] ⁺
1			4.7	525.3
2			6.0	534.3
3			6.4	536.3
4			6.5	597.3
5			6.1	510.4
6			4.9	559.3
7			6.4	611.4
8			7.1	620.4




FORMULA 7

		R2	Tr (min)	[M+H] ⁺
1			4.6	469.4
2			5.0	533.3
3			4.6	485.4
4			4.9	489.4
5			5.3	523.3




FORMULA 8

		R2	Tr (min)	[M+H] ⁺
1			7.0	887.5
2			7.3	751.3
3			8.9	703.4
4			7.2	707.4
5			7.5	741.3




FORMULA 9

	R2	Tr (min)	[M+H] ⁺
1		3.8 ; 3.4	420.3
2		3.8 ; 3.6	417.3
3		3.8 ; 3.5	439.3
4		3.7 ; 3.4	403.3
5		3.9 ; 3.6	411.4




FORMULA 10

		R2	Tr (min)	[M+H] ⁺
1			4.4	520.2
2			4.5	517.2
3			4.4	539.3
4			4.4	503.2
5			4.5	511.3
6			5.1	523.3
7			5.5	559.3




FORMULA 11

			Analyses	
			*=(M+TFA-H)-	
		R2	Tr (min)	(M+H)+
1			4.6	455.2
2			4.9	515.2
3			4.8	473.2
4			4.9	612.2*
5			4.8	500.2
6			4.2	526.3
7			5.4	539.2
8			5.1	539.1
9			5.1	483.3
10			5.0	495.2
11			4.1	519.2*
12			4.4	524.3




FORMULA 12

		R2	Analyses	
			Tr (min)	[M+H] ⁺
1			6.9	673.3
2			7.0	733.3
3			7.0	691.3
4			7.1	718.3
5			7.0	718.3
6			7.4	744.4
7			7.6	757.3
8			7.3	757.2
9			7.3	701.3
10			7.2	713.3
11			6.5	625.3
12			6.3	742.3




FORMULA 13

		R2	Analysis	
			Tr (min)	[M+H] ⁺
1			3.8	425.3
2			4.2	485.4
3			4.0	438.4
4			4.0	403.3
5			3.9	425.4
6			3.6	452.4
7			3.8	403.3
8			5.1	438.3
9			4.6	432.3
10			6.2	506.4
11			3.8	409.3




FORMULA 14

		R2	Analysis	
			Tr (min)	[M+H] ⁺
1			4.6	525.3
2			5.0	585.3
3			4.8	538.3
4			4.9	503.3
5			4.6	525.4
6			4.3	552.3
7			4.5	503.3




FORMULA 15

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
1			5.9	623.4
2			7.6	699.4
3			7.9	733.3
4			7.9	682.4
5			7.7	668.4
6			7.9	710.3
7			7.7	699.4
8			7.9	688.3
9			8.2	722.3




FORMULA 15

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
10			7.5	712.4
11			7.6	634.4
12			7.3	673.3
13			7.6	707.3
14			7.6	556.4
15			7.4	642.4
16			7.6	684.3
17			7.4	673.3
18			7.6	662.3




FORMULA 15

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
19			7.9	696.3
20			7.2	686.4
21			7.3	608.4
22			6.0	722.3
23			6.4	756.3
24			6.3	705.4
25			6.1	691.4
26			6.4	733.3
27			6.1	722.3




FORMULA 15

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
28			6.3	711.3
29			6.7	745.2
30			5.9	735.3
31			6.0	657.4




FORMULA 16

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
1			5.7	477.2
2			6.0	511.1
3			6.1	540.2
4			6.3	574.1
5			6.0	523.3
6			4.4	437.3
7			4.2	423.3
8			4.8	443.3




FORMULA 16

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
9			6.8	563.2
10			7.0	597.2
11			6.1	479.3
12			6.5	513.2
13			6.0	462.3
14			5.8/5.9	448.3
15			6.4	490.2
16			6.1	479.3
17			6.4	468.2




FORMULA 16

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
18			6.8	502.2
19			6.0	492.3
20			6.5	512.2
21			5.9	453.3
22			6.2	487.2
23			5.7	436.3
24			5.5/5.6	422.3
25			6.2	464.2
26			5.9/6.0	453.3
27			6.1	442.2



FORMULA 16


	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
28			6.5	476.2
29			5.7	466.3
30			6.2	486.2
31			4.7	502.2
32			5.0	536.2
33			4.6	485.3
34			4.5	471.3
35			5.0	513.2
36			4.7	502.2
37			4.9	491.2



FORMULA 16


	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
38			5.3	525.2
39			4.6	515.2
40			5.0	535.1

FORMULA 17




	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
1			14.3	403.2
2			15.0	479.2
3			14.8	453.2
4			14.4	463.2
5			14.6	437.1
6			15.0	471.1
7			14.8	451.1
8			14.8	481.0
9			14.5	421.2

FORMULA 17




	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
10			14.3	428.1
11			14.5	444.2
12			14.5	448.1
13			14.5	448.1
14			14.0	355.2
15			14.3	403.2
16			15.2	479.2
17			14.9	453.2
18			14.4	433.2

FORMULA 17




	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
19			14.5	463.2
20			14.8	437.1
21			15.1	474.1
22			15.0	451.1
23			14.8	481.0
24			14.5	421.2
25			14.4	428.1
26			14.7	444.1
27			14.6	448.1

FORMULA 17




	R1	R2	Analyses	
			Tr (mm)	[M+H] ⁺
28			14.5	448.1
29			13.9	355.2
30			15.2	364.2
31			16.3	440.2
32			15.9	414.2
33			15.1	394.2
34			15.1	424.2
35			15.1	435.2
36			15.8	398.1
37			16.8	432.1
38			16.3	412.1

FORMULA 17






















	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
39			16.1	442.0
40			15.6	409.1
41			15.6	409.1
42			14.4	316.2
43			15.1	479.2
44			15.6	529.2
45			15.0	509.2
46			15.2	539.2
47			15.2	550.2
48			15.6	513.1
49			16.0	547.1

FORMULA 17



	R1	R2	Analyses	
			Tr. (min)	[M+H] ⁺
50			15.8	527.2
51			15.6	557.0
52			15.2	497.2
53			15.7	520.2
54			15.4	524.2
55			14.5	431.2



















				
FORMULA 18				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
1	(S) 		15.4	521.2
2	(S) 		16.5	597.1
3	(S) 		16.1	571.2
4	(S) 		15.3	551.2
5	(S) 		15.3	581.2
6	(S) 		15.8	592.2
7	(S) 		16.1	555.1
8	(S) 		16.7	589.0
9	(S) 		16.4	569.1

















































FORMULA 18

























	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
10	(S)		16.1	599.0
11	(S)		15.6	539.1
12	(S)		15.4	546.2
13	(S)		15.8	562.1
14	(S)		15.8	566.1
15	(S)		15.7	566.1
16	(S)		14.8	473.2
17	(S)		15.5	521.2
18	(R)		16.5	597.1





FORMULA 18				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
19			16.1	571.1
20			15.4	551.2
21			15.4	581.1
22			15.9	592.2
23			16.3	555.1
24			16.8	589.0
25			16.7	569.1
26			16.4	599.0
27			15.8	539.1

				
FORMULA 18				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
28			15.6	546.1
29			16.0	562.1
30			15.9	566.1
31			15.8	566.1
32			15.0	473.2
33			16.7	482.2
34			18.0	558.2
35			16.4	512.2
36			16.5	542.2
37			17.0	553.2
38			17.6	516.1


				
FORMULA 18				
	R1	R2	Analyses	
			Tr (mm)	[M+H] ⁺
39			18.2	550.1
40			18.0	530.1
41			17.7	560.0
42			16.9	500.2
43			16.7	507.2
44			17.2	523.2
45			16.9	527.2
46			16.8	527.2
47			15.8	434.2
48			15.8	557.2
49			16.8	673.2
50			16.5	647.2
51			15.8	627.2

				
FORMULA 18				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
52			15.8	657.2
53			16.5	631.1
54			17.2	665.1
55			16.7	645.1
56			16.5	675.1
57			16.0	615.1
58			15.9	622.1
59			16.1	638.2
60			16.1	642.1
61			16.2	642.1
62			15.4	549.2
63			15.9	563.2

				
FORMULA 18				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
64			17.0	639.2
65			16.5	613.2
66			15.7	593.2
67			15.8	623.2
68			16.2	634.2
69			16.6	597.1
70			17.4	631.1
71			17.0	611.1
72			16.7	641.1
73			16.1	581.2
74			15.9	588.2
75			16.2	604.2
76			16.2	608.2


				
FORMULA 18				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
77			16.1	508.2
78			15.3	515.3

FORMULA 19




	R1	R2	Analysis	
			* = [M+TFA-H] ⁻	
			Tr	[M+H] ⁺
1			6.2	433.2
2			7.0	509.2
3			6.8	483.2
4			6.2	463.2
5			6.5	493.2
6			5.4	504.3
7			6.5	467.2
8			6.9	501.1
9			6.8	481.2
10			6.6	511.1
11			6.3	451.2

FORMULA 19




	R1	R2	Analyses * = [M+TFA-H] ⁻	
			Tr	[M+H] ⁺
12			6.2	458.2
13			6.5	474.2
14			6.3	478.2
15			6.3	478.2
16			5.7	385.2
17			6.9	433.2
18			7.0	509.2
19			6.7	483.2
20			6.2	463.2
21			6.3	493.2
22			5.3	504.3
23			6.5	467.2

FORMULA 19




	R1	R2	Analyses * = [M+TFA-H] ⁻	
			Tr	[M+H] ⁺
24	(S)		6.8	501.1
25	(S)		6.7	481.2
26	(S)		6.5	511.1
27	(S)		6.2	451.2
28	(S)		6.1	458.2
29	(S)		6.4	474.2
30	(S)		6.3	478.2
31	(S)		6.3	478.2
32	(S)		5.6	385.2
33			6.5	481.1
34			7.4	557.1
35			7.1	531.1
36			6.6	511.1
37			6.8	541.1

FORMULA 19




	R1	R2	Analyses * = [M+TFA-H]-	
			Tr	[M+H] ⁺
38			5.7	552.2
39			6.9	515.0
40			7.3	549.0
41			7.1	529.1
42			7.0	670.1*
43			6.6	499.1
44			6.6	506.1
45			6.8	522.1
46			6.8	526.1
47			6.7	526.1
48			6.0	433.1
49			6.6	448.2
50			7.7	524.2
51			7.4	496.2

FORMULA 19




	R1	R2	Analyses * = [M+TFA-H] ⁻	
			Tr	[M+H] ⁺
52			6.6	478.2
53			6.7	508.2
54			5.8	519.2
55			7.2	482.1
56			7.7	518.1
57			7.5	496.2
58			7.3	528.1
59			6.8	466.2
60			6.8	473.2
61			7.1	489.2
62			7.1	493.1
63			7.0	493.2
64			5.8	400.2
65			5.8	383.2






















FORMULA 19











































	R1	R2	Analyses * = [M+TFA-H] ⁻	
			Tr	[M+H] ⁺
66			6.8	459.2
67			6.5	433.2
68			5.9	413.2
69			6.2	443.3
70			5.0	454.3
71			6.3	417.2
72			6.6	451.1
73			6.5	431.2
74			6.3	461.1
75			6.0	401.2
76			5.8	408.2
77			6.2	424.2
78			6.0	426.2
79			6.0	426.2

FORMULA 19 				
			Analyses	
			* = [M+TFA-H]-	
	R1	R2	Tr	[M+H]+
50			5.3	335.3

FORMULA 20 LFP1b2-02font.xls				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
1			6.9	487.2
2			6.3	461.3
3			6.3	447.3
4			6.2	493.3
5			6.7	482.2
6			7.2	509.3
7			7.7	473.4
8			5.8	472.3
9			7.3	507.2
10			6.6	459.3
11			6.6	487.2
12			6.7	470.3




















FORMULA 20		LFP1b2-02fonL.xls		
			Analyses	
	R1	R2	Tr (min)	[M+H] ⁺
13			7.2	538.2
14			6.8	456.3
15			6.8	431.3
16			6.5	439.3
17			7.1	517.3
18			6.5	491.3
19			6.4	477.3
20			6.4	523.3
21			6.9	512.3
22			7.3	539.3
23			7.8	503.4

FORMULA 20		LFPb2-02fonLds		
			Analyses	
	R1	R2	Tr (min)	[M+H] ⁺
24			6.0	502.3
25			7.4	537.3
26			6.8	489.3
27			6.8	517.2
28			6.8	500.3
29			7.4	562.2
30			6.7	486.4
31			6.8	461.3









				
FORMULA 20				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
32			6.7	469.3
33			7.4	532.3
34			6.6	506.3
35			6.6	492.3
36			6.6	538.3
37			7.3	527.2
38			7.5	554.3
39			8.1	518.3
40			6.1	517.3
41			8.1	552.2
42			7.0	504.3
43			7.2	532.1


















FORMULA 20





















	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
44			7.4	515.3
45			8.1	583.2
46			6.8	501.3
47			6.9	476.3
48			7.0	484.3
49			7.3	565.2
50			6.7	539.2
51			6.7	525.2
52			6.7	571.2
53			7.1	560.1


FORMULA 20 				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
54			7.6	587.2
55			8.0	551.3
56			6.3	550.2
57			7.7	585.1
58			7.0	537.2
59			7.0	565.0
60			7.2	548.2
61			7.7	616.1
62			7.0	534.2
63			7.0	509.2
64			6.9	517.2

FORMULA 20				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
65			6.8	467.3
66			6.1	444.3
67			6.1	427.3
68			6.1	473.4
69			6.6	462.3
70			7.1	489.4
71			7.6	453.4
72			5.6	452.3
73			7.2	487.3
74			6.5	439.3
75			6.5	467.2

				
FORMULA 20				
	R1	R2	Analyses	
			Tr (min)	[M+H] ⁺
76			6.5	450.3
77			7.1	518.2
78			6.3	436.3
79			6.5	411.3
80			6.4	419.3

				
FORMULA 2*		Analyses		
	R1	R2	* = [M+TFA-H]	
			Tr (min)	[M+H] ⁺
1			7.0	551.2
2			7.8	627.2
3			7.5	601.2
4			7.1	581.2
5			7.1	611.2
6			7.5	622.3
7			7.4	585.2
8			7.7	619.1
9			7.7	599.2
10			7.4	629.1


				
FORMULA 21			Analyses	
	R1	R2	* = [M+TFA-H]	
			Tr (min)	[M+H] ⁺
11			7.1	569.2
12			7.0	576.2
13			7.3	592.2
14			7.2	596.2
15			7.1	596.2
16			6.5	503.3
17			7.0	551.2
18			7.8	627.2
19			7.5	601.2
20			7.0	581.2
21			7.1	611.2



FORMULA 21

Analyses


	R1	R2	* = [M+TFA-H]	
			Tr (min)	[M+H] ⁺
22	(S)		7.5	622.3
23	(S)		7.4	585.2
24	(S)		7.7	619.1
25	(S)		7.6	599.2
26	(S)		7.4	629.1
27	(S)		7.4	569.2
28	(S)		6.9	576.2
29	(S)		7.3	704.2*
30	(S)		7.1	596.2
31	(S)		7.0	596.2
32	(S)		6.5	503.2
33			8.1	599.1
34			9.0	675.1



FORMULA 21


Analyses

	R1	R2	* = [M+TFA-H]	
			Tr (min)	[M+H] ⁺
35			8.7	649.1
36			8.1	629.1
37			8.0	659.1
38			8.4	670.2
39			8.6	633.1
40			9.0	667.0
41			8.8	647.1
42			8.6	677.0
43			8.3	617.1
44			8.2	624.1
45			8.4	640.1
46			8.4	644.1













FORMULA 21


	R ¹	R ²	Analyses	
			* = [M+TFA-H]	
			Tr (min)	[M+H] ⁺
47			8.3	544.1
48			7.6	551.1
49			8.7	566.2
50			9.7	642.2
51			9.3	616.2
52			8.5	596.2
53			8.7	626.2
54			9.1	637.2
55			9.2	600.1
56			9.6	634.1
57			9.5	614.1
58			9.3	644.1



FORMULA 21


	R1	R2	Analyses	
			* = [M+TFA-H]	
			Tr (min)	[M+H] ⁺
59			8.8	584.2
50			8.7	591.2
61			9.0	607.2
52			8.9	611.1
53			8.8	611.1
54			8.2	518.2
65			6.7	501.3
56			7.5	577.2
67			7.2	551.3
68			6.8	531.3
69			6.9	561.2
70			7.3	572.3

				
FORMULA 21				
	R1	R2	Analysis	
			Tr. (min)	[M+H] ⁺
71			7.0	535.2
72			7.3	569.1
73			7.3	549.2
74			7.1	579.1
75			6.8	519.2
76			6.6	526.3
77			7.0	542.2
78			6.8	546.2
79			6.7	546.2
80			6.2	453.3




FORMULA 22

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
1	(R)		6.6	505.3
2	(R)		6.3	579.3
3	(R)		6.3	565.3
4	(R)		6.3	511.3
5	(R)		6.5	— 600.2
6	(R)		6.6	627.3
7	(R)		6.9	
8	(R)		5.9	590.3
9	(R)		6.9	625.2
10	(R)		6.5	577.3




FORMULA 22

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
11			6.6	(605.12)THEO
12			6.6	588.3
13			7.0	656.2
14			6.4	574.3
15			6.5	549.3
16			6.5	557.3
17			6.5	635.3
18			6.2	609.3
19			6.2	595.3




FORMULA 22

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
20			6.2	641.3
21			6.4	630.2
22			6.5	657.3
23			6.8	621.4
24			5.9	
25			6.7	655.2
26			6.4	607.2
27			6.4	635.2
28			6.5	618.3




FORMULA 22

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
29			6.7	686.2
30			2.0 or 6.3?	504.3
31			6.4	579.3
32			6.3	587.2
33			7.3	650.2
34			7.0	624.2
35			7.0	610.2
36			7.0	656.3
37			7.0	645.1




FORMULA 22

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
38			7.3	672.3
39			7.6	636.3
40			7.8	635.2
41			7.5 ?	670.2 ?
42			7.3 ?	622.2 ?
43			7.3	650.1
44			7.3	633.2
45			7.6	701.2
46			7.2	594.3
47			7.2	602.2




FORMULA 22

	R ¹	R ²	Analysis	
			t _r (min)	[M+H] ⁺
48			7.0	(683.14)THEO
49			6.7	657.2
50			6.7	643.1
51			6.7	689.2
52			7.0?	678.1?
53			7.0	705.2
54			7.2	699.3
55			7.3	668.1
56			9.5	703.0
57			8.6	655.0




FORMULA 22

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
58			8.7	683.0
59			9.0	666.1
60			9.8	734.0
51			9.0	652.1
62			8.5	627.1
63			8.5	635.1
64			7.3	585.2
65			6.7	559.2
66			6.7	545.2
67			6.7	591.3




FORMULA 22

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
68			7.0	580.2
69			7.6	607.3
70			8.0	571.3
71			6.1	570.3
72			7.6	605.2
73			7.1	557.2
74			7.0	585.1
75			7.1	568.2
76			7.6	636.2




FORMULA 22

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
77			6.8	554.2
78			7.1	529.3
79			6.9	537.2




FORMULA 23

	R1	Analysis	
		Tr	[M+H] ⁺
1		5.6	448.3
2		5.8	482.2
3		5.9	482.2
4		5.7	478.3
5		6.2	516.2
6		6.5	504.3
7		5.7	484.3
8		6.3	532.2
9		6.2	530.2
10		5.6	506.3
11		5.5	454.2



FORMULA 23


	R1	Analysis	
		Tr	[M+H] ⁺
12	C	5.0	386.3



FORMULA 24


FORMULA 24				Analysis	
	R1	R2	R3	Tr	[M+H] ⁺
1	(S)			5.6	403.1
2	(S)		C	4.9	335.2
3	(S)			5.3	403.2
4	(S)		C	4.8	335.3
5	(R)			5.1	442.2
6	(R)		C	4.7	374.2
7	(R,S)			5.2	442.2
8	(R,S)		C	4.7	374.2
9	(R,S)			4.5	392.2
10	(R,S)		C	4.3	324.3

FORMULA 24					
	R1	R2	R3	Analysis	
				Tr	[M+H] ⁺
11				48	455.2
12				45	387.2
13				53	373.2
14				47	305.2




FORMULA 25

	R1	Analysis	
		Tr	[M+H] ⁺
1		5.1	436.4
2		6.5	520.3
3		6.0	486.4
4		5.0	436.4
5		5.3	436.4
6		6.4	474.4
7		6.4	532.4
8		6.6	488.4







FORMULA 26


	R1		Analysis	
			Tr	[M+H] ⁺
1			6.1	435.3
2			5.9	451.3
3			5.8	451.3
4			6.2	453.3
5			6.2	465.3
6			6.1	465.3
7			6.2	465.3
8			6.2	480.4
9			6.2	480.4
10			6.7	503.3
11			6.4	510.4
12			6.5	513.3
13			6.0	441.3



FORMULA 26



















	R1	Analysis	
		Tr	[M+H] ⁺
14		6.1	525.4
15		7.0	541.4
16		6.1	453.4
17		6.5	479.4
18		6.6	503.4
19		6.9	511.4
20		6.4	513.3
21		5.8	478.4
22		6.8	519.3
23		5.1	536.5
24		6.2	483.4












				
FORMULA 26				
	R1		Analysis	
			Tr	[M+H] ⁺
25			7.0	491.4
26			6.5	513.3
27			6.9	557.4


























FORMULA 27

	R1	R2	Analysis	
			Tr	[M+H] ⁺
1		(R)	6.4	478.3
2		(R)	5.6	444.3
3		(R)	4.8	394.3
4		(R)	4.9	394.3
5		(S)	4.8	394.3
6		(S)	6.4	478.3
-		(S)	5.6	444.3
8		(S)	4.7	394.3
9		(S)	4.9	394.3
10		(R,S)	4.9	424.3
11		(R,S)	6.6	508.3
12		(R,S)	5.7	474.3

				
FORMULA 27				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
13		(R,S) 	4.9	424.3
14		(R,S) 	5.0	424.3
15		(R) 	4.9	424.3
16		(R) 	6.5	508.3
17		(R) 	5.6	474.3
18		(R) 	4.9	424.3
19		(R) 	5.0	424.3
20		(S) 	4.9	424.3
21		(S) 	6.5	508.3
22		(S) 	5.6	474.3
23		(S) 	4.9	424.3
24		(S) 	5.0	424.3














				
FORMULA 28				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
1		(S) 	6.1	441.2
2		(S) 	6.4	471.1
3		(S) 	5.8	359.3
4		(S) 	6.1	373.3
5		(S) 	5.8	391.2
6		(S) 	6.2	387.3
7		(S) 	7.1	437.5
8		(S) 	6.3	399.3
9		(S) 	6.8	449.3
10		(S) 	6.4	387.3
11		(R,S) 	6.1	471.2
12		(R,S) 	6.5	501.1
13		(R,S) 	5.8	389.3
14		(R,S) 	6.1	403.3


				
FORMULA 28				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
15			5.8	421.2
16			6.2	417.3
17			7.0	467.2
18			6.3	429.3
19			6.9	479.3
20			6.4	417.3
21			6.0	471.2
22			6.4	501.1
23			6.0	403.3
24			6.1	417.3
25			6.9	467.1
26			6.3	429.3



FORMULA 28


	R1	R2	Analysis	
			Tr	[M+H] ⁺
27		(R)	6.8	479.3
28		(R)	6.4	417.3
29		(S)	6.0	471.2
30		(S)	6.4	501.1
31		(S)	5.8	389.3
32		(S)	6.2	417.3
33		(S)	6.9	467.1
34		(S)	6.3	429.3
35		(S)	6.8	479.3
36		(S)	6.4	417.3

				
FORMULA 29				
	R1		Analysis	
			Tr	[M+H] ⁺
1			5.9	393.3
2			5.7	409.3
3			5.6	409.3
4			5.1	411.3
5			6.0	423.3
6			5.1	423.3
7			5.1	438.3
8			6.6	461.2
9			6.2	468.3
10			6.4	471.2
11			5.9	399.3
12			5.9	483.4
13			6.3	471.2




FORMULA 29

	R1	Analysis	
		Tr	[M+H] ⁺
14		6.7	477.3
15		6.5	494.4
16		6.1	441.3
17		6.3	387.3
18		6.4	437.3
19		6.4	399.4
20		6.5	449.4
21		6.5	387.4




FORMULA 3C

R1		Analysis	
		T _r	[M+H] ⁺
1		5.4	458.2
2		5.7	460.2
3		5.3	499.3
4		6.1	522.3
5		6.3	531.3
6		6.4	533.3
7		6.6	543.3
8		5.1	547.3
9		6.5	551.3
10		6.1	563.3
11		6.9	567.2




FORMULA 30

	R1	Analysis	
		Tr	[M+H] ⁺
12		7.2	568.2
13		6.5	578.2
14		6.1	564.3
15		6.8	567.2
16		4.9	534.3
17		7.0	546.3
18		6.8	578.3
19		5.1	591.3
20		7.1	601.3




FORMULA 30

	R1	Analysis	
		Tr	[M+H] ⁺
21	 <chem>c1ccc(cc1)N2CCN(C2)C(=O)N</chem>	6.2	602.3
22	 <chem>Clc1ccccc1N2CCNCC2C(=O)N</chem>	6.9	567.2
23	 <chem>Oc1ccc(cc1)N2CCNCC2C(=O)N</chem>	5.2	549.2
24	 <chem>Nc1cccc2ccccc12</chem>	6.7	528.2
25	 <chem>Cc1cccc(c1)N2CCNCC2C(=O)N</chem>	7.1	561.3
26	 <chem>Nc1ccccc1</chem>	7.0	568.2
27	 <chem>c1ccccc1COC(=O)N2CCNCC2C(=O)N</chem>	6.5	591.3
28	 <chem>c1ccc2c(c1)n[nH]c2N3CCNCC3C(=O)N</chem>	6.0	588.2
29	 <chem>Nc1ccc(cc1)CN</chem>	5.7	571.2




FORMULA 30

	R1	Analysis	
		Tr	[M+H] ⁺
30		5.7	551.2
31		6.9	653.3
32		7.4	612.3
33		5.0	563.3
34		6.0	623.3
35		5.2	549.3
36		4.4	558.3
37		6.6	551.3




FORMULA 31

	R1	Analysis	
		Tr	[M+H] ⁺
1		4.7	473.3
2		6.6	484.3
3		6.3	492.3
4		6.2	508.3
5		6.5	522.3
6		6.1	552.3
7		4.8	482.3
8		6.0	568.2
9		6.4	537.2
10		6.5	472.3




FORMULA 31

	R1	Analysis	
		m/z	$[M+H]^+$
11		47	479.3
12		48	493.3
13		48	515.3
14		59	543.3
15		50	553.2
16		66	538.2
17		55	510.3
18		49	514.3
19		61	444.3
20		58	610.3






FORMULA 31


	R1		Analysis	
			Tr	[M+H] ⁺
21			7.0	554.3
22			4.9	479.3
23			6.5	512.2
24			7.2	582.3
25			6.6	506.3
26			4.8	485.3
27			6.7	526.2
28			6.4	510.3
29			6.4	510.3



FORMULA 31


	R1	Analysis	
		Tr	[M+H] ⁺
30		6.7	526.2
31		6.8	570.2
32		6.7	546.2
33		6.8	546.2
34		4.8	479.3
35		5.3	508.3
36		5.4	512.2
37		6.3	496.3
38		6.2	496.3

				
FORMULA 31				
	R1		Analysis	
			Tr	[M+H] ⁺
39			6.3	496.3
40			4.5	528.3




FORMULA 32

		Analysis	
	R1	Tr	[M+H] ⁺
1		5.4	498.2
2		6.6	498.2
3		6.6	498.2
4		6.4	542.1
5		6.6	542.1
6		6.7	542.1
7		6.3	482.2
8		6.3	500.2
9		6.4	500.2
10		6.3	509.2














FORMULA 32


	R1	Analysis	
		Tr	[M+H] ⁺
11		6.4	509.2
12		6.4	509.2
13		6.5	532.2
14		6.8	532.2
15		6.8	532.2
16		6.3	524.2
17		6.2	494.2
18		6.1	494.2
19		6.9	566.1




FORMULA 32

	R1	Analysis	
		Tr	[M+H] ⁺
20		6.4	527.2

FORMULA 33				
			Analysis	
	R1		T _r	[M+H] ⁺
1			6.4	456.1
2			6.2	500.1
3			6.4	500.1
4			6.4	500.1
5			6.1	440.1
6			6.2	458.1
7			6.1	467.1
8			6.2	467.1
9			6.2	490.1
10			6.6	490.1
11			6.1	482.2

























FORMULA 33











	R1	Analysis	
		Tr	[M+H] ⁺
12		6.0	452.2
13		5.9	452.2
14		6.7	524.1
15		6.2	485.1









FORMULA 34				
	R ¹		Analysis	
			Tr	[M+H] ⁺
			3.9	348.3
2			4.0	382.2
3			4.3	382.2
4			4.1	378.2
5			4.5	416.2
6			5.0	404.3
7			4.0	384.2
8			4.7	432.2
9			4.5	430.2
10			3.9	406.2
11			3.8	354.2


				
FORMULA 34				
			Analysis	
	R1		Tr	[M+H] ⁺
12	C		32	286.3

				
FORMULA 35				
	R1	Analysis		
		Tr	[M+H] ⁺	
1		3.7	358.2	
2		3.9	360.2	
3		3.5	399.2	
4		4.4	422.2	
5		4.7	431.2	
6		4.7	433.2	
7		5.0	443.2	
8		3.8	447.3	
9		4.8	451.2	
10		4.6	463.2	











				
FORMULA 35		Analysis		
	R1	Tr	[M-H] ⁺	
11		5.2	467.2	
12		5.4	468.2	
13		4.9	478.2	
14		4.6	464.2	
15		5.2	467.2	
16		3.5	434.2	
17		5.3	446.2	
18		5.0	478.2	
19		3.8	491.2	
20		5.5	501.2	

FORMULA 35				
				
	R:		Analysis	
			Tr	[M+H] ⁺
21			4.6	502.3
22			5.1	467.2
23			3.8	449.2
24			5.0	428.2
25			5.4	461.2
26			5.4	468.2
27			5.0	491.2
28			4.5	488.2
29			4.0	471.2


FORMULA 35				
		Analysis		
	R1	Tr	[M+H] ⁺	
30		4.1	451.2	
31		5.2	553.3	
32		5.6	512.2	
33		4.5	463.3	
34		4.7	523.3	
35		3.8	449.3	
36		3.1	458.3	
37		4.8	451.2	












FORMULA 36				
	R1		T _r	[M+H] ⁺
1			3.2	373.3
2			4.8	384.3
3			4.7	392.2
4			4.5	408.2
5			4.8	422.2
6			4.5	452.2
7			3.3	382.2
8			4.4	468.2
9			4.7	437.2





				
FORMULA 36				
	R1		Tr	[M+H] ⁺
10			4.8	372.3
11			3.2	379.2
12			3.3	393.2
13			3.3	415.2
14			4.4	443.3
15			4.4	453.2
16			5.0	438.2
17			3.9	410.2
18			3.6	414.3
19			4.3	344.3













FORMULA 36









	R1	Tr	[M+H] ⁺
20		4.5	510.2
21		5.3	454.2
22		3.4	379.2
23		4.5	412.1
24		5.5	482.3
25		5.0	406.2
26		3.3	385.2
27		5.0	426.2

				
FORMULA 36				
	R1		Tr	[M+H] ⁺
28			4.7	410.2
29			4.8	410.2
30			5.0	426.2
31			5.1	470.2
32			5.1	446.2
33			5.1	446.2
34			3.3	379.2
35			4.6	408.2
36			4.8	412.1

FORMULA 36 				
	R1		Tr	[M+H] ⁺
37			4.6	396.2
38			4.5	396.2
39			4.6	396.2
40			3.1	428.3


FORMULA 37				
				
	R ¹		Analysis	
			Tr	[M+H] ⁺
1			4.4	388.5
2			4.5	388.3
3			4.2	388.3
4			4.4	402.3
5			4.4	432.3
6			4.2	404.3
7			4.7	418.3
8			4.9	430.5
9			4.6	416.4
10			3.9	418.3
11			4.8	480.2

FORMULA 37 				
		Analysis		
	R1	Tr.	[M+H] ⁺	
12		4.5	416.4	
13		4.8	419.3	
14		4.8	419.3	
15		4.7	389.3	




FORMULA 38

	R1	Analysis	
		Tr	[M+H] ⁺
1		5.1	431.2
2		4.4	453.4
3		4.6	377.4
4		4.5	399.3
5		4.5	399.3
6		3.9	339.3
7		4.1	350.4
8		4.5	395.3
9		4.8	399.3
10		4.7	400.3
11		4.5	400.3
12		4.4	400.3
13		4.2	400.3




FORMULA 38

	R1	Analysis	
		Tr	[M+H] ⁺
14	 <chem>c1ccc2ncnc2c1</chem>	4.3	441.3
15	 <chem>CCOS(=O)(=O)c1ccccc1</chem>	4.3	441.3
16	 <chem>Cc1ccsc1</chem>	4.2	389.3
17	 <chem>CCOS(=O)(=O)c1ncnc1</chem>	3.9	397.3
18	 <chem>c1ccncc1</chem>	3.8	350.3








FORMULA 39











	R1	Analysis	
		Tr	[M+H] ⁺
1		4.5	397.3
2		4.7	397.3
3		4.7	397.3
4		4.6	441.2
5		4.8	441.2
6		4.8	441.2
7		4.3	381.3
8		4.4	381.3
9		4.4	381.3
10		4.3	408.3





FORMULA 39









	R1		Analysis	
			Tr	[M+H] ⁺
11			4.4	408.3
12			4.5	408.3
13			4.7	431.3
14			4.9	431.3
15			5.0	431.3
16			4.4	393.3
17			4.4	393.4
18			4.4	393.3
19			4.3	363.4
20			3.7	406.3


FORMULA 40 				
	R1		Analysis	
			Tr	[M+H] ⁺
1			3.6	336.4
2			4.9	420.3
3			4.5	386.4
4			3.5	336.4
5			3.8	336.4
6			4.9	432.3

FORMULA 41			
			
	R1	Analysis	
		Tr	[M+H] ⁺
1		4.5	335.3
2		4.3	351.3
3		4.2	351.3
4		4.6	353.3
5		4.6	365.3
6		4.6	365.3
7		4.6	365.3
8		4.5	380.3
9		4.6	380.3
10		5.1	403.2
11		4.7	410.3
12		4.9	413.2
13		4.3	341.3

FORMULA 41				
	R1		Analysis	
			Tr	[M+H] ⁺
14			4.6	425.3
15			5.4	441.3
16			4.5	353.3
17			4.9	403.3
18			5.3	411.3
19			4.7	415.2
20			5.2	419.3
21			3.9	436.4
22			4.6	383.3
23			5.4	391.4
24			4.9	413.2



FORMULA 41 				
			Analysis	
	R1		Tr	[M+H] ⁺
25			5.4	457.4


				
FORMULA 42				
	R1		Analysis	
			Tr	[M+H] ⁺
1			4.7	398.1
2			4.9	398.1
3			4.9	398.1
4			4.7	442.1
5			5.0	442.1
6			5.0	442.1
7			4.7	382.2
8			4.6	400.2
9			4.8	400.2
10			4.7	409.2



FORMULA 42


	R1		Analysis	
			Tr	[M+H] ⁺
11			4.8	409.2
12			5.0	409.2
13			4.8	432.2
14			5.2	432.2
15		—	5.3	432.2
16			4.7	424.2
17			4.6	394.2
18			4.5	394.2
19			5.2	466.1

FORMULA 42 				
R1			Analysis	
			Tr	[M+H] ⁺
20			49	427.2
























FORMULA 43


	R3	R2	Analysis	
			Tr	[M+H] ⁺
1		(R)	5.5	374.2
2		(R)	5.4	360.2
3		(R)	5.4	388.2
4		(R)	5.5	416.3
5		(R)	5.4	374.2
6		(R)	6.1	422.2
7		(R)	5.5	368.2
8		(R)	5.5	402.2
9		(R)	5.5	436.2
10		(R)	5.7	436.2
11		(R,S)		
12		(R,S)	5.3	340.3
13		(R,S)	5.4	368.3



FORMULA 43






















	R3	R2	Analysis	
			Tr	[M+H] ⁺
14		(R,S)	5.4	396.3
15		(R,S)	5.3	354.3
16		(R,S)	6.0	402.2
17		(R,S)	5.5	368.3
18		(R,S)	5.4	382.3
19		(R,S)	5.5	416.3
20		(R,S)		416.3


				
FORMULA 44				
			Analysis	
			• = [M+TFA-H] ⁺	
	R1	R2	Tr	[M+H] ⁺
1		(R) 	6.0	485.3
2		(R) 	6.2	485.3
3		(R) 	6.2	485.3
4		(R) 	6.1	529.2
5		(R) 	6.2	529.2
6		(R) 	6.3	529.2
7		(R) 	5.9	469.3
8		(R) 	5.9	469.3
9		(R) 	5.9	469.3
10		(R) 	5.8	496.3



FORMULA 44




















	R1	R2	Analysis	
			* = [M+TFA-H] ⁺	
			Tr	[M+H] ⁺
11		(R)	5.9	496.3
12		(R)	6.0	496.3
13		(R)	6.2	519.3
14		(R)	6.4	519.3
15		(R)	6.4	519.3
16		(R)	5.9	481.3
17		(R)	5.9	481.3
18		(R)	5.9	481.3
19		(R)	5.8	451.3


				
FORMULA 44				
Analysis				
• = [M+TFA-H] ⁺				
	R1	R2	Tr	[M+H] ⁺
20		(R) 	4.9	494.4
21		(R) 	6.5	519.2
22		(R) 	5.7	541.3
23		(R) 	6.0	465.3
24		(R) 	5.4	467.3
25		(R) 	5.9	487.3
26		(S) 	6.0	485.3
27		(S) 	6.1	485.3
28		(S) 	6.2	485.3
29		(S) 	6.0	529.2



FORMULA 44


	R1	R2	Analysis	
			* = [M+TFA-H]	
			Tr	[M+H] ⁺
30		(S)	6.2	529.2
31		(S)	6.2	529.2
32		(S)	5.8	469.3
33		(S)	5.9	469.3
34		(S)	5.9	469.3
35		(S)	5.8	496.3
36		(S)	5.9	496.3
37		(S)	5.9	496.3
38		(S)	6.2	519.3

				
FORMULA 44				
			A-27338	
			* = [M+TFA-H] ⁻	
	R1	R2	Tr	[M+H] ⁺
39		(S) 	6.4	519.3
40		(S) 	6.4	519.3
41		(S) 	5.9	481.3
42		(S) 	5.9	481.3
43		(S) 	5.8	481.3
44		(S) 	5.8	563.3*
45		(S) 	4.8	494.4
46		(S) 	6.4	519.2
47		(S) 	5.7	541.3




FORMULA 44

		Analysis	
		* = [M+TFA-H] ⁻	
	R1	R2	Tr [M+H] ⁺
48		(S)	6.0 465.3
49		(S)	5.4 467.3
50		(S)	6.0 487.3




FORMULA 45

	R1	Analysis	
		Tr	[M+H] ⁺
1		5.9	488.4
2		6.1	488.4
3		5.9	488.4
4		6.0	502.4
5		6.0	502.4
6		6.0	532.4
7		5.7	504.4
8		6.3	518.4
9		5.4	530.4
10		6.2	516.4
11		5.5	518.4




FORMULA 45

	R1	Analysis	
		Tr	[M+H] ⁺
12		6.4	580.3
13		6.1	516.4
14		6.4	519.3
15		6.4	519.3
16		6.3	489.4




FORMULA 46

	R1	Analysis	
		Tr	[M+H] ⁺
1		6.7	531.3
2		5.9	553.4
3		6.3	477.4
4		6.2	499.3
5		6.2	499.4
6		5.6	439.3
7		5.7	450.4
8		6.2	495.3
9		6.4	499.4
10		6.4	500.4
11		6.2	500.4
12		5.9	500.4
13		5.7	500.4




FORMULA 46

	R1		Analysis	
			Tr	[M+H] ⁺
14			5.9	541.3
15			5.9	541.3
16			5.9	469.3
17			5.5	497.4
18			5.3	450.4





FORMULA 47



















	R1	Analysis	
		Tr	[M+H] ⁺
1		6.2	497.3
2		6.3	497.3
3		6.4	497.3
4		6.2	541.2
5		6.4	541.2
6		6.5	541.2
7		6.0	481.3
8		6.1	481.3
9		6.1	481.3
10		6.0	508.3

























FORMULA 47

	R1		Analysis	
			Tr	[M+H] ⁺
11			6.1	508.3
12			5.1	508.3
13			6.4	531.3
14			6.6	531.3
15			6.6	531.3
16			6.1	493.4
17			6.0	493.4
18			6.0	493.4
19			6.0	463.4

FORMULA 47 				
			Analysis	
	R1		Tr	[M+H] ⁺
20			5.0	506.4


				
FORMULA 48				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
1		(R,S) 	6.9	519.2
2		(R,S) 	6.5	541.3
3		(R,S) 	6.7	465.3
4		(R,S) 	6.3	467.3
5		(R,S) 	6.6	487.2
6		(R,S) 	7.0	567.0
7		(R,S) 	6.7	589.1
8		(R,S) 	6.9	513.2
9		(R,S) 	6.5	515.1
10		(R,S) 	6.8	535.1
11		(R,S) 	7.2	534.1

				
FORMULA 48				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
12			6.8	556.2
13			6.8	480.1
14			5.8	482.1
15			6.7	502.1
16			6.3	560.1
17			5.5	582.2
18			5.8	506.3
19			5.1	508.2
20			5.7	528.2
21			6.5	489.1
22			5.7	511.2




FORMULA 48

	R1	R2	Analysis	
			Tr	[M+H] ⁺
23		(R)	6.1	435.2
24		(R)	5.4	437.2
25		(R)	6.0	457.2




FORMULA 49

		R1	Analysis	
			(min)	[M+H] ⁺
1			6.6	455.2
2			6.6	455.2
3			6.6	455.2
4			6.6	499.2
5			6.7	499.2
6			6.7	499.2
7			6.5	439.2
8			6.5	439.2
9			6.5	439.2
10			6.5	466.2




FORMULA 49

		R1	Analysis	
			(min)	[M+H] ⁺
11			6.5	466.2
12			6.5	466.2
13			6.7	489.2
14			6.7	489.2
15			6.8	489.2
16			6.5	451.3
17			6.5	451.3
18			6.5	451.3
19			6.5	421.3




FORMULA 49

		R1	Analysis	
			(min)	[M+H] ⁺
20			5.8	464.3












FORMULA 50

	R1	R2	Analysis	
			Tr	[M+H] ⁺
1		(R)	6.3	474.3
2		(R)	6.3	460.3
3		(R)	6.3	488.3
4		(R)	6.4	516.3
5		(R)	6.3	474.3
6		(R)	6.5	522.3
7		(R)	6.5	488.3
8		(R)	6.4	502.3
9		(R)	6.5	536.3
10		(R)	6.5	536.3




FORMULA 50

	R1	R2	Analysis	
			Tr	[M+H] ⁺
11		(R,S)	6.2	454.3
12		(R,S)	6.2	440.3
13		(R,S)	6.3	468.3
14		(R,S)	6.4	496.3
15		(R,S)	6.2	454.3
16		(R,S)	6.5	502.3
17		(R,S)	6.4	468.3
18		(R,S)	6.3	482.3
19		(R,S)	6.4	516.3
20		(R,S)	6.4	516.3


























					
FORMULA 51					
	R1	R2	R3	Analysis	
				Tr	[M+H] ⁺
1	(S) 			5.6	397.2
2	(S) 			5.9	431.2
3	(S) 			6.0	431.2
4	(S) 			5.8	427.2
5	(S) 			6.3	465.2
6	(S) 			6.7	453.3
7	(S) 			5.8	433.2
8	(S) 			6.4	481.2
9	(S) 			6.3	479.1
10	(S) 			5.7	455.2


FORMULA 51					
	R1	R2	R3	Analysis	
				Tr	[M+H] ⁺
11				5.4	397.2
12				5.0	431.2
13				5.8	431.2
14				5.5	427.2
15				6.0	455.2
16				6.5	453.3
17				5.5	433.2
18				6.2	481.2
19				6.1	479.1
20				5.5	455.2



















FORMULA 51

Formula 31				Analysis	
	R1	R2	R3	Tr	[M+H] ⁺
21				5.3	406.2
22				5.5	440.1
23				5.7	440.2
24				5.5	436.2
25				6.0	474.2
26				6.4	462.3
27				5.5	442.2
28				6.1	490.2
29				6.0	488.1












					
FORMULA 51					
	R1	R2	R3	Analysis	
				Tr	[M+H] ⁺
30	(R) 			5.4	464.2
31	(R) 			5.2	436.2
32	(R) 			5.4	470.2
33	(R) 			5.6	470.2
34	(R) 			5.4	466.2
35	(R) 			5.9	504.2
36	(R) 			6.2	492.3
37	(R) 			5.4	472.2
38	(R) 			6.0	520.1





















FORMULA 51


















FORMULA 51				Analysis	
	R1	R2	R3	T _r	[M+H] ⁺
39	(R) 			5.8	518.1
40	(R) 			5.3	494.2
41	(R,S) 			5.2	436.2
42	(R,S) 			5.4	470.2
43	(R,S) 			5.5	470.2
44	(R,S) 			5.4	466.2
45	(R,S) 			5.9	504.2
46	(R,S) 			6.2	492.3
47	(R,S) 			5.4	472.2


FORMULA 51					
	R1	R2	R3	Analysis	
				Tr	[M+H] ⁺
48	(R,S)			6.0	520.1
49	(R,S)			5.9	518.1
50	(R,S)			5.3	494.2
51	(R,S)			4.6	386.2
52	(R,S)			4.7	420.2
53	(R,S)			4.9	420.2
54	(R,S)			4.8	416.2
55	(R,S)			5.2	454.2
56	(R,S)			5.6	442.3

FORMULA 51 $\begin{array}{c} \text{R3} \quad \text{R1} \\ \quad \\ \text{H} \cdot \text{N} \text{---} \text{N} \text{---} \text{C} \text{---} \text{N} \text{---} \text{R2} \\ \\ \text{H} \end{array}$					
	R1	R2	R3	Analysis	
				Tr	[M+H] ⁺
57	(R,S) 			4.7	422.2
58	(R,S) 			5.3	470.2
59	(R,S) 			5.2	468.2
60	(R,S) 			4.8	444.2
61	(S) 			4.9	449.2
62	(S) 			5.0	483.2
63	(S) 			5.2	483.2
64	(S) 			5.0	477.2

FORMULA 51					
					
	R1	R2	R3	Analysis	
				Tr	[M+H] ⁺
65				5.4	515.1
66				5.8	503.3
67				4.9	483.2
68				5.5	531.2
69				5.4	531.1
70				4.9	507.2
71				5.3	367.2
72				5.6	401.2
73				5.7	401.1




















FORMULA 51					
	R1	R2	R3	Analysis	
				Tr	[M+H] ⁺
74	(S)			5.5	397.2
75	(S)			6.0	435.2
76	(S)			5.5	423.3
77	(S)			5.5	403.2
78	(S)			6.2	451.2
79	(S)			6.1	449.1
80	(S)			5.4	425.2




















				
FORMULA 52				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
1		(S) 	5.9	393.2
2		(S) 	5.7	409.2
3		(S) 	5.6	409.2
4		(S) 	6.0	411.2
5		(S) 	6.0	423.2
6		(S) 	6.0	423.2
7		(S) 	6.0	423.2
8		(S) 	6.0	438.2
9		(S) 	6.0	438.2
10		(S) 	6.5	461.1







































FORMULA 52




















	R1	R2	Analysis	
			Tr	[M+H] ⁺
11		(S)	6.1	468.2
12		(S)	6.4	471.1
13		(S)	5.8	511.2 ^a
14		(S)	5.9	483.3
15		(S)	5.9	411.2
16		(S)	6.4	461.2
17		(S)	6.2	471.1
18		(S)	5.5	436.3
19		(S)	6.6	477.2


				
FORMULA 52				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
20		(S) 	4.9	494.3
21		(R,S) 	6.0	423.3
22		(R,S) 	5.7	439.2
23		(R,S) 	5.6	439.2
24		(R,S) 	6.1	441.2
25		(R,S) 	6.0	453.2
26		(R,S) 	5.9	453.2
27		(R,S) 	6.0	453.2
28		(R,S) 	6.2	468.2

				
FORMULA 52				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
29			6.1	468.2
30			6.7	491.2
31			6.1	498.2
32			6.5	501.1
33			6.0	429.2
34			5.9	513.2
35			6.1	441.2
36			6.6	491.2
37			6.4	501.1

				
FORMULA 52				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
38			5.5	466.3
39			6.7	507.2
40			4.9	524.3
41			5.9	423.2
42			5.6	439.2
43			5.5	439.2
44			6.0	441.2
45			6.0	453.2
46			5.9	453.2














				
FORMULA 52				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
47			6.0	453.2
48			6.1	468.2
49			6.1	468.2
50			6.6	491.1
51			6.2	498.2
52			6.4	501.1
53			5.8	429.2
54			5.8	513.2
55			6.0	441.2


				
FORMULA 52				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
56			6.5	491.2
57			6.3	501.1
58			5.4	466.3
59			6.6	507.2
60			4.9	524.3
61			5.9	423.2
62			5.6	439.2
63			5.5	439.2
64			6.0	441.2



FORMULA 52


	R1	R2	Analysis	
			Tr	[M+H] ⁺
65			6.0	453.2
66			5.9	453.2
67			6.0	453.2
68			6.0	468.2
69			6.0	468.2
70			6.6	491.1
71			6.2	498.2
72			6.4	501.1
73			5.9	429.2

				
FORMULA 52				
	R1	R2	Analysis	
			Tr	[M+H] ⁺
74			5.8	513.3
75			6.0	441.2
76			6.5	491.2
77			6.3	501.1
78			5.4	466.3
79			6.6	507.2




FORMULA 53

	R1	R2	Analysis	
			T _r (min)	[M+H] ⁺
1		(R)	5.2	416.2
2		(R)	5.5	418.1
3		(R)	5.0	430.2
4		(R)	5.0	457.2
5		(R)	5.9	480.2
6		(R)	6.1	491.2
7		(R)	6.4	501.2
8		(R)	4.9	505.2
9		(R)	6.3	509.2




FORMULA 53

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
10		(R)	5.9	521.2
11		(R)	6.7	525.2
12		(R)	7.0	526.2
13		(R)	6.3	536.2
14		(R)	5.9	522.2
15		(R)	6.7	525.2
16		(R)	4.6	492.2
17		(R)	6.9	504.2
18		(R)	5.4	472.2




FORMULA 53

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
19			5.9	506.2
20			6.6	536.2
21			4.9	549.2
22			6.9	559.2
23			6.0	560.2
24			6.7	525.2
25			5.0	507.2
26			6.9	519.2




FORMULA 53

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
27	 Chiral		5.0	416.2
28			6.4	549.2
29			5.8	546.2
30			5.5	509.2
31			6.8	611.2
32			7.2	570.2
33			5.8	521.2




FORMULA 53

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
34		(R)	5.8	581.2
35		(R)	5.1	507.2
36		(R)	4.2	516.3
37		(R)	6.4	509.2
38		(R)	6.7	537.2
39		(R,S)	5.1	396.2
40		(R,S)	5.4	398.2
41		(R,S)	5.0	410.2




FORMULA 53

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
42		(R,S) $\rightarrow$ -	4.9	437.2
43		(R,S) $\rightarrow$ -	5.8	460.2
44		(R,S) $\rightarrow$ -	6.0	471.3
45		(R,S) $\rightarrow$ -	6.4	481.2
46		(R,S) $\rightarrow$ -	4.8	485.3
47		(R,S) $\rightarrow$ -	6.2	489.2
48		(R,S) $\rightarrow$ -	5.8	501.3
49		(R,S) $\rightarrow$ -	6.7	505.2
50		(R,S) $\rightarrow$ -	6.9	506.3
51		(R,S) $\rightarrow$ -	6.2	516.2




FORMULA 53

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
52		(R,S) $\rightarrow$	5.9	502.2
53		(R,S) $\rightarrow$	6.6	505.2
54		(R,S) $\rightarrow$	4.5	472.3
55		(R,S) $\rightarrow$	6.8	484.3
56		(R,S) $\rightarrow$	5.3	452.3
57		(R,S) $\rightarrow$	5.8	486.3
58		(R,S) $\rightarrow$	6.5	516.3
59		(R,S) $\rightarrow$	4.8	529.2
60		(R,S) $\rightarrow$	6.9	539.2




FORMULA 53

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
61		(R,S) $\rightarrow$ -	6.0	540.2
62		(R,S) $\rightarrow$ -	6.6	505.2
63		(R,S) $\rightarrow$ -	4.9	487.3
64		(R,S) $\rightarrow$ -	6.9	499.3
65		(R,S) $\rightarrow$ -	4.9	396.2
66		(R,S) $\rightarrow$ -	6.3	529.2
67		(R,S) $\rightarrow$ -	5.7	526.3
68		(R,S) $\rightarrow$ -	5.4	489.2




FORMULA 53

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
69		(R,S) $\rightarrow$ -	6.7	591.3
70		(R,S) $\rightarrow$ -	7.2	550.3
71		(R,S) $\rightarrow$ -	5.7	501.3
72		(R,S) $\rightarrow$ -	5.7	561.3
73		(R,S) $\rightarrow$ -	5.0	487.3
74		(R,S) $\rightarrow$ -	4.1	496.4
75		(R,S) $\rightarrow$ -	6.3	489.3
76		(R,S) $\rightarrow$ -	6.7	517.2




FORMULA 54

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
1			4.4	431.2
2			6.3	442.2
3			6.1	450.2
4			5.9	466.2
5			6.2	480.2
6			5.9	510.2
7			4.5	440.2
8			5.8	526.2




FORMULA 54

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
9			6.1	495.2
10			6.3	430.3
11			4.5	437.2
12			4.5	451.2
13			4.5	473.3
14			5.7	501.3
15			5.8	511.2
16			6.4	496.2
17			5.3	468.2
18			4.7	472.3




FORMULA 54

	R1	R2	Analysis	
			Tr (mm)	[M+H] ⁺
19		(R)	5.8	402.2
20		(R)	5.6	568.2
21		(R)	5.8	512.2
22		(R)	4.6	437.2
23		(R)	6.3	470.2
24		(R)	7.0	540.2
25		(R)	6.4	464.2
26		(R)	4.5	443.3




FORMULA 54

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
27			6.5	484.2
28			6.2	468.2
29			6.2	468.2
30			6.5	484.2
31			6.6	528.1
32			6.5	504.2
33			6.5	504.2
34			4.5	437.2
35			6.1	466.2




FORMULA 54

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
36		(R)	6.2	470.2
37		(R)	6.0	454.2
38		(R)	6.0	454.2
39		(R)	5.0	454.2
40		(R)	4.3	486.3
41		(R,S)	4.4	411.3
42		(R,S)	6.3	422.3
43		(R,S)	6.0	430.3
44		(R,S)	5.9	446.2




FORMULA 54

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
45		(R,S)	6.2	460.3
46		(R,S)	5.5	490.3
47		(R,S)	4.4	420.3
48		(R,S)	5.7	506.3
49		(R,S)	6.1	475.2
50		(R,S)	6.2	410.3
51		(R,S)	4.4	417.2




FORMULA 54

	R1	R2	Analysis	
			Tr (mm)	[M+H] ⁺
52		(R,S)	4.4	431.2
53		(R,S)	4.4	453.3
54		(R,S)	5.7	481.3
55		(R,S)	5.7	491.2
56		(R,S)	6.4	476.3
57		(R,S)	5.2	448.2
58		(R,S)	4.6	452.3
59		(R,S)	5.7	382.3
60		(R,S)	5.5	548.2




FORMULA 54

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
61		(R,S)	6.7	492.3
62		(R,S)	4.5	417.2
63		(R,S)	6.2	450.2
64		(R,S)	7.0	520.3
65		(R,S)	6.3	444.3
66		(R,S)	4.4	423.3
67		(R,S)	6.4	464.2




FORMULA 54

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
68		(RS)	6.1	448.2
69		(RS)	6.2	448.2
70		(RS)	6.4	464.2
71		(RS)	6.5	510.1
72		(RS)	6.5	484.2
73		(RS)	6.5	484.2
74		(RS)	4.4	417.2




FORMULA 54

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
75		(R,S) $\rightarrow$	6.0	446.2
76		(R,S) $\rightarrow$	6.2	450.2
77		(R,S) $\rightarrow$	6.0	434.2
78		(R,S) $\rightarrow$	5.9	434.2
79		(R,S) $\rightarrow$	6.0	434.2
80		(R,S) $\rightarrow$	4.1	466.3




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
1		(R,S)	6.4	486.2
2		(R,S)	6.6	486.2
3		(R,S)	6.6	486.2
4		(R,S)	6.4	530.1
5		(R,S)	6.7	530.1
6		(R,S)	6.6	530.1
7		(R,S)	6.3	470.2
8		(R,S)	6.3	488.2




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
9		(R,S)	6.4	488.2
10		(R,S)	6.3	497.2
11		(R,S)	6.4	497.2
12		(R,S)	6.4	497.2
13		(R,S)	6.4	520.2
14		(R,S)	6.8	520.2
15		(R,S)	6.8	520.2
16		(R,S)	6.3	512.2




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
17		(R,S)	6.2	482.2
18		(R,S)	6.1	482.2
19		(R,S)	6.8	554.1
20		(R,S)	6.4	515.1
21		(R,S)	6.7	534.0
22		(R,S)	6.9	534.0
23		(R,S)	6.8	534.0
24		(R,S)	6.7	578.0
25		(R,S)	6.9	578.0




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
26		(R,S)	6.9	578.0
27		(R,S)	6.6	518.1
28		(R,S)	6.6	536.1
29		(R,S)	6.7	536.1
30		(R,S)	6.6	545.0
31		(R,S)	6.7	545.0
32		(R,S)	6.7	545.0
33		(R,S)	6.7	568.0
34		(R,S)	7.1	568.0




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
35		(R,S)	7.1	568.0
36		(R,S)	8.6	560.1
37		(R,S)	6.5	530.1
38		(R,S)	6.4	530.1
39		(R,S)	7.1	602.0
40		(R,S)	6.7	563.0
41		(R,S)	6.6	501.1
42		(R,S)	6.8	501.1
43		(R,S)	6.8	501.1




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
44		(R,S)	6.7	545.0
45		(R,S)	6.9	545.0
46		(R,S)	6.9	545.0
47		(R,S)	6.5	485.1
48		(R,S)	6.5	503.2
49		(R,S)	6.7	503.2
50		(R,S)	6.6	512.2
51		(R,S)	6.6	512.2
52		(R,S)	6.6	512.2




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
53		(R,S)	6.7	535.1
54		(R,S)	7.1	535.1
55		(R,S)	7.1	535.1
56		(R,S)	6.4	527.2
57		(R,S)	6.3	497.2
58		(R,S)	6.2	497.2
59		(R,S)	7.2	569.1
60		(R,S)	6.7	530.1




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
61		(R,S)	5.9	527.2
62		(R,S)	6.2	527.2
63		(R,S)	6.1	527.2
64		(R,S)	5.9	571.1
65		(R,S)	6.3	571.1
66		(R,S)	6.2	571.1
67		(R,S)	5.9	511.3




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
68		(R,S)	5.8	529.2
69		(R,S)	6.0	529.2
70		(R,S)	5.8	538.2
71		(R,S)	5.9	538.2
72		(R,S)	6.0	538.2
73		(R,S)	6.0	561.2
74		(R,S)	6.4	561.2




FORMULA 55

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
75		(R,S)	6.5	561.0
76		(R,S)	5.8	553.3
77		(R,S)	5.7	523.3
78		(R,S)	5.6	523.3
79		(R,S)	6.5	595.2
80		(R,S)	6.0	556.2




FORMULA 56

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
1		(R,S)	5.8	485.2
2		(R,S)	5.8	485.2
3		(R,S)	6.0	485.2
4		(R,S)	5.8	529.2
5		(R,S)	6.0	529.2
6		(R,S)	6.0	529.2
7		(R,S)	5.5	469.2
8		(R,S)	5.7	469.3




FORMULA 56

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
9		(R,S)	5.6	489.2
10		(R,S)	5.5	496.3
11		(R,S)	5.6	496.3
12		(R,S)	5.6	496.3
13		(R,S)	6.0	519.2
14		(R,S)	6.2	519.2
15		(R,S)	6.2	519.2
16		(R,S)	5.5	481.1






















FORMULA 56


	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
17		(R,S)	5.5	481.2
18		(R,S)	5.4	481.2
19		(R,S)	5.4	451.2
20		(R,S)	4.3	494.2
21		(R,S)	6.1	533.1
22		(R,S)	6.2	533.1
23		(R,S)	6.3	533.1
24		(R,S)	6.1	577.0
25		(R,S)	6.3	577.0



FORMULA 56


















	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
26		(R,S)	6.3	577.0
27		(R,S)	5.9	517.1
28		(R,S)	6.0	517.1
29		(R,S)	6.0	517.1
30		(R,S)	5.8	544.1
31		(R,S)	6.0	544.1
32		(R,S)	6.0	544.1
33		(R,S)	6.3	567.1
34		(R,S)	6.5	567.1


				
FORMULA 56				
	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
35		(R,S) 	6.5	567.1
36		(R,S) 	5.9	529.1
37		(R,S) 	5.9	529.1
38		(R,S) 	5.9	529.1
39		(R,S) 	5.9	499.1
40		(R,S) 	4.7	542.1
41		(R,S) 	6.2	500.2
42		(R,S) 	6.4	500.2
43		(R,S) 	6.9	500.1



FORMULA 56


	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
44		(R,S)	6.8	544.0
45		(R,S)	7.0	544.0
46		(R,S)	7.0	544.0
47		(R,S)	6.5	484.2
48		(R,S)	6.6	484.2
49		(R,S)	6.6	484.2
50		(R,S)	6.4	511.2
51		(R,S)	6.6	511.2
52		(R,S)	6.6	511.2

				
FORMULA 56				
	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
53		(R,S) 	7.0	534.1
54		(R,S) 	7.1	534.1
55		(R,S) 	7.2	534.1
56		(R,S) 	6.6	496.2
57		(R,S) 	6.5	496.2
58		(R,S) 	6.5	496.2
59		(R,S) 	6.5	466.2
60		(R,S) 	5.4	509.2




FORMULA 56

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
61		(R,S)	5.8	526.2
62		(R,S)	6.0	526.3
63		(R,S)	6.0	526.3
64		(R,S)	5.9	570.2
65		(R,S)	6.1	570.1
66		(R,S)	6.1	570.1
67		(R,S)	5.6	510.3
68		(R,S)	5.7	510.3




FORMULA 56

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
69		(R,S)	5.6	537.2
70		(R,S)	5.7	537.2
71		(R,S)	5.7	537.3
72		(R,S)	6.1	560.2
73		(R,S)	6.2	560.2
74		(R,S)	6.3	560.2
75		(R,S)	5.7	522.3



FORMULA 56


	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
76		(R,S)	5.6	522.3
77		(R,S)	5.6	522.3
78		(R,S)	5.6	492.3
79		(R,S)	4.7	535.3



FORMULA 57










	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
1		(R)	14.4	414.2
2		(R)	6.4	418.2
3		(R)	11.1	445.3
4		(R)	10.8	457.3
5		(R)	14.3	462.2
6		(R)	14.5	466.1
7		(R)	14.5	489.2
8		(R)	12.2	519.4
9		(R)	10.1	466.1












FORMULA 57				
	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
10		(R)	14.8	486.1
11		(R)	12.1	459.3
12		(R)	14.4	480.1
13		(R)	14.8	476.1
14		(R)	14.4	442.1
15		(R)	14.8	504.1
16		(R)	14.7	470.1
17		(R)	14.7	574.1




FORMULA 57

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
18		(R)	15.0	526.2
19		(R)	12.0	454.3
20		(R)	8.0	529.1
21		(S)	14.4	414.2
22		(S)	6.3	418.2
23		(S)	11.3	445.3
24		(S)	10.7	457.3
25		(S)	14.3	462.2








				
FORMULA 57				
	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
26		(S) 	14.6	466.1
27		(S) 	14.5	489.2
28		(S) 	12.2	519.2
29		(S) 	11.7	466.1
30		(S) 	14.8	486.1
31		(S) 	12.0	459.3
32		(S) 	14.4	480.1
33		(S) 	14.8	476.2


















				
FORMULA 57				
	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
34		(S) 	14.4	442.1
35		(S) 	14.7	504.1
36		(S) 	14.7	470.1
37		(S) 	14.7	574.1
38		(S) 	14.9	526.2
39		(S) 	11.8	454.3
40		(S) 	8.5	529.1
41		(R) 	14.3	394.2




FORMULA 57

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
42		(R)	6.0	396.2
43		(R)	14.2	442.2
44		(R)	14.6	446.2
45		(R)	14.6	469.2
46		(R)	10.7	446.2
47		(R)	14.8	466.2
48		(R)	11.8	439.3
49		(R)	14.4	460.1

				
FORMULA 57				
	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
50		(R) 	14.8	456.2
51		(R) 	14.4	422.1
52		(R) 	14.8	484.1
53		(R) 	14.7	450.1
54		(R) 	14.7	554.1
55		(R) 	15.0	506.2
56		(R) 	11.6	434.3


				
FORMULA 57				
	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
57		(R) 	8.1	509.1
58		(S) 	14.4	394.2
59		(S) 	11.4	398.2
60		(S) 	14.2	442.2
61		(S) 	14.6	446.2
62		(S) 	14.6	468.2
63		(S) 	11.0	446.2
64		(S) 	14.8	466.2



FORMULA 57


	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
65		(S)	11.8	439.3
66		(S)	11.4	460.2
67		(S)	14.8	456.2
68		(S)	14.3	422.1
69		(S)	14.7	484.2
70		(S)	14.6	450.2
71		(S)	14.7	554.1

FORMULA 57				
	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
72			14.9	506.2
73			11.7	434.3
74			8.4	509.2




FORMULA 58

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
1		(R)	12.9	422.2
2		(R)	13.3	456.2
3		(R)	12.9	436.2
4		(R)	13.6	472.3
5		(R)	14.5	514.2
6		(R)	14.6	506.3
7		(R)	14.2	490.2
8		(R)	13.5	494.2

















FORMULA 58


	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
9		(R)	13.3	458.2
10		(R)	13.3	467.2
11		(R)	13.2	438.2
12		(R)	13.8	466.2
13		(R)	13.9	452.2
14		(R)	13.8	488.2
15		(R)	14.8	544.2
16		(R)	14.3	480.2



FORMULA 58


	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
17		(R)	14.2	472.2
18		(R)	14.7	446.3
19		(R)	10.4	475.2
20		(R)	13.8	496.2
21		(S)	13.1	422.2
22		(S)	13.4	456.2
23		(S)	13.1	436.2
24		(S)	13.7	472.3

				
FORMULA 58				
	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
25		(S) 	14.7	514.2
26		(S) 	14.7	506.3
27		(S) 	14.3	490.2
28		(S) 	13.7	494.2
29		(S) 	13.4	458.2
30		(S) 	13.6	467.2
31		(S) 	13.3	438.2
32		(S) 	13.9	466.2




FORMULA 58

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
33		(S)	13.9	452.2
34		(S)	14.0	488.2
35		(S)	15.1	544.2
36		(S)	14.5	480.2
37		(S)	14.2	472.2
38		(S)	13.8	496.2
39		(R)	13.1	402.2
40		(R)	13.6	436.2




FORMULA 58

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
41		(R)	13.6	452.2
42		(R)	14.8	494.2
43		(R)	14.9	486.3
44		(R)	14.3	470.2
45		(R)	13.7	474.3
46		(R)	13.4	438.2
47		(R)	13.2	418.2




FORMULA 58

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
48		(R)	13.6	446.2
49		(R)	10.0	432.1
50		(R)	10.1	468.1
51		(R)	14.2	460.2
52		(R)	14.0	452.2
53		(R)	14.8	426.3
54		(R)	10.4	455.3
55		(R)	13.9	476.2



FORMULA 58

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
56		(S)	13.6	436.2
57		(S)	14.9	486.3
58		(S)	14.4	470.2
59		(S)	13.8	474.3
60		(S)	13.4	438.2
61		(S)	13.3	447.2
62		(S)	13.1	418.2
63		(S)	13.5	446.2



FORMULA 58

	R1	R2	Analysis	
			Tr (min)	[M+H] ⁺
64		(S)	13.5	432.2
65		(S)	13.7	468.2
66		(S)	14.7	524.2
67		(S)	14.3	460.2
68		(S)	14.2	452.2
69		(S)	13.8	476.2

Example 13777: N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine

13777.1) 2-((tert-butoxycarbonyl)amino)-6-methylheptanoic acid

A solution of diisopropylamine (13.2 ml; 0.094 mol) in 130 ml tetrahydrofurane (THF) was cooled down to about -40 °C. *n*-Butyllithium (37 ml of a 2.5 M solution in hexane; 0.094 mol) was added dropwise. The temperature was left to return to about 0 °C. At this temperature, Boc-glycine (5 g; 0.028 mol) in solution in 30 ml THF was introduced into the mixture. After ten minutes at this temperature, 1-bromo-4-methylpentane (7.9 ml; 0.056 mol) in solution in 20 ml THF was quickly added. The temperature was then left to return to about 23 °C and the mixture agitated for about one hour at this temperature. After hydrolysis with 100 ml water and acidification with 150 ml of a saturated potassium hydrogensulfate solution, the obtained mixture was extracted with 2 times 50 ml ethyl acetate. The organic phase was washed with 100 ml water followed by 100 ml of a saturated sodium chloride solution. After drying on magnesium sulfate and evaporation of the solvent, the residue obtained was purified on a silica column (eluent : ethyl acetate - heptane / 6-4) to produce a white-colored powder with a yield of 50%. MH⁺ = 260.3.

13777.2) tert-butyl 1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexylcarbamate

A mixture of 2-((tert-butoxycarbonyl)amino)-6-methylheptanoic acid (3.5 g; 0.0135 mol) and cesium carbonate (4.89 g; 0.015 mol) in 100 ml ethanol was agitated at about 23°C for about 1 hour. The ethanol was eliminated by evaporation under reduced pressure in a rotative evaporator. The mixture obtained was dissolved in 100 ml of dimethylformamide and 3-bromophenacyl bromide (3.75 g; 0.0135 mol) was then added. After about 16 hours agitation, the solvent was evaporated under reduced pressure. The mixture obtained was taken up in ethyl acetate and the cesium bromide was then filtered. The ethyl acetate of the filtrate was evaporated and the reaction oil was taken up in a mixture of xylene (100 ml) and ammonium acetate (46.2 g; 0.6 mol). The mixture was then heated to reflux for about one hour and a half and, after cooling, a mixture of icy water and ethyl acetate was poured in the reaction medium. After phase separation, the organic phase was washed with a sodium saturated bicarbonate solution, dried over magnesium sulfate and then evaporated under vacuum. The solid obtained was filtered and then washed with ether to produce a white powder (yield of 63%). Melting point: 134-136 °C. MH⁺ = 436.2.

13777.3) 1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methyl-1-hexanamine

tert-Butyl 1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexylcarbamate (obtained at stage 13777.2; 3.5 g; 0.008 mol) was agitated in 120 ml of an ethyl acetate solution saturated in hydrochloric acid for about 2.5 at a temperature of about 55 °C. The solid obtained was filtered and washed with ether. A white powder was obtained with a yield of 97%. Melting point: 200-202 °C. MH⁺ = 336.2.

13777.4) N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine

A mixture containing 1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methyl-1-hexanamine (obtained at stage 13777.3; 0.8 g; 0.0019 mol), triethylamine (0.4 ml; 0.003 mol) and cyclohexanone (0.32 ml; 0.0023 mol) in 10 ml methanol was agitated for about 30 minutes at about 23 °C. Sodium triacetoxyborohydride (630 mg; 0.003 mol) was then added. The reaction mixture was agitated for about 16 hours and then poured into water. After extraction with ethyl acetate, the organic phase was washed with a saturated sodium chloride solution and then dried over magnesium sulfate. The solvent was evaporated and the residue purified over a silica column (eluent: mixture CH₂Cl₂-MeOH / 95-05). A white-colored powder was obtained with a yield of 38%. Melting point: 236-238 °C. MH⁺ = 418.2.

Example 13778: N-{1-(4-(4-fluorophenyl)-1H-imidazol-2-yl)heptyl}cyclohexanamine13778.1) *tert*-butyl 1-(4-(4-fluorophenyl)-1H-imidazol-2-yl)heptylcarbamate

This compound was obtained according to a protocol analogous to that of stage 13777.2 of example 13777, using 2-((*tert*-butoxycarbonyl)amino)octanoic acid (6.2 g; 0.024 mol) instead of 2-((*tert*-butoxycarbonyl)amino)-6-methylheptanoic acid and 2-bromo-4-fluoroacetophenone (5.2 g; 0.024 mol) instead of 3-bromophenacyl bromide. A white powder was obtained (yield: 58%), which was sufficiently clean to be used as was for the following stage.

13778.2) 1-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-1-heptanamine

This compound was obtained according to a protocol analogous to that of stage 13777.3 of example 13777, using *tert*-butyl 1-(4-(4-fluorophenyl)-1H-imidazol-2-yl)heptylcarbamate (5.2 g; 0.014 mol) as starting compound. After purification over a silica column (eluent: CH₂Cl₂-MeOH-NH₄OH / 89-10-1), a gray powder was obtained (yield of 72%). Melting point: 148-150 °C. MH⁺ = 276.2.

13778.3) *N*-{1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)heptyl}cyclohexanamine

This compound was obtained according to a protocol analogous to that of stage 13777.4 of example 13777, using 1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine (0.5 g; 0.0014 mol) as starting amine and cyclohexanone (0.17 ml; 0.0014 mol) as starting ketone. A white powder was obtained with a yield of 15%. Melting point: 190-192°C. MH⁺ = 358.2.

Example 13779: (1*R*)-*N*-benzyl-1-(1-benzyl-4-*tert*-butyl-1*H*-imidazol-2-yl)-2-(1*H*-indol-3-yl)ethanamine

Triethylamine (0.83 ml; 0.006 mol) was added at about 23 °C to a solution of (1*R*)-1-(1-benzyl-4-*tert*-butyl-1*H*-imidazol-2-yl)-2-(1*H*-indol-3-yl)ethanamine (0.7 g; 0.002 mol; prepared according to experimental conditions analogous to the preceding examples and using the appropriate starting compounds and reaction products) in 15 ml acetonitrile. The mixture was agitated about one hour at about 23°C and benzyl chloride (0.23 ml; 0.002 mol) was added. Agitation was maintained for about 16 hours. The reaction mixture was concentrated using a rotative evaporator and the oil obtained was taken up in ethyl acetate and water. The aqueous phase was extracted with ethyl acetate and washed with water and then with a saturated solution of sodium chloride. The solvents were evaporated under vacuum. After purification over a silica column (eluent: ethyl acetate - heptane / 7-3), a strong beige solid was obtained in the form of a glue (yield of 5%). Free base. Melting point: 60-62 C. MH⁺ = 463.3.

Example 13780: (R,S)-*N*-benzyl-1-(1-benzyl-4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

(R,S)-1-(4-phenyl-1*H*-imidazol-2-yl)heptylamine (1 g; 0.003 mol; prepared according to experimental conditions analogous to the preceding examples and using the appropriate starting compounds and reaction products) was diluted in 20 ml dimethylformamide. Potassium carbonate (2.2 g; 0.016 mol) was added at about 23 °C and then benzyl bromide (1.2 ml; 0.010 mol) was added quite slowly. The mixture was agitated about 72 hours at about 23 °C before being poured in icy water. The mixture was extracted with ethyl acetate. The organic phase was washed with water and then a saturated solution of sodium chloride. After drying over magnesium sulfate, the solvents were concentrated using a rotative evaporator. After purification over a silica column (eluent: ethyl acetate - heptane / 10-90), a white powder was obtained (yield of 31%). Free base. Melting point: 94-96 °C. MH⁺ = 438.3.

Example 13781: *N*-benzyl-*N*-((4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methyl)-1-hexanamine

N-benzyl(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methanamine (1 g; 0.0024 mol; prepared according to experimental conditions analogous to the preceding examples and using the appropriate starting compounds and reaction products) was diluted in 15 ml dimethylformamide. Potassium carbonate (1 g; 0.0073 mol) was added at about 23 °C and then hexane bromide (0.34 ml; 0.0024 mol) was added quite slowly. The reaction mixture was brought around the temperature of about 70°C for about 3 hours before being poured in icy water. The mixture was extracted with ethyl acetate and the organic phase washed with water. After drying over magnesium sulfate, the solvents were concentrated using a rotative evaporator. After purification over a silica column (eluent: ethyl acetate - heptane / 7-3), a light yellow solid was obtained in the form of a glue (yield of 13%). Free base. Melting point: 120-122 °C. MH⁺ = 424.3.

Example 13782: *N*-benzyl(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-*N*-methylmethanamine

(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-*N*-methylmethanamine (1 g; 0.003 mol; prepared according to experimental conditions analogous to the preceding examples and using the appropriate starting compounds and reaction products) was diluted in 20 ml dimethylformamide. Potassium carbonate (1.23 g; 0.009 mol) was added at about 23 °C and then benzyl bromide (0.34 ml; 0.003 mol) was added quite slowly. The reaction mixture was agitated at this temperature for about 48 hours then poured in icy water. The mixture was extracted with ethyl acetate and the organic phase washed with water. After drying over magnesium sulfate, the solvents were concentrated using a rotative evaporator. After purification over a silica column (eluent: ethyl acetate - heptane / 8-2), a white solid was obtained in the form of a glue (yield of 16%). Free base. Melting point: 106-108 °C. MH⁺ = 354.2.

Example 13783: (R,S)-*N,N*-dihexyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

(R,S)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine (1 g; 0.003 mol; prepared according to experimental conditions analogous to the preceding examples and using the appropriate starting compounds and reaction products) was diluted in 10 ml methanol. Triethylamine (0.9 ml; 0.006 mol) was added dropwise and the mixture was agitated for about 30 minutes at about 23 °C. Hexanal (0.45 ml; 0.0036 mol) was then added and the mixture was

agitated for about one hour at about 23°C. Sodium triacetoxyborohydride (1.3 g; 0.006 mol) was finally added. After about two hours agitation at about 23 °C, water was added and the reaction mixture extracted with ethyl acetate. The organic phase was washed with water and dried over magnesium sulfate before evaporation of the solvents. After purification over a silica column (eluent: ethyl acetate - heptane / 6-4), a chestnut solid was obtained in the form of a glue (yield of 3%). Free base. The melting point could not be measured (sticks). MH+ = 426.4.

Example 13784: *N-((1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)-2-pyrimidinamine*

- (1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine (2 g; 0.0066 mol; prepared according to experimental conditions analogous to the preceding examples and using the appropriate starting compounds and reaction products) was diluted in 10 ml *n*-butanol. 2-bromopyrimidine (1 g; 0.0066 mol) and then diisoehtylamine (1.15 ml; 0.0066 mol) were added dropwise. The mixture was then heated to around 80 °C for about 16 hours. The *n*-butanol was evaporated and the residue taken up in water and ethyl acetate. The organic phase was washed with water and then with a saturated solution of sodium chloride before being dried over magnesium sulfate and concentrated using a rotative evaporator. After purification over a silica column (eluent: ethyl acetate - heptane / 7-3, followed by CH₂Cl₂-MeOH-NH₄OH/ 95-4.5-0.5 and ethyl acetate). A white powder was obtained (yield of 20%). Free base. Melting point: 138-140 °C. MH+ = 381.2.

Example 13785: *(1R)-N-benzyl-2-(1H-indol-3-yl)-N-methyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine*

- (1R)-N-benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine (0.5 g; 0.00127 mol; prepared according to experimental conditions analogous to that of example 38 using the appropriate starting compounds and reaction products) was diluted in 25 ml tetrahydrofuran. Methyl tosylate (0.24 g; 0.00127 mol) was added to the preceding at about 23 °C and then potassium *tert*-butylate (0.15 g; 0.00127 mol) was added quite slowly. Agitation at about 23 °C was maintained for about two hours and then the mixture was heated to around 60°C for about 8 hours. The solvent was evaporated and the residue obtained taken up in ethyl acetate and a 10% sodium bicarbonate solution. After phase separation, the organic phase was washed with water and dried over magnesium sulfate. The solvent was then evaporated. After purification over a silica column (eluent: ethyl

acetate - heptane / 7-3), a light beige solid was obtained in the form of a glue (yield of 4%). Free base. Melting point: 110-112 °C. $MH^+ = 407.3$.

Example 13786: (1-benzyl-4-phenyl-1*H*-imidazol-2-yl)-*N,N*-dimethylmethanamine

(1-benzyl-4-phenyl-1*H*-imidazol-2-yl)methanamine (0.6 g; 0.0018 mol; prepared according to experimental conditions analogous to the preceding examples and using the appropriate starting compounds and reaction products) was diluted in 15 ml tetrahydrofurane. Triethylamine (1.12 ml; 0.008 mol) and then methyl 4-toluenesulfonate (0.75 g; 0.004 mol) were added dropwise. The mixture was agitated about 48 hours at about 23°C and then poured in icy water. After extraction with ether and phase separation, the organic phase was washed with water and afterwards with a saturated solution of sodium chloride. The organic phase was then dried over magnesium sulfate and concentrated using a rotative evaporator. After purification over a silica column (eluent: ethyl acetate - heptane / 7-3 followed by CH_2Cl_2 -MeOH / 95-5), a white powder was obtained (yield of 44%). Free base. Melting point: 78-80 °C. $MH^+ = 292.2$.

The following further examples were made according to the procedures described in examples 13777 to 13786 and to the general procedures described in this application.

Example 13787: *tert*-butyl (1*R*)-1-(4-*tert*-butyl-1*H*-imidazol-2-yl)-2-(1*H*-indol-3-yl)-ethylcarbamate

Free base. Melting point: 104-106 °C.

Example 13788: (4-phenyl-1*H*-imidazol-2-yl)methanamine

Hydrochloride. Melting point: 228-230 °C.

Example 13789: *N*-((1*S*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethyl)-1-hexanamine

Hydrochloride. Melting point: 132-134 °C.

Example 13790: *tert*-butyl (R,S)-1-(4-phenyl-1*H*-imidazol-2-yl)heptylcarbamate

Free base. Melting point: 102-104 °C.

Example 13791: (4-(1,1'-biphenyl)-4-yl-1-methyl-1*H*-imidazol-2-yl)methanamine

Hydrochloride. Melting point: 279-280 °C.

Example 13792: (1*S*)-3-methyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-butanamine

Hydrochloride. Melting point: 150-152 °C.

- 5 Example 13793: (R,S)-*N*-(2-(1-methyl-1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethyl)-1-butanamine

Free base. The melting point could not be measured (sticks).

Example 13794: (R,S)-*N*-benzyl-2-(6-fluoro-1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

- 10 Free base. Melting point: 98-100 °C.

Example 13795: (R,S)-4-(2-{1-((*tert*-butoxycarbonyl)amino)pentyl}-1*H*-imidazol-4-yl)-1,1'-biphenyl

Free base. Melting point: 172-176 °C.

- 15 Example 13796: (R,S)-*N*-benzyl-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-1-pentanamine

Free base. Melting point: 201-203 °C.

Example 13797: (1*R*)-*N*-benzyl-2-phenyl-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

Free base. Melting point: 228-230 °C.

- 20 Example 13798: *tert*-butyl (R,S)-1-(4-phenyl-1*H*-imidazol-2-yl)hexylcarbamate

Free base. The melting point could not be measured (sticks).

Example 13799: (R,S)-*N*-hexyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Free base. Melting point: 140-142 °C.

Example 13800: (R,S)-1-(4-phenyl-1*H*-imidazol-2-yl)hexylamine

Hydrochloride. Melting point: 146-148 °C.

Example 13801: (R,S)-*N*-benzyl-1-(4-(4-methoxyphenyl)-1*H*-imidazol-2-yl)-1-heptanamine

5 Hydrochloride. Melting point: starting from 115 °C.

Example 13802: (R,S)-*N*-(2,6-dichlorobenzyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Free base. The melting point could not be measured (sticks).

Example 13803: (R,S)-*N*-(4-chlorobenzyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Free base. The melting point could not be measured (sticks).

Example 13804: (R,S)-1-(4-(3-methoxyphenyl)-1*H*-imidazol-2-yl)heptylamine

Hydrochloride. Melting point: 110-112 °C.

Example 13805: (R,S)-*N*-(2-chlorobenzyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Free base. The melting point could not be measured (sticks).

Example 13806: (R,S)-*N*-(2-fluorobenzyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Free base. The melting point could not be measured (sticks).

20 Example 13807: (R,S)-*N*-butyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Free base. The melting point could not be measured (sticks).

Example 13808: (R,S)-*N*-isopentyl-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)amine

Free base. The melting point could not be measured (sticks).

Example 13809: (R,S)-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-*N*-hexyl-1-heptanamine

Free base. The melting point could not be measured (sticks).

Example 13810: (R,S)-*N*-pentyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

- 5 Free base. Melting point: 118-120 °C.

Example 13811: (R,S)-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)cyclohexanamine

Free base. Melting point: 68-70 °C.

Example 13812: (R,S)-*N*-benzyl-1-(4-(3,4-dichlorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

- 10 Free base. Melting point: 192-194 °C.

Example 13813: butyl (4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methylcarbamate

Free base. Melting point: 130-132 °C.

Example 13814: (R,S)-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)cyclopentanamine

Free base. The melting point could not be measured (sticks).

- 15 Example 13815: (R,S)-*N*-{1-(4-(2-chlorophenyl)-1*H*-imidazol-2-yl)heptyl}-cyclohexanamine

Hydrochloride. Melting point: 155-157 °C.

Example 13816: (R,S)-*N*-{1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)heptyl}-cyclobutanamine

Hydrochloride. Melting point: 144-146 °C.

- 20 Example 13817: (1*R*)-*N*-benzyl-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

Free base. Melting point: 100-102 °C.

Example 13818: (R,S)-2-(1*H*-indol-3-yl)-1-(5-methyl-4-phenyl-1*H*-imidazol-2-yl)ethanamine

Hydrochloride. Melting point: 208-210 °C.

Example 13819: (R,S)-2-phenyl-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

5 Hydrochloride. Melting point: 180-182 °C.

Example 13820: (R,S)-2-(1-methyl-1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethylamine

Hydrochloride. Melting point: 110-114 °C.

Example 13821: (1*S*)-*N*-benzyl-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

Free base. Melting point: 118-120 °C.

Example 13822: (1*R*)-*N*-benzyl-2-(1*H*-indol-3-yl)-1-(5-methyl-4-phenyl-1*H*-imidazol-2-yl)ethanamine

Free base. Melting point: 120-122 °C.

15 Example 13823: *tert*-butyl (1*R*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethylcarbamate

Free base. Melting point: 208-210 °C.

Example 13824: (1*R*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

Hydrochloride. The melting point could not be measured (sticks).

20 Example 13825: *N*-((1*R*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethyl)-benzamide

Free base. Melting point: 218-220 °C.

Example 13826: benzyl (1*R*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)-ethylcarbamate

Free base. Melting point: 105-108 °C.

Example 13827: *tert*-butyl (1*R*)-2-(1*H*-indol-3-yl)-1-(4-(4-nitrophenyl)-1*H*-imidazol-2-yl)ethylcarbamate

Free base. Melting point: 220-222 °C.

Example 13828: *tert*-butyl (4-phenyl-1*H*-imidazol-2-yl)methylcarbamate

- 5 Free base. Melting point: 170-172 °C.

Example 13829: *tert*-butyl (1-benzyl-4-phenyl-1*H*-imidazol-2-yl)methylcarbamate

Free base. Melting point: 140-142 °C.

Example 13830: (1*R*)-2-(1*H*-indol-3-yl)-*N*-(2-phenylethyl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

- 10 Free base. The melting point could not be measured (sticks).

Example 13831: (1*R*)-2-(1*H*-indol-3-yl)-1-(4-(4-nitrophenyl)-1*H*-imidazol-2-yl)ethanamine

Hydrochloride. Melting point: begins to stick around 220 °C.

Example 13832: (1-benzyl-4-phenyl-1*H*-imidazol-2-yl)methanamine

Hydrochloride. Melting point: 248-250 °C.

- 15 Example 13833: (1*R*)-2-(1*H*-indol-3-yl)-*N*-(2-phenoxyethyl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

Free base. Melting point: 94-96 °C.

Example 13834: (1*R*)-1-(4-*tert*-butyl-1*H*-imidazol-2-yl)-2-(1*H*-indol-3-yl)ethylamine

Hydrochloride. Melting point: 230-232 °C.

- 20 Example 13835: *N*-benzyl(1-benzyl-4-phenyl-1*H*-imidazol-2-yl)methanamine

Free base. Melting point: 60-62 °C.

Example 13836: (1*R*)-2-(1-benzothien-3-yl)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

Free base. Melting point: 152-154 °C.

5 Example 13837: *tert*-butyl (R,S)-2-(6-chloro-1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethylcarbamate

Free base. Melting point: 208-210 °C.

Example 13838: (R,S)-2-(6-chloro-1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)-ethanamine

Hydrochloride. Melting point: 210-212 °C.

Example 13839: *tert*-butyl (1*R*)-3-methyl-1-(4-phenyl-1*H*-imidazol-2-yl)butylcarbamate

10 Free base. Melting point: 88-90 °C.

Example 13840: (1*R*)-*N*-benzyl-3-methyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-butanamine

Free base. Melting point: 134-135 °C.

Example 13841: *tert*-butyl (R,S)-phenyl(4-phenyl-1*H*-imidazol-2-yl)-methylcarbamate

Free base. Melting point: 134-136 °C.

15 Example 13842: (R,S)-phenyl(4-phenyl-1*H*-imidazol-2-yl)methylamine

Hydrochloride. The melting point could not be measured (sticks).

Example 13843: *tert*-butyl (1*R*)-3-phenyl-1-(4-phenyl-1*H*-imidazol-2-yl)-propylcarbamate

Free base. Melting point: 72-74 °C.

Example 13844: (1*R*)-3-phenyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-propanamine

20 Hydrochloride. Melting point: 174-176 °C.

Example 13845: (R,S)-*N*-benzyl(phenyl)(4-phenyl-1*H*-imidazol-2-yl)methanamine

Free base. Melting point: 144-146 °C.

Example 13846: (1*R*)-*N*-benzyl-3-phenyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-propanamine

Free base. Melting point: 142-144 °C.

Example 13847: 4-(2-(((*tert*-butoxycarbonyl)amino)methyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl

5 Free base. Melting point: 100-102 °C.

Example 13848: *N*-benzyl(4-phenyl-1*H*-imidazol-2-yl)methanamine

Free base. The melting point could not be measured (sticks).

Example 13849: 4-(1-benzyl-2-(((*tert*-butoxycarbonyl)amino)methyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl

10 Free base. Melting point: 167-169 °C.

Example 13850: (4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methanamine

Hydrochloride. Melting point: 240-242 °C.

Example 13851: (R,S) 1-(4-phenyl-1*H*-imidazol-2-yl)heptylamine

Hydrochloride. Melting point: 131-134 °C.

15 Example 13852: (1-benzyl-4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methanamine

Hydrochloride. Melting point: 170-174 °C.

Example 13853: (R,S)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Free base. Melting point: 160-162 °C.

20 Example 13854: 4-(2-(((*tert*-butoxycarbonyl)amino)methyl)-1-methyl-1*H*-imidazol-4-yl)-1,1'-biphenyl

Free base. Melting point: 208-210 °C.

Example 13855: *tert*-butyl (1*R*)-2-(1*H*-indol-3-yl)-1-(1-methyl-4-phenyl-1*H*-imidazol-2-yl)ethylcarbamate

Free base. Melting point: 96-100 °C.

5 Example 13856: 4-(2-(((*tert*-butoxycarbonyl)(methyl)amino)methyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl

Free base. Melting point: 72-74 °C.

Example 13857: (1*R*)-2-(1*H*-indol-3-yl)-1-(1-methyl-4-phenyl-1*H*-imidazol-2-yl)-ethanamine

Hydrochloride. Melting point: 206-210 °C.

Example 13858: *tert*-butyl methyl((5-methyl-4-phenyl-1*H*-imidazol-2-yl)-methyl)carbamate

10 Free base. Melting point: 70-72 °C.

Example 13859: (4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-*N*-methylethanamine

Hydrochloride. Melting point: 218-220 °C.

Example 13860: *N*-methyl-(5-methyl-4-phenyl-1*H*-imidazol-2-yl)methanamine

Hydrochloride. Melting point: 218-220 °C.

15 Example 13861: 4-(2-((benzyl(*tert*-butoxycarbonyl)amino)methyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl

Free base. Melting point: 130-132 °C.

Example 13862: (1*R*)-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-3-phenyl-1-propanamine

20 Hydrochloride. Melting point: 215-218 °C.

Example 13863: *N*-benzyl(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methanamine

Hydrochloride. Melting point: > 250 °C.

Example 13864: (1*R*)-*N*-benzyl-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-3-phenyl-1-propanamine

Free base. Melting point: 210-213 °C.

Example 13865: *tert*-butyl (R,S)-1-(4-phenyl-1*H*-imidazol-2-yl)pentylcarbamate

5 Free base. Melting point: 126 °C.

Example 13866: (R,S)-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-1-pentanamine

Hydrochloride. Melting point: 197-200 °C.

Example 13867: (R,S)-1-(4-phenyl-1*H*-imidazol-2-yl)pentylamine

Hydrochloride. Melting point: 178-180 °C.

10 Example 13868: *tert*-butyl (R,S)-1-(4-(4-methylphenyl)-1*H*-imidazol-2-yl)-heptylcarbamate

Free base. Melting point: 77-80 °C.

Example 13869: *tert*-butyl (R,S)-1-(4-(2-methoxyphenyl)-1*H*-imidazol-2-yl)-heptylcarbamate

Free base. Melting point: 64-65 °C.

15 Example 13870: (R,S)-1-(4-(4-methylphenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Hydrochloride. Melting point: 157-160 °C.

Example 13871: (R,S)-1-(4-(2-methoxyphenyl)-1*H*-imidazol-2-yl)heptylamine

Hydrochloride. Melting point: 238-240 °C.

Example 13872: (R,S)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-pentanamine

20 Free base. Melting point: 200-202 °C.

Example 13873: *tert*-butyl (R,S)-1-(4-(4-methoxyphenyl)-1*H*-imidazol-2-yl)-heptylcarbamate

Free base. Melting point: 125-127 °C.

Example 13874: (R,S)-1-(4-(1,1'-biphenyl)-4-yl)-1*H*-imidazol-2-yl)-1-heptanamine

Hydrochloride. Melting point: 182-184 °C.

Example 13875: *tert*-butyl (R,S)-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-heptylcarbamate

Free base. Melting point: 141-143 °C.

5 Example 13876: (R,S)-1-(4-(4-methoxyphenyl)-1*H*-imidazol-2-yl)heptylamine

Hydrochloride. Melting point: 231-232 °C.

Example 13877: (R,S)-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Hydrochloride. Melting point: 230-231 °C.

10 Example 13878: (R,S)-4-(2-{1-((*tert*-butoxycarbonyl)amino)heptyl}-1*H*-imidazol-4-yl)-1,1'-biphenyl

Free base. Melting point: 142-144 °C.

Example 13879: (R,S)-*N*-benzyl-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Acétate. Melting point: 115-116 °C.

15 Example 13880: 4-(2-((1*S*)-1-((*tert*-butoxycarbonyl)amino)propyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl

Free base. Melting point: 138-140 °C.

Example 13881: (R,S)-*N*-benzyl-1-(4-(1,1'-biphenyl)-4-yl)-1*H*-imidazol-2-yl)-1-heptanamine

Free base. Melting point: 100-102 °C.

Example 13882: (1*S*)-1-(4-(1,1'-biphenyl)-4-yl)-1*H*-imidazol-2-yl)-1-propanamine

5 Hydrochloride. Melting point: > 250 °C.

Example 13883: (1*S*)-*N*-benzyl-1-(4-(1,1'-biphenyl)-4-yl)-1*H*-imidazol-2-yl)-1-propanamine

Free base. Melting point: 220-222 °C.

Example 13884: (R,S)-*N*-benzyl-1-(4-(4-methylphenyl)-1*H*-imidazol-2-yl)-1-heptanamine

10 Hydrochloride. Melting point: 185-188 °C.

Example 13885: (R,S)-*N*-benzyl-1-(4-(2-methoxyphenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Free base. Melting point: 155-157 °C.

15 Example 13886: (R,S)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-hexanamine

Free base. Melting point: 192-194 °C.

Example 13887: (R,S)-4-(2-(1-aminoheptyl)-1*H*-imidazol-4-yl)benzonitrile

Hydrochloride. Melting point: 218-220 °C.

Example 13888: (R,S)-1-(4-(4-bromophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

20 Free base. Melting point: starting from 126 °C.

Example 13889: *tert*-butyl (1*R*)-1-(4-phenyl-1*H*-imidazol-2-yl)butylcarbamate

Free base. Melting point: 156-158 °C.

Example 13890: 4-(2-((1*R*)-1-((*tert*-butoxycarbonyl)amino)butyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl

Free base. Melting point: 145.6 °C.

Example 13891: (1*R*)-1-(4-(1,1'-biphenyl)-4-yl)-1*H*-imidazol-2-yl)-1-butanamine

5 Hydrochloride. Melting point: 155.4 °C.

Example 13892: (R,S)-4-(2-(1-aminoheptyl)-1*H*-imidazol-4-yl)-2,6-di(*tert*-butyl)-phenol

Hydrochloride. Melting point: 204-206 °C.

Example 13893: (1*R*)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-butanamine

Hydrochloride. Melting point: 182-184 °C.

10 Example 13894: (R,S)-*N*-benzyl-1-(4-(4-bromophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Free base. Melting point: begins to stick around 130 °C.

Example 13895: (1*R*)-*N*-benzyl-1-(4-(1,1'-biphenyl)-4-yl)-1*H*-imidazol-2-yl)-1-butanamine

15 Free base. Melting point: 78.6 °C.

Example 13896: (1*R*)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-butanamine

Free base. Melting point: 218-220 °C.

Example 13897: (R,S)-*N*-(3-chlorobenzyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

20 Free base. The melting point could not be measured (sticks).

Example 13898: (R,S)-*N*-benzyl-1-(4-(3-methoxyphenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Free base. Melting point: 141-142 °C.

Example 13899: (R,S)-4-{2-(1-(benzylamino)heptyl)-1*H*-imidazol-4-yl}benzonitrile

Free base. Melting point: 188-189 °C.

Example 13900: (R,S)-4-(2-(1-aminoheptyl)-1*H*-imidazol-4-yl)-*N,N*-diethylaniline

Hydrochloride. Melting point: 192 °C.

5 Example 13901: (1*R*)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

Hydrochloride. Melting point: 178-181 °C.

Example 13902: (R,S)-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Hydrochloride. Melting point: 148-150 °C.

Example 13903: (R,S)-1-(4-(2-chlorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

10 Hydrochloride. Melting point: 138-140 °C.

Example 13904: *N*-((1*S*)-1-(4-(1,1'-biphenyl)-4-yl)-1*H*-imidazol-2-yl)propyl)-1-butanamine

Free base. The melting point could not be measured (sticks).

Example 13905: (1*R*)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine

15 Free base. The melting point could not be measured (sticks).

Example 13906: (R,S)-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)-*N*-propylamine

Free base. Melting point: 94-98 °C.

Example 13907: (R,S)-*N*-benzyl-1-(4-(3-methoxyphenyl)-1*H*-imidazol-2-yl)-1-heptanamine

20 Hydrochloride. Melting point: starting from 120 °C.

Example 13908: (R,S)-4-{2-(1-(benzylamino)heptyl)-1*H*-imidazol-4-yl}benzonitrile

Hydrochloride. Melting point: starting from 185 °C.

Example 13909: (R,S)-*N*-(4-methoxybenzyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Free base. Melting point: 126-128 °C.

5 Example 13910: (R,S)-*N*-benzyl-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Hydrochloride. Melting point: starting from 110 °C.

Example 13911: (R,S)-*N*-benzyl-1-(4-(2-chlorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Hydrochloride. Melting point: starting from 90 °C.

10 Example 13912: (R,S)-*N*-benzyl-*N*-(1-{4-(4-(diethylamino)phenyl)-1*H*-imidazol-2-yl}heptyl)amine

Hydrochloride. Melting point: 170 °C.

Example 13913: (R,S)-1-(4-(3,4-dichlorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Hydrochloride. Melting point: 148-150 °C.

15 Example 13914: *tert*-butyl (R,S)-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-5-methylhexylcarbamate

Free base. Melting point: 134-136 °C.

Example 13915: (R,S)-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-5-methyl-1-hexanamine

20 Hydrochloride. Melting point: 200-202 °C.

Example 13916: (R,S)-*N*-isobutyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Acetate. Melting point: 70-72 °C.

Example 13917: (R,S)-*N*-benzyl-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-5-methyl-1-hexanamine

Free base. Melting point: 92-94 °C.

5 Example 13918: (R,S)-*N*-benzyl-1-(4-(4-methoxyphenyl)-1*H*-imidazol-2-yl)-1-heptanamine

Free base. Oil.

Example 13919: (R,S)-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)cyclobutanamine

Free base. Melting point: 148-150 °C.

10 Example 13920: 4-(2-((1*S*)-1-((butoxycarbonyl)amino)ethyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl

Free base. Melting point: 118-122 °C.

Example 13921: 4-(2-((1*R*)-1-((butoxycarbonyl)amino)ethyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl

Free base. Melting point: 114-116 °C.

15 Example 13922: (R,S)-*N*-isopropyl-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)amine

Free base. Melting point: 114-116 °C.

Example 13923: (R,S)-*N*-{1-(4-(3,4-dichlorophenyl)-1*H*-imidazol-2-yl)heptyl}-cyclohexanamine

Hydrochloride. Melting point: 194 °C.

20 Example 13924: (R,S)-*N*-(1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)heptyl)-cyclohexanamine

Hydrochloride. Melting point: 168-170 °C.

Example 13925: (R,S)-2-(5-fluoro-1*H*-indol-3-yl)-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)ethylamine

Hydrochloride. Melting point: 220-222 °C.

Example 13926: *N*-{(4-(3-bromophenyl)-1*H*-imidazol-2-yl)methyl}cyclohexanamine

5 Free base. Melting point: 202-204 °C.

Example 13927: (R,S)-*N*-{2-(5-fluoro-1*H*-indol-3-yl)-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)ethyl}cyclobutanamine

Hydrochloride. Melting point: 180-190 °C.

10 Example 13928: (R,S)-*N*-{1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)-4-methylpentyl}-cyclohexanamine

Hydrochloride. Melting point: 230-232 °C.

Example 13929: (R,S)-*N*-(cyclohexylmethyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine

Hydrochloride. Melting point: 142-144 °C.

15 Example 13930: (R,S)-*N*-{1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-5-methylhexyl}-cyclohexanamine

Hydrochloride. Melting point: 216.7 °C.


Example 13931: *N*-{(1*R*)-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)-2-methylpropyl}-cyclohexanamine

20 Free base. Melting point: 224-226 °C.

CLAIMS

What is claimed is:

1. A compound of the formula (I),




the racemic-diastereomeric mixtures and optical isomers of said compound of formula (I), the pharmaceutically-acceptable salts and prodrugs thereof or a pharmaceutically acceptable salt thereof,

wherein

— represents an optional bond;


R¹ is H, -(CH₂)_m-C(O)-(CH₂)_m-Z¹, -(CH₂)_m-Z¹, -(CH₂)_m-O-Z¹ or -(C₆-C₆)alkyl-C(O)-NH-(CH₂)_m-Z³;

Z¹ is an optionally substituted moiety selected from the group consisting of (C₁-C₁₂)alkyl, benzo[b]thiophene, phenyl, naphthyl, benzo[b]furanyl, thiophene,



R² is H or (C₁-C₆)alkyl;

or R¹ and R² are taken together with the nitrogen atoms to which they are attached to form a compound of formula (Ia), (Ib) or (Ic),



R³ is -(CH₂)_m-E-(CH₂)_m-Z²;

E is O, S, -C(O)-, -C(O)-O-, -NH-C(O)-O- or a bond;

Z^2 is H, (C_1-C_{12}) alkyl, amino, (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, (C_1-C_{12}) alkylguanidino, or an optionally substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl;

5 R^4 is H or $-(CH_2)_m-A^1$;

A^1 is $-C(=Y)-N(X^1X^2)$, $-C(=Y)-X^2$, $-C(=NH)-X^2$ or X^2 ;


Y is O or S;

X^1 is H, (C_1-C_{12}) alkyl, $-(CH_2)_m-NH-(C_1-C_6)$ alkyl, $-(CH_2)_m-N-di-(C_1-C_6)$ alkyl or $-(CH_2)_m$ -aryl;

10 X^2 is $-(CH_2)_m-Y^1-X^3$ or optionally substituted (C_1-C_{12}) alkyl;


Y^1 is O, S, NH, C=O, (C_2-C_{12}) alkenyl having one or more double bonds, $-NH-CO-$, $-CO-NH-$, $-NH-CO-O-(CH_2)_m-$, $-C\equiv C-$, SO_2 or a bond;

X^3 is H, an optionally substituted moiety selected from the group consisting of (C_1-C_{12}) alkyl, (C_3-C_8) cycloalkyl, (C_1-C_{12}) alkoxy, aryloxy, (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, $-CH-di-(C_1-C_{12})$ alkoxy, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl, indolyl, morpholino, benzo[b]furanyl, quinolinyl, isoquinolinyl, $-(CH_2)_m$ -phenyl, naphthyl, fluorenyl, phthalamidyl, pyrimidinyl,



20

or X^1 and X^2 are taken together with the nitrogen to which they are attached to form an optionally substituted moiety selected from the group consisting of thiazolyl




Y^2 is $CH-X^4$, $N-X^4$, $-C(X^4X^4)$, O or S;

X^4 for each occurrence is independently $-(CH_2)_m-Y^3-X^5$;

Y^3 is $-C(O)-$, $-C(O)O-$ or a bond;

5

X^5 is hydroxy, (C_1-C_{12}) alkyl, amino, (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, or an optionally substituted moiety selected from the group consisting of aryl, aryl- (C_1-C_4) alkyl, furanyl, pyridinyl, indolyl, $-CH(phenyl)_2$.



10 R^5 is (C_1-C_{12}) alkyl, (C_0-C_6) alkyl- $C(O)-O-Z^5$, (C_0-C_6) alkyl- $C(O)-NH-(CH_2)_m-Z^3$ or optionally substituted aryl;


Z^3 for each occurrence is independently amino, (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, $-NH-C(O)-O-(CH_2)_m-phenyl$, $-NH-C(O)-O-(CH_2)_m-(C_1-C_6)$ alkyl or an optionally substituted moiety selected from the group consisting of imidazolyl,

15 pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl and thiophene;

R^6 is H or (C_1-C_6) alkyl;

R^7 is (C_1-C_{12}) alkyl or $-(CH_2)_m-Z^4$;

Z^4 is an optionally substituted moiety selected from the group consisting of phenyl, naphthyl, indolyl, thiophene, benzo[b]furan, benzo[b]thiophene, isoxazolyl,



Z^5 is H, (C_1-C_{12}) alkyl, $(CH_2)_m$ -aryl;

- 5 wherein an optionally substituted moiety is optionally substituted by one or more substituents, each independently selected from the group consisting of Cl, F, Br, I, CF_3 , CN, N_3 , NO_2 , OH, SO_2NH_2 , $-OCF_3$, (C_1-C_{12}) alkoxy, $-(CH_2)_m$ -phenyl- $(X^6)_n$, $-S$ -phenyl- $(X^6)_n$, $-S-(C_1-C_{12})$ alkyl, $-O-(CH_2)_m$ -phenyl- $(X^6)_n$, $-(CH_2)_m-C(O)-O-(C_1-C_6)$ alkyl, $-(CH_2)_m-C(O)-(C_1-C_6)$ alkyl, $-O-(CH_2)_m-NH_2$, $-O-(CH_2)_m-NH-(C_1-C_6)$ alkyl, $-O-(CH_2)_m-N-di-((C_1-C_6)$ alkyl) and
- 10 $-(C_6-C_{12})$ alkyl- $(X^6)_n$;

X^6 for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, NO_2 , N_3 , CN, OH, $-CF_3$, $-OCF_3$, (C_1-C_{12}) alkyl, (C_1-C_{12}) alkoxy, $-(CH_2)_m-NH_2$, $-(CH_2)_m-NH-(C_1-C_6)$ alkyl, $-(CH_2)_m-N-di-((C_1-C_6)$ alkyl) and $-(CH_2)_m$ -phenyl;

- 15 m for each occurrence is independently 0 or an integer from 1 to 6; and
n for each occurrence is independently an integer from 1 to 5;


provided that:

- (a) when R^5 is (C_1-C_{12}) alkyl, or $-C(O)-O-Z^5$ and Z^5 is (C_1-C_{12}) alkyl or optionally substituted aryl; R^6 is H or (C_1-C_6) alkyl; R^7 is (C_1-C_{12}) alkyl or Z^4 and Z^4 is thiophene or optionally substituted phenyl, then R^3 is not $-C(O)-O-(CH_2)_m-Z$ where m is 0 and Z is H or (C_1-C_{12}) alkyl or where m is 1 to 6 and Z is H;
- 20 (b) when R^5 is (C_1-C_{12}) alkyl or optionally substituted phenyl; R^6 is H or (C_1-C_6) alkyl; R^7 is (C_1-C_{12}) alkyl and R^3 is $-O-(CH_2)-Z^2$, then Z^2 is not an optionally substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl, and naphthyl; and
- 25 (c) when R^5 is H or (C_1-C_{12}) alkyl; R^6 is (C_1-C_6) alkyl; R^7 is (C_1-C_{12}) alkyl; and R^3 is $-O-Z^2$ or $-S-Z^2$, then Z^2 is not an optionally substituted moiety selected from the group consisting of phenyl, naphthyl, thiophene, benzothienyl and indolyl.

2. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-CH_2$ -phenyl; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;
- 30 where A^1 is $-C(=Y)-N(X^1X^2)$;
- Y is O; X^1 is H or methyl;

X^2 is $-(CH_2)_m-Y^1-X^3$;

m in the definition of X^2 is 0, 1, 2 or 3; Y^1 is a bond or O; and X^3 is N-methylpyrrolidin-2-yl, diethylamino, pyridinyl, thiophene, imidazolyl, diethoxymethyl, 1-benzyl-piperidin-4-yl, optionally substituted phenyl or




5

3. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-CH_2-$ phenyl; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H; where A^1 is $-C(=Y)-N(X^1X^2)$;

Y is O;

10 X^1 is benzyl and X^2 is 2-hydroxyethyl;

or X^1 and X^2 are taken together with the nitrogen atom to which they are




attached to form

where Y^2 is $C-X^4$ or $N-X^4$;

X^4 is $-(CH_2)_m-Y^3-X^5$ where m in the definition of X^4 is 0 or 1; and

15 X^5 is selected from the group consisting of furanyl, benzyl, phenyl, amino,



-

4. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-CH_2-$ phenyl; R^4 is $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;


where A^1 is $-C(=Y)-X^2$;

20 Y is O; X^2 is $-(CH_2)_m-Y^1-X^3$;

where m in the definition of X^2 is 0, 1 or 2;

Y^1 is O, $-NH-CO-$, $-CO-NH-$, $-NH-CO-O-CH_2-$, SO_2 or a bond; and

X^3 is methyl, furanyl, pentyl, phenyl, indolyl, $p-NO_2$ -phenyl, naphthyl, fluorenyl, $-CH(phenyl)_2$, benzothiazolyl, phthalamidyl, N,N-dimethylamino,




5. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-\text{CH}_2-$ indol-3-yl; R^4 is $-(\text{CH}_2)_m-\text{A}^1$ where m in the definition of R^4 is 0; R^5 is phenyl or t-Bu; R^6 is H;

5 A^1 is $-\text{C}(=\text{Y})-\text{N}(\text{X}^1\text{X}^2)$;

Y is O or S; X^1 is H; X^2 is $-(\text{CH}_2)_m-\text{Y}^1-\text{X}^3$;

m in the definition of X^2 is 0, 1 or 2;

Y^1 is a bond; and X^3 is phenyl, o-Cl-phenyl, m-Cl-phenyl, p-phenyloxy-phenyl, 2,6-di-isopropylphenyl, m- CF_3 -phenyl, p-ethoxycarbonyl-phenyl, 2,4-difluorophenyl, m- NO_2 -phenyl, p-benzyloxyphenyl, o-isopropylphenyl, n-hexyl, 4-



morpholino, naphthyl or


6. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-\text{CH}_2-$ indol-3-yl; R^4 is $-(\text{CH}_2)_m-\text{A}^1$ where m in the definition of R^4 is 0; R^5 is phenyl or t-Bu; R^6 is H;

15 where A^1 is $-\text{C}(=\text{Y})-\text{X}^2$;

Y is O; X^2 is $-(\text{CH}_2)_m-\text{Y}^1-\text{X}^3$;

where m in the definition of X^2 is 0, 1 or 2;

Y^1 is O, $-\text{CO}-\text{NH}-$, $-\text{NH}-\text{CO}-\text{O}-\text{CH}_2-$ or a bond; and X^3 is methyl, 3-pentyl, phenyl, p- NO_2 -phenyl, phthalamidyl, N,N-dimethylamino, p-aminophenyl, fluorenyl or



20


7. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-\text{CH}_2-$ indol-3-yl; R^4 is $-(\text{CH}_2)_m-\text{A}^1$ where m in the definition of R^4 is 0; R^5 is phenyl or t-Bu; R^6 is H;

where A^1 is $-\text{C}(=\text{Y})-\text{N}(\text{X}^1\text{X}^2)$;

25 Y is O; X^1 is hydrogen; X^2 is $-(\text{CH}_2)_m-\text{Y}^1-\text{X}^3$;

where m in the definition of X^2 is 0, 1, 2 or 3;

Y^1 is O, or a bond; and X^3 is cyclopentyl, 4-OH-butyl, N,N-diethylamino, N-methyl-pyrrolidin-3-yl, $-\text{CH}(\text{ethoxy})_2$, phenyl, $p\text{-SO}_2\text{NH}_2\text{-phenyl}$, $p\text{-OH-phenyl}$, $o\text{-CF}_3\text{-phenyl}$, $p\text{-Cl-phenyl}$, $-\text{CH}(\text{phenyl})_2$,



- 5 8. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-\text{CH}_2\text{-indol-3-yl}$; R^4 is $-(\text{CH}_2)_m\text{-A}^1$ where m in the definition of R^4 is 0; R^5 is phenyl or $t\text{-Bu}$; R^6 is H;

where A^1 is $-\text{C}(=\text{Y})\text{-X}^2$;

Y is O; X^2 is $-(\text{CH}_2)_m\text{-Y}^1\text{-X}^3$;

- 10 where m in the definition of X^2 is 0, 1, 2 or 3;

Y^1 is $-\text{NH-CO-}$, $-\text{C}=\text{C-}$, $-\text{C}\equiv\text{C-}$ or a bond; and X^3 is $t\text{-butyl}$, 1-methylcarbonyl-piperidin-4-yl, phenyl, $p\text{-Cl-phenyl}$, $m\text{-CF}_3\text{-phenyl}$, 4-nitro-naphthyl, $p\text{-methoxy-phenyl}$, $m\text{-(phenylethyl)-phenyl}$, indol-3-yl or $p\text{-aminophenyl}$.

9. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-\text{CH}_2\text{-indol-3-yl}$, $-(\text{CH}_2)_4\text{-NH-CO-O-}t\text{-Bu}$ or $-(\text{CH}_2)_4\text{-NH}_2$; R^4 is $-(\text{CH}_2)_m\text{-A}^1$ where m in the definition of R^4 is 0; R^5 is phenyl, $o\text{-methoxyphenyl}$, $p\text{-Br-phenyl}$, $p\text{-nitro-phenyl}$ or $p\text{-N,N-diethylamino-phenyl}$; R^6 is H;

where A^1 is $-\text{C}(=\text{Y})\text{-N}(\text{X}^1\text{X}^2)$;

Y is O; X^1 is H; X^2 is $-(\text{CH}_2)_m\text{-Y}^1\text{-X}^3$;

- 20 where m in the definition of X^2 is 0;

Y^1 is a bond; and X^3 is $o\text{-Br-phenyl}$, $m\text{-Br-phenyl}$, $p\text{-Br-phenyl}$, $o\text{-Cl-phenyl}$, $m\text{-Cl-phenyl}$, $p\text{-Cl-phenyl}$, $o\text{-nitro-phenyl}$, $m\text{-nitro-phenyl}$, $p\text{-nitro-phenyl}$, $o\text{-CF}_3\text{-phenyl}$, $m\text{-CF}_3\text{-phenyl}$, $p\text{-CF}_3\text{-phenyl}$, $p\text{-F-phenyl}$, 2,4-di-F-phenyl, 2,5-di-F-phenyl, 2,5-di-methoxy-phenyl, $m\text{-OMe-phenyl}$, $p\text{-OMe-phenyl}$, 2- CF_3 -4-Cl-phenyl or 3-nitro-4-F-phenyl.

10. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-\text{CH}_2\text{-indol-3-yl}$, $-(\text{CH}_2)_4\text{-NH-CO-O-}t\text{-Bu}$ or $-(\text{CH}_2)_4\text{-NH}_2$; R^4 is $-(\text{CH}_2)_m\text{-A}^1$ where m in the definition of R^4 is 0; R^5 is phenyl, $o\text{-methoxyphenyl}$, $p\text{-methoxyphenyl}$, $p\text{-Br-phenyl}$, $p\text{-nitro-phenyl}$ or $p\text{-N,N-diethylamino-phenyl}$; R^6 is H;

- 30 where A^1 is $-\text{C}(=\text{Y})\text{-X}^2$;

Y is O; X^2 is $-(\text{CH}_2)_m\text{-Y}^1\text{-X}^3$;

where m in the definition of X^2 is 1;

Y¹ is a bond; and X³ is phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, o-Cl-phenyl, m-Cl-phenyl, p-Cl-phenyl, o-nitro-phenyl, m-nitro-phenyl, p-nitro-phenyl, o-CF₃-phenyl, m-CF₃-phenyl, p-CF₃-phenyl, o-F-phenyl, m-F-phenyl, p-F-phenyl, N,N-di-methylamino-phenyl, o-OMe-phenyl, m-OMe-phenyl, p-OMe-phenyl, 3,4-di-Cl-phenyl, 3,4,5-tri-OMe-phenyl, p-Me-phenyl, p-OH-phenyl or 2,4-di-F-phenyl.

11. A compound according to claim 9 wherein R⁵ is phenyl and R³ is -(CH₂)-indol-3-yl and the stereochemistry at the carbon to which R³ is attached is the R-configuration.

12. A compound according to claim 10 wherein R⁵ is phenyl and R³ is -(CH₂)-indol-3-yl and the stereochemistry at the carbon to which R³ is attached is the R-configuration.

13. A compound according to claim 10 wherein R⁵ is o-OMe-phenyl and R³ is -(CH₂)-indol-3-yl and the stereochemistry at the carbon to which R³ is attached is the R-configuration.

14. A compound according to claim 10 wherein R⁵ is o-OMe-phenyl and R³ is -(CH₂)-indol-3-yl and the stereochemistry at the carbon to which R³ is attached is the S-configuration.

15. A compound according to claim 1 wherein R¹ is H; R² is H; R³ is -(CH₂)₄-NH-CO-O-t-Bu or -(CH₂)₄-NH₂; R⁴ is -(CH₂)_m-A¹ where m in the definition of R⁴ is 0; R⁵ is phenyl; R⁶ is H;

where A¹ is -C(=Y)-X²;

Y is O; X² is -(CH₂)_m-Y¹-X³;

where m in the definition of X² is 0, 1 or 2;

Y¹ is S, SO₂ or a bond; and X³ is phenyl, 3,4-di-Cl-phenyl, 3,4,5-tri-OMe-phenyl, p-Me-phenyl, p-OH-phenyl, 2,4-di-F-phenyl, 2-furanyl, 2-pyridinyl, 3-pyridinyl, naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 8-quinolinyl, 1-isoquinolinyl, 2-thiophene or 2-pyrimidinyl.

16. A compound according to claim 1 wherein R¹ is H; R² is H; R³ is -(CH₂)₄-NH-CO-O-t-Bu or -(CH₂)₄-NH₂; R⁴ is -(CH₂)_m-A¹ where m in the definition of R⁴ is 0; R⁵ is phenyl; R⁶ is H;

where A¹ is -C(=Y)-X²;

Y is O; X² is -(CH₂)_m-Y¹-X³;

where m in the definition of X² is 0, 1, 2 or 3;

Y^1 is a bond; and X^3 is 5-indolyl, 3-indolyl, 4-indolyl, 2-indolyl, 5-OMe-indol-3-yl, 5-OMe-indol-2-yl, 5-OH-indol-2-yl, 5-OH-indol-3-yl, 5-Br-indol-3-yl, 2-Me-indol-3-yl, 2-benzothiophene, 3-benzothiophene or 2-benzofuran.

17. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-(CH_2)_m$ -indol-3-yl, $-(CH_2)_4$ -NH-CO-O-t-Bu or $-(CH_2)_4$ -NH₂; R^4 is $-(CH_2)_m$ -A¹ where m in the definition of R^4 is 0; R^5 is phenyl, o-OMe-phenyl or p-OMe-phenyl; R^6 is H;

where A¹ is X^2 ;

X^2 is $-(CH_2)_m$ - Y^1 - X^3 ;

where m in the definition of X^2 is 1, 2 or 3;

10 Y^1 is S, O or a bond; and X^3 is phenyl, o-OH-phenyl, p-OH-phenyl, o-F-phenyl, m-F-phenyl, p-F-phenyl, o-CF₃-phenyl, o-OMe-phenyl, m-OMe-phenyl, o-nitro-phenyl, p-nitro-phenyl, 3,4-di-Cl-phenyl, 2-nitro-3-OMe-phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, 2-thiophene, 3,4,5-tri-OMe-phenyl, p-N,N-dimethylamino-phenyl, p-OCF₃-phenyl, p-(3-(N,N-dimethylamino)propoxy)phenyl, 3-F-4-OMe-phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-Cl-quinolin-3-yl, 2-quinolinyl, methyl, n-butyl, n-pentyl, n-hexyl, 3,3-dimethyl-butyl, benzyl, cyclohexyl or p-t-Bu-phenyl.

18. A compound according to claim 1 wherein R^1 is H; R^2 is H; R^3 is $-(CH_2)_4$ -NH-CO-O-t-Bu or $-(CH_2)_4$ -NH₂; R^4 is $-(CH_2)_m$ -A¹ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

where A¹ is X^2 ;

X^2 is $-(CH_2)_m$ - Y^1 - X^3 ;

where m in the definition of X^2 is 1, 2 or 3;

25 Y^1 is O or a bond; and X^3 is phenyl, o-OH-phenyl, p-OH-phenyl, o-F-phenyl, m-F-phenyl, p-F-phenyl, o-CF₃-phenyl, o-OMe-phenyl, m-OMe-phenyl, p-OMe-phenyl, o-nitro-phenyl, p-nitro-phenyl, 3,4-di-Cl-phenyl, 2-nitro-3-OMe-phenyl, o-Br-phenyl, m-Br-phenyl, p-Br-phenyl, p-phenyl-phenyl, 2-thiophene, 3,4,5-tri-OMe-phenyl, p-N,N-dimethylamino-phenyl, p-benzyloxy-phenyl, p-OCF₃-phenyl, p-(3-(N,N-dimethylamino)propoxy)phenyl, 3-F-4-OMe-phenyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-Cl-quinolin-3-yl, 2-quinolinyl, 3-indolyl, 6-methoxycarbonyl-indol-3-yl, 1-methyl-indol-3-yl, 2-methyl-indol-3-yl, methyl, n-butyl, n-pentyl, n-hexyl, 3,3-dimethyl-butyl, benzyl, cyclohexyl or p-t-Bu-phenyl.

19. A compound according to claim 1 wherein R^1 is $-(CH_2)$ -CO-Z¹; R^2 is H; R^3 is $-(CH_2)_4$ -NH-CO-O-t-Bu, $-(CH_2)_4$ -NH-CO-O-benzyl, $-(CH_2)$ -phenyl or $-(CH_2)$ -indol-3-yl; 35 R^4 is $-(CH_2)_m$ -A¹ where m in the definition of R^4 is 0; R^5 is phenyl; R^6 is H;

where Z^1 is ethyl, phenyl, p-OMe-phenyl, p-phenyl-phenyl, p-Cl-phenyl, p-Br-phenyl, p- N_3 -phenyl, p-F-phenyl, m-nitro-phenyl, p-nitro-phenyl, p-CN-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, N,N-dimethylamino-phenyl, 3-methyl-4-Cl-phenyl or naphthyl;

5 A^1 is $-C(=Y)-X^2$;


Y is O; X^2 is $-(CH_2)_m-Y^1-X^3$;

where m in the definition of X^2 is 0;

Y^1 is O; and X^3 is t-Bu.

20. A compound according to claim 1 wherein R^1 is $-(CH_2)-CO-(CH_2)_m-Z^1$
 10 where m in the definition of R^1 is 0, 1 or 2; R^2 is H; R^3 is $-(CH_2)$ -indol-3-yl or $-(CH_2)_4-NH-CO-O-t-Bu$; R^4 is H or $-(CH_2)_m-A^1$ where m in the definition of R^4 is 0; R^5 is phenyl, o-OMe-phenyl, p-nitro-phenyl, p-Br-phenyl, t-Bu, $-CH(CH_3)_2-CO-NH-(CH_2)_2-CO-O-t-Bu$, $-CH(CH_3)_2-CO-NH-(CH_2)_3$ -imidazol-1-yl, $-CH(CH_3)_2-CO-NH-(CH_2)_2$ -pyridin-2-yl, $-CH(CH_3)_2-CO-NH-(CH_2)_3$ -4-morpholino, $-CH(CH_3)_2-CO-NH-(CH_2)$ -pyridin-4-yl or
 15 $-CH(CH_3)_2-CO-NH-(CH_2)_2$ -N,N-diethylamino; R^6 is H;

where Z^1 is ethyl, propyl, phenyl, p-OMe-phenyl, p-Cl-phenyl, p-Br-phenyl, p-F-phenyl, p-nitro-phenyl, m-nitro-phenyl, p-CN-phenyl, p- N_3 -phenyl, p-phenyl-phenyl, 3-Me-4-Cl-phenyl, p-N,N-diethylamino-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, 3,4-di-F-phenyl, p-OCF₃-phenyl, p-benzyloxy-phenyl, p-pentyl-phenyl, 3,4,5-tri-OMe-phenyl, 3-nitro-4-Cl-phenyl, 3-Cl-4-nitro-phenyl, 3-methyl-5-chloro-benzothiophen-2-yl, 2-benzofuranyl, 3-benzothiophene, 3-phenyl-isoxazol-5-yl, 3-(2,4-di-Cl-phenyl)-isoxazol-5-yl, 3-indolyl, 5-Br-thiophen-2-yl, naphthyl,



A^1 is $-C(=Y)-X^2$;

25 Y is O; X^2 is $-(CH_2)_m-Y^1-X^3$;

where m in the definition of X^2 is 0;

Y^1 is O; and X^3 is t-Bu.


21. A compound according to claim 1 wherein R^1 and R^2 are taken together to form a compound of formula (Ib) or (Ic);

30 R^3 is $-(CH_2)$ -indol-3-yl, $-(CH_2)$ -phenyl, $-(CH_2)_4-NH-CO-O$ -benzyl or $-(CH_2)_4-NH_2$;


R^5 is phenyl, o-OMe-phenyl, p-OMe-phenyl, p-Br-phenyl, p-nitro-phenyl, t-Bu or

$-CH(CH_3)_2-CO-NH-(CH_2)_2-NH_2$; R^6 is H;

- 5 R^7 is ethyl, propyl, phenyl, p-OMe-phenyl, p-Cl-phenyl, p-Br-phenyl, p-F-phenyl, p-nitro-phenyl, m-nitro-phenyl, p-CN-phenyl, p-N₃-phenyl, p-phenyl-phenyl, 3-Me-4-Cl-phenyl, p-N,N-diethylamino-phenyl, 2,5-di-OMe-phenyl, 3,4-di-Cl-phenyl, 3,4-di-F-phenyl, p-OCF₃-phenyl, p-benzyloxy-phenyl, p-pentyl-phenyl, 3,4,5-tri-OMe-phenyl, 3-nitro-4-Cl-phenyl, 3-Cl-4-nitro-phenyl, 3-methyl-5-chloro-benzothiophen-2-yl, 2-bezofuranyl, 3-benzothiophene, 3-phenyl-isoxazol-5-yl, 3-(2,4-di-Cl-phenyl)-isoxazol-5-yl, 3-indolyl, 5-Br-thiophen-2-yl, naphthyl,



22. A compound of the formula (II),




the racemic-diastereomeric mixtures and optical isomers of said compound of formula (II), the pharmaceutically-acceptable salts or prodrugs thereof or a pharmaceutically acceptable salt of said prodrug,

15 wherein

— represents an optional bond;

R^1 is H, $-(CH_2)_m-C(O)-(CH_2)_m-Z^1$, $-(CH_2)_m-Z^1$, $-(CH_2)_m-O-Z^1$ or $-(C_6-C_8)alkyl-C(O)-NH-(CH_2)_m-Z^1$;


20 Z^1 is an optionally substituted moiety selected from the group consisting of $(C_1-C_{12})alkyl$, benzo[b]thiophene, phenyl, naphthyl, benzo[b]furanyl, thiophene,



isoxazolyl, indolyl,

R^2 is H or $(C_1-C_8)alkyl$;

or R^1 and R^2 are taken together with the nitrogen atoms to which they are attached to form a compound of formula (IIa), (IIb) or (IIc),



R³ is $-(CH_2)_m-E-(CH_2)_m-Z^2$;

E is O, S, $-C(O)-$, $-C(O)-O-$, $-NH-C(O)-O-$, $-N(C_1-C_6)alkyl-C(O)-O-$ or a bond;

- 5 Z² is H, $(C_1-C_{12})alkyl$, amino, $(C_1-C_{12})alkylamino$, N,N-di- $(C_1-C_{12})alkylamino$, $(C_1-C_{12})alkylguanidino$, or an optionally substituted moiety selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl and naphthyl;

R⁴ is H or $-(CH_2)_m-A^1$;

- 10 A¹ is $-C(=Y)-N(X^1X^3)$, $-C(=Y)-X^2$, $-C(=NH)-X^2$ or X^2 ;


Y is O or S;


X¹ is H, $(C_1-C_{12})alkyl$, $-(CH_2)_m-NH-(C_1-C_6)alkyl$, $-(CH_2)_m-N-di-(C_1-C_6)alkyl$ or $-(CH_2)_m-aryl$;

X² is $-(CH_2)_m-Y^1-X^3$ or optionally substituted $(C_1-C_{12})alkyl$;


- 15 Y¹ is O, S, NH, C=O, $(C_2-C_{12})alkenyl$ having one or more double bonds, $-NH-CO-$, $-CO-NH-$, $-NH-CO-O-(CH_2)_m-$, $-C\equiv C-$, SO₂ or a bond;

- 20 X³ is H, an optionally substituted moiety selected from the group consisting of $(C_1-C_{12})alkyl$, $(C_3-C_6)cycloalkyl$, $(C_1-C_{12})alkoxy$, aryloxy, $(C_1-C_{12})alkylamino$, N,N-di- $(C_1-C_{12})alkylamino$, $-CH-di-(C_1-C_{12})alkoxy$, pyrrolidinyl, pyridinyl, thiophene, imidazolyl, piperidinyl, piperazinyl, benzothiazolyl, furanyl, indolyl, morpholino, benzo[b]furanyl, quinolinyl, isoquinolinyl, $-(CH_2)_m-phenyl$, naphthyl, fluorenyl, phthalamidyl, pyrimidinyl,





or X^1 and X^2 are taken together with the nitrogen to which they are attached to form an optionally substituted moiety selected from the group consisting of thiazolyl,



5


Y^2 is $CH-X^4$, $N-X^4$, $-C(X^4X^4)$, O or S;

X^4 for each occurrence is independently H or $-(CH_2)_m-Y^3-X^5$;

Y^3 is $-C(O)-$, $-C(O)O-$ or a bond;


X^5 is hydroxy, (C_1-C_{12}) alkyl, amino, (C_1-C_{12}) alkylamino, N,N-di- (C_1-C_{12}) alkylamino, or an optionally substituted moiety selected from the group consisting of aryl, aryl (C_1-C_4) alkyl, furanyl, pyridinyl, indolyl, piperidinyl, $-CH(phenyl)_2$,

10




R^5 is (C_1-C_{12}) alkyl, (C_0-C_9) alkyl- $C(O)-O-Z^3$, (C_0-C_9) alkyl- $C(O)-NH-(CH_2)_m-Z^3$ or optionally substituted aryl;

- 5 Z^3 for each occurrence is independently amino, (C_1-C_{12}) alkylamino, amino (C_1-C_{12}) alkyl, (C_5-C_7) cycloalkylamino, amino (C_5-C_7) cycloalkyl, $N-(C_1-C_{12})$ alkylamino, N,N -di- (C_1-C_{12}) alkylamino, $-NH-C(O)-O-(CH_2)_m$ -phenyl, $-NH-C(O)-O-(CH_2)_m-(C_1-C_6)$ alkyl, $-CH(phenyl)_2$, (C_5-C_7) cycloalkyl,



optionally-substituted phenyl- $(CH_2)_m-O-C(O)-NH-(C_1-C_6)alkyl \rightarrow$




- 10 or an optionally substituted moiety selected from the group consisting of imidazolyl, pyridinyl, morpholino, piperidinyl, piperazinyl, pyrazolidinyl, furanyl, phenyl, indolyl and thiophene, provided that when m is 0 in the formula for R^5 then Z^3 is not $-NH-C(O)-O-(CH_2)_m$ -phenyl or $-NH-C(O)-O-(CH_2)_m-(C_1-C_6)alkyl$;

R^6 is H or $(C_1-C_6)alkyl$;

- 15 R^7 is $(C_1-C_{12})alkyl$ or $-(CH_2)_m-Z^4$;

Z^4 is an optionally substituted moiety selected from the group consisting of phenyl, naphthyl, indolyl, thiophene, benzo[b]furan, benzo[b]thiophene, isoxazolyl,



Z^5 is H, $(C_1-C_{12})alkyl$, or $-(CH_2)_m$ -aryl;

- 20 wherein an optionally substituted moiety is optionally substituted by one or more substituents, each independently selected from the group consisting of Cl, F, Br, I, CF_3 , CN, N_3 , NO_2 , OH, SO_2NH_2 , $-OCF_3$, $(C_1-C_{12})alkoxy$, $-(CH_2)_m$ -phenyl- $(X^6)_n$, $-S$ -phenyl- $(X^6)_n$, $-S-(C_1-C_{12})alkyl$, $-O-(CH_2)_m$ -phenyl- $(X^6)_n$, $-(CH_2)_m-C(O)-O-(C_1-C_6)alkyl$, $-(CH_2)_m-C(O)-(C_1-C_6)alkyl$, $-O-(CH_2)_m-NH_2$, $-O-(CH_2)_m-NH-(C_1-C_6)alkyl$, $-O-(CH_2)_m-N-di-((C_1-C_6)alkyl)$,
25 $-(C_0-C_{12})alkyl-(X^6)_n$ and $-(CH_2)_m$ -phenyl- X^7 ;

X^6 for each occurrence is independently selected from the group consisting of hydrogen, Cl, F, Br, I, NO_2 , N_3 , CN, OH, $-\text{CF}_3$, $-\text{OCF}_3$, $(\text{C}_1\text{-C}_{12})\text{alkyl}$, $(\text{C}_1\text{-C}_{12})\text{alkoxy}$, $-(\text{CH}_2)_m\text{-NH}_2$, $-(\text{CH}_2)_m\text{-NH-(C}_1\text{-C}_6\text{)alkyl}$, $-(\text{CH}_2)_m\text{-N-di-((C}_1\text{-C}_6\text{)alkyl)}$ and $-(\text{CH}_2)_m\text{-phenyl}$;

5 X^7 is $-\text{NH-C(=NH-HI)-X}^8$, wherein X^8 is thiophene, $(\text{C}_1\text{-C}_6)\text{alkyl}$ or phenyl;

m for each occurrence is independently 0 or an integer from 1 to 6; and

n for each occurrence is independently an integer from 1 to 5;


provided that

10 (a) when R^5 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$, or $-\text{C(O)-O-Z}^5$ and Z^5 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ or optionally substituted aryl; R^6 is H or $(\text{C}_1\text{-C}_6)\text{alkyl}$; R^7 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ or Z^4 and Z^4 is thiophene or optionally substituted phenyl, then R^3 is not $-\text{C(O)-O-(CH}_2)_m\text{-Z}$ where m is 0 and Z is H or $(\text{C}_1\text{-C}_{12})\text{alkyl}$ or where m is 1 to 6 and Z is H;


(b) when R^5 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ or optionally substituted phenyl; R^6 is H or $(\text{C}_1\text{-C}_6)\text{alkyl}$; R^7 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$ and R^3 is $-\text{O-(CH}_2)_n\text{-Z}^2$, then Z^2 is not an optionally substituted moiety
15 selected from the group consisting of phenyl, indolyl, imidazolyl, thiophene, benzothiophene, pyridinyl, and naphthyl; and

(c) when R^5 is H or $(\text{C}_1\text{-C}_{12})\text{alkyl}$; R^6 is $(\text{C}_1\text{-C}_6)\text{alkyl}$; R^7 is $(\text{C}_1\text{-C}_{12})\text{alkyl}$; and R^3 is $-\text{O-Z}^2$ or $-\text{S-Z}^2$, then Z^2 is not an optionally substituted moiety selected from the group consisting of phenyl, naphthyl, thiophene, benzothienyl and indolyl.

20 23. A compound according to claim 22 of the formula




wherein




Z^3 is $-\text{CH}_2\text{-NH}_2$, $-(\text{CH}_2)_2\text{-NH}_2$, $-(\text{CH}_2)_3\text{-NH}_2$ or

X^1 is $-(\text{CH}_2)_2\text{-N(CH}_3)_2$ and X^2 is benzyl; or


25 X^1 and X^2 are taken together with the nitrogen atom to which they are attached, to form



24. A compound according to claim 22 of the formula:




5 wherein
Z³ is




X¹ is -(CH₂)₂-N(CH₃)₂ and X² is benzyl; or

X¹ and X² are taken together with the nitrogen atom to which they are attached, to form




10

25. A compound according to claim 22 of the formula




wherein X^2 is *p*-chloro-phenyl, *p*-methoxy-phenyl, 2,4-difluoro-phenyl or thienyl.

26. A compound according to claim 22 of the formula




5 wherein X^2 is *p*-chloro-phenyl, *p*-methoxy-phenyl, phenyl or thienyl.

27. A compound according to claim 22 of the formula




28. A compound according to claim 22 of the formula







10

29. A compound according to claim 22 of the formula



wherein



30. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

31. A method of eliciting an agonist effect from one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to said subject.

32. A method of eliciting an antagonist effect from one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to said subject.

33. A method of binding one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to said subject.

34. A method of treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas, in a subject in need thereof, which comprises administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to said subject.

35. A method of treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, Nephropathy, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, acute or chronic pancreatitis, gastrointestinal hormone secreting tumors, angiogenesis, inflammatory disorders, chronic allograft rejection, angioplasty, graft vessel bleeding or gastrointestinal bleeding in a subject in need thereof, which comprises administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof to said subject.

36. A method of inhibiting the proliferation of helicobacter pylori in a subject in need thereof, which comprises administering a compound according claim 1 or a pharmaceutically acceptable salt thereof, to said subject.

37. A pharmaceutical composition comprising a compound according to claim 22 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

38. A method of eliciting an agonist effect from one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound according to claim 22 or a pharmaceutically acceptable salt thereof to said subject.

39. A method of eliciting an antagonist effect from one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises

administering a compound according to claim 22 or a pharmaceutically acceptable salt thereof to said subject.

40. A method of binding one or more somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound according to claim 22 or a pharmaceutically acceptable salt thereof to said subject.

41. A method of treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas, in a subject in need thereof, which comprises administering a compound according to claim 22 or a pharmaceutically acceptable salt thereof to said subject.

42. A method of treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, Nephropathy, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, acute or chronic pancreatitis, gastrointestinal hormone secreting tumors, angiogenesis, inflammatory disorders, chronic allograft rejection, angioplasty, graft vessel bleeding or gastrointestinal bleeding in a subject in need thereof, which comprises administering a compound according to claim 22 or a pharmaceutically acceptable salt thereof to said subject.

43. A method of inhibiting the proliferation of helicobacter pylori in a subject in need thereof, which comprises administering a compound according claim 22 or a pharmaceutically acceptable salt thereof, to said subject.

44. A compound selected from the group consisting of:

N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine;

N-{1-(4-(4-fluorophenyl)-1H-imidazol-2-yl)heptyl}cyclohexylamine;

(4-phenyl-1H-imidazol-2-yl)methanamine;

5 (1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine;

(R,S)-N-(2-(1-methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)-1-butanamine;

(R,S)-N-benzyl-2-(6-fluoro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine;

(1R)-N-benzyl-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine;

(1R)-2-(1H-indol-3-yl)-N-(2-phenylethyl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine;

10 (1R)-N-benzyl-2-(1H-indol-3-yl)-N-methyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine;

N-benzyl(4-phenyl-1H-imidazol-2-yl)methanamine;

tert-butyl (1R)-1-(4-*tert*-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)-ethylcarbamate;

(1R)-N-benzyl-1-(1-benzyl-4-*tert*-butyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine;

N-((1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)-1-hexanamine;

15 *tert*-butyl (R,S)-1-(4-phenyl-1H-imidazol-2-yl)heptylcarbamate;

(4-(1,1'-biphenyl)-4-yl-1-methyl-1H-imidazol-2-yl)methanamine;

(R,S)-N-benzyl-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-1-heptanamine;

N-benzyl-N-((4-(1,1'-biphenyl)-4-yl-1H-imidazol-2-yl)methyl)-1-hexanamine;

N-benzyl(4-(1,1'-biphenyl)-4-yl-1H-imidazol-2-yl)-N-methylmethanamine;

20 (R,S)-4-(2-{1-(((*tert*-butoxycarbonyl)amino)pentyl)-1H-imidazol-4-yl}-1,1'-biphenyl);

(R,S)-N-benzyl-1-(4-(1,1'-biphenyl)-4-yl-1H-imidazol-2-yl)-1-pentanamine;

(R,S)-N,N-dihexyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine;

tert-butyl (R,S)-1-(4-phenyl-1H-imidazol-2-yl)hexylcarbamate;

(R,S)-N-hexyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine;

25 (R,S)-1-(4-phenyl-1H-imidazol-2-yl)hexylamine;

(R,S)-N-benzyl-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-1-heptanamine;

(R,S)-N-(2,6-dichlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine;

(R,S)-N-(4-chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine;

(R,S)-1-(4-(3-methoxyphenyl)-1H-imidazol-2-yl)heptylamine;

30 (R,S)-N-(2-chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine;

(R,S)-N-(2-fluorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine;

(R,S)-N-butyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine;

(R,S)-N-isopentyl-N-(1-(4-phenyl-1H-imidazol-2-yl)heptyl)amine;

(R,S)-1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-N-hexyl-1-heptanamine;

- (R,S)-*N*-pentyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine;
(R,S)-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)cyclohexanamine;
(R,S)-*N*-benzyl-1-(4-(3,4-dichlorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
butyl (4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methylcarbamate;
5 (R,S)-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)cyclopentanamine;
(R,S)-*N*-{1-(4-(2-chlorophenyl)-1*H*-imidazol-2-yl)heptyl}-cyclohexanamine;
(R,S)-*N*-{1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)heptyl}-cyclobutanamine;
(1*R*)-*N*-benzyl-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine;
(R,S)-2-(1*H*-indol-3-yl)-1-(5-methyl-4-phenyl-1*H*-imidazol-2-yl)ethanamine;
10 (R,S)-2-phenyl-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine;
(R,S)-2-(1-methyl-1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethylamine;
(1*S*)-*N*-benzyl-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine;
(1*R*)-*N*-benzyl-2-(1*H*-indol-3-yl)-1-(5-methyl-4-phenyl-1*H*-imidazol-2-yl)-ethanamine;
tert-butyl (1*R*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethylcarbamate;
15 (1*R*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine;
N-((1*R*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethyl)-benzamide;
benzyl (1*R*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethylcarbamate;
tert-butyl (1*R*)-2-(1*H*-indol-3-yl)-1-(4-(4-nitrophenyl)-1*H*-imidazol-2-yl)-ethylcarbamate;
tert-butyl (4-phenyl-1*H*-imidazol-2-yl)methylcarbamate;
20 *tert*-butyl (1-benzyl-4-phenyl-1*H*-imidazol-2-yl)methylcarbamate;
N-((1*R*)-2-(1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)ethyl)-2-pyrimidinamine;
(1*R*)-2-(1*H*-indol-3-yl)-1-(4-(4-nitrophenyl)-1*H*-imidazol-2-yl)ethanamine;
(1-benzyl-4-phenyl-1*H*-imidazol-2-yl)methanamine;
(1*R*)-2-(1*H*-indol-3-yl)-*N*-(2-phenoxyethyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-ethanamine;
25 (1*R*)-1-(4-*tert*-butyl-1*H*-imidazol-2-yl)-2-(1*H*-indol-3-yl)ethylamine;
N-benzyl(1-benzyl-4-phenyl-1*H*-imidazol-2-yl)methanamine;
(1*R*)-2-(1-benzothien-3-yl)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine;
tert-butyl (R,S)-2-(6-chloro-1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)-ethylcarbamate;
(R,S)-2-(6-chloro-1*H*-indol-3-yl)-1-(4-phenyl-1*H*-imidazol-2-yl)-ethylamine;
30 *tert*-butyl (1*R*)-3-methyl-1-(4-phenyl-1*H*-imidazol-2-yl)butylcarbamate;
(1*R*)-*N*-benzyl-3-methyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-butanamine;
tert-butyl (R,S)-phenyl(4-phenyl-1*H*-imidazol-2-yl)methylcarbamate;
(R,S)-phenyl(4-phenyl-1*H*-imidazol-2-yl)methylamine;
tert-butyl (1*R*)-3-phenyl-1-(4-phenyl-1*H*-imidazol-2-yl)-propylcarbamate;

- (1*R*)-3-phenyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-propanamine;
(*R,S*)-*N*-benzyl(phenyl)(4-phenyl-1*H*-imidazol-2-yl)methanamine;
(1*R*)-*N*-benzyl-3-phenyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-propanamine;
4-(2-(((*tert*-butoxycarbonyl)amino)methyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl;
5 (1-benzyl-4-phenyl-1*H*-imidazol-2-yl)-*N,N*-dimethylmethanamine;
4-(1-benzyl-2-(((*tert*-butoxycarbonyl)amino)methyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl;
(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methanamine;
(*R,S*) 1-(4-phenyl-1*H*-imidazol-2-yl)heptylamine;
(1-benzyl-4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methanamine;
10 (*R,S*)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine;
4-(2-(((*tert*-butoxycarbonyl)amino)methyl)-1-methyl-1*H*-imidazol-4-yl)-1,1'-biphenyl;
tert-butyl (1*R*)-2-(1*H*-indol-3-yl)-1-(1-methyl-4-phenyl-1*H*-imidazol-2-yl)ethylcarbamate;
4-(2-(((*tert*-butoxycarbonyl)(methyl)amino)methyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl;
(1*R*)-2-(1*H*-indol-3-yl)-1-(1-methyl-4-phenyl-1*H*-imidazol-2-yl)-ethanamine;
15 *tert*-butyl methyl((5-methyl-4-phenyl-1*H*-imidazol-2-yl)-methyl)carbamate;
(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-*N*-methylmethanamine;
N-methyl-(5-methyl-4-phenyl-1*H*-imidazol-2-yl)methanamine;
4-(2-((benzyl(*tert*-butoxycarbonyl)amino)methyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl;
(1*R*)-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-3-phenyl-1-propanamine;
20 *N*-benzyl(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)methanamine;
(1*R*)-*N*-benzyl-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-3-phenyl-1-propanamine;
tert-butyl (*R,S*)-1-(4-phenyl-1*H*-imidazol-2-yl)pentylcarbamate;
(*R,S*)-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-1-pentanamine;
(*R,S*)-1-(4-phenyl-1*H*-imidazol-2-yl)pentylamine;
25 *tert*-butyl (*R,S*)-1-(4-(4-methylphenyl)-1*H*-imidazol-2-yl)-heptylcarbamate;
tert-butyl (*R,S*)-1-(4-(2-methoxyphenyl)-1*H*-imidazol-2-yl)-heptylcarbamate;
(*R,S*)-1-(4-(4-methylphenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
(*R,S*)-1-(4-(2-methoxyphenyl)-1*H*-imidazol-2-yl)heptylamine;
(*R,S*)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-pentanamine;
30 *tert*-butyl (*R,S*)-1-(4-(4-methoxyphenyl)-1*H*-imidazol-2-yl)heptylcarbamate;
(*R,S*)-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-1-heptanamine;
tert-butyl (*R,S*)-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-heptylcarbamate;
(*R,S*)-1-(4-(4-methoxyphenyl)-1*H*-imidazol-2-yl)heptylamine;
(*R,S*)-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;

- (R,S)-4-(2-{1-((*tert*-butoxycarbonyl)amino)heptyl}-1*H*-imidazol-4-yl)-1,1'-biphenyl;
(R,S)-*N*-benzyl-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
4-(2-{(1*S*)-1-((*tert*-butoxycarbonyl)amino)propyl}-1*H*-imidazol-4-yl)-1,1'-biphenyl;
(R,S)-*N*-benzyl-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-1-heptanamine;
5 (1*S*)-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-1-propanamine;
(1*S*)-*N*-benzyl-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-1-propanamine;
(R,S)-*N*-benzyl-1-(4-(4-methylphenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
(R,S)-*N*-benzyl-1-(4-(2-methoxyphenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
(R,S)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-hexanamine;
10 (R,S)-4-(2-(1-aminoheptyl)-1*H*-imidazol-4-yl)benzonitrile;
(R,S)-1-(4-(4-bromophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
tert-butyl (1*R*)-1-(4-phenyl-1*H*-imidazol-2-yl)butylcarbamate;
4-(2-{(1*R*)-1-((*tert*-butoxycarbonyl)amino)butyl}-1*H*-imidazol-4-yl)-1,1'-biphenyl;
(1*R*)-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-1-butanamine;
15 (R,S)-4-(2-(1-aminoheptyl)-1*H*-imidazol-4-yl)-2,6-di(*tert*-butyl)-phenol;
(1*R*)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-butanamine;
(R,S)-*N*-benzyl-1-(4-(4-bromophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
(1*R*)-*N*-benzyl-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)-1-butanamine;
(1*R*)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-butanamine;
20 (R,S)-*N*-(3-chlorobenzyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine;
(R,S)-*N*-benzyl-1-(4-(3-methoxyphenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
(R,S)-4-{2-(1-(benzylamino)heptyl)-1*H*-imidazol-4-yl}benzonitrile;
(R,S)-4-(2-(1-aminoheptyl)-1*H*-imidazol-4-yl)-*N,N*-diethylaniline;
(1*R*)-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine;
25 (R,S)-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
(R,S)-1-(4-(2-chlorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
N-((1*S*)-1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)propyl)-1-butanamine;
(1*R*)-*N*-benzyl-1-(4-phenyl-1*H*-imidazol-2-yl)ethanamine;
(R,S)-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)-*N*-propylamine;
30 (R,S)-*N*-benzyl-1-(4-(3-methoxyphenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
(R,S)-4-{2-(1-(benzylamino)heptyl)-1*H*-imidazol-4-yl}benzonitrile;
(R,S)-*N*-(4-methoxybenzyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine;
(R,S)-*N*-benzyl-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
(R,S)-*N*-benzyl-1-(4-(2-chlorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;

- (R,S)-*N*-benzyl-*N*-(1-{4-(4-(diethylamino)phenyl)-1*H*-imidazol-2-yl}heptyl)amine;
 (R,S)-1-(4-(3,4-dichlorophenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
tert-butyl (R,S)-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-5-methylhexylcarbamate;
 (R,S)-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-5-methyl-1-hexanamine;
 5 (R,S)-*N*-isobutyl-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine;
 (R,S)-*N*-benzyl-1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-5-methyl-1-hexanamine;
 (R,S)-*N*-benzyl-1-(4-(4-methoxyphenyl)-1*H*-imidazol-2-yl)-1-heptanamine;
 (R,S)-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)cyclobutanamine;
 4-(2-((1*S*)-1-((butoxycarbonyl)amino)ethyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl;
 10 4-(2-((1*R*)-1-((butoxycarbonyl)amino)ethyl)-1*H*-imidazol-4-yl)-1,1'-biphenyl;
 (R,S)-*N*-isopropyl-*N*-(1-(4-phenyl-1*H*-imidazol-2-yl)heptyl)amine;
 (R,S)-*N*-(1-(4-(3,4-dichlorophenyl)-1*H*-imidazol-2-yl)heptyl)-cyclohexanamine;
 (R,S)-*N*-(1-(4-(1,1'-biphenyl)-4-yl-1*H*-imidazol-2-yl)heptyl)-cyclohexanamine;
 (R,S)-2-(5-fluoro-1*H*-indol-3-yl)-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)ethylamine;
 15 *N*-{(4-(3-bromophenyl)-1*H*-imidazol-2-yl)methyl}cyclohexanamine;
 (R,S)-*N*-(2-(5-fluoro-1*H*-indol-3-yl)-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)ethyl)-
 cyclobutanamine;
 (R,S)-*N*-(1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)-4-methylpentyl)-cyclohexanamine;
 (R,S)-*N*-(cyclohexylmethyl)-1-(4-phenyl-1*H*-imidazol-2-yl)-1-heptanamine;
 20 (R,S)-*N*-(1-(4-(3-bromophenyl)-1*H*-imidazol-2-yl)-5-methylhexyl)-cyclohexanamine; and
N-{(1*R*)-1-(4-(4-fluorophenyl)-1*H*-imidazol-2-yl)-2-methylpropyl}-cyclohexanamine;
 or a pharmaceutically acceptable salt thereof.

45. A pharmaceutical composition comprising a compound according to claim 44
 25 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

46. A method of eliciting an agonist effect from one or more of a somatostatin
 subtype receptor in a subject in need thereof, which comprises administering a compound
 according to claim 44 or a pharmaceutically acceptable salt thereof to said subject.

30

47. A method of eliciting an antagonist effect from one or more of a somatostatin
 subtype receptor in a subject in need thereof, which comprises administering a compound
 according to claim 44 or a pharmaceutically acceptable salt thereof to said subject.

48. A method of binding one or more of a somatostatin subtype receptor in a subject in need thereof, which comprises administering a compound according to claim 44 or a pharmaceutically acceptable salt thereof to said subject.

5 49. A method of treating acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS
10 related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas, in a subject in need thereof, which comprises administering an effective amount of a compound according to claim 44 or a pharmaceutically acceptable
15 salt thereof to said subject.

50. A method of treating diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, Nephropathy, peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, Dumping syndrome, watery
20 diarrhea syndrome, acute or chronic pancreatitis, gastrointestinal hormone secreting tumors, angiogenesis, inflammatory disorders, chronic allograft rejection, angioplasty, graft vessel bleeding or gastrointestinal bleeding in a subject in need thereof, which comprises administering an effective amount of a compound according to claim 44 or a pharmaceutically acceptable salt thereof to said subject.

25 51. A method of inhibiting the proliferation of helicobacter pylori in a subject in need thereof, which comprises administering an effective amount of a compound according claim 44 or a pharmaceutically acceptable salt thereof, to said subject.